123 Doc EDUCATION

# FOUNDATION YEARS JOURNAL

MARCH 2011

Volume 5, Issue 2: **Nephrology Immunology**



**You can email us at info@123doc.com or visit us online at www.123doc.com. Alternatively, call 0207 253 4363.**
**123 Doc.**

FOUNDATION YEARS JOURNAL 2011

Volume 5, Issue 2

## Foundation Years Journal

**Foundation Years Journal** is an international peer-viewed journal which seeks to be the pre-eminent journal in the field of patient safety and clinical practice for Foundation Years' doctors and educators. The Journal welcomes papers on any aspect of health care and medical education which will be of benefit to doctors in the Foundation training grade in the UK or international equivalents.

## Editor In Chief



## Associate Editor



## Publisher's Office

**Emmanuelle Roumy Guerry**
Managing Editor
123Doc Education
72 Harley Street
London
W1G 7HG
Tel: +44 (0)207 253 4363
Email: emmanuelle@123doc.com

## Reviewers



## Volume 5, Issue 2: Nephrology Immunology

**Foundation Years Journal** is the ONLY journal for Foundation Years doctors and educators, specifically written according to the MMC curriculum. It focuses on one or two medical specialties per month, each issue delivers practical and informative articles tailored to the needs of junior doctors. The Journal closely follows the Foundation Years syllabus to provide the best educational value for junior doctors. In addition to good clinical and acute care articles, assessment questions give junior doctors the chance to gauge their learning. The answers will be published in the next issue, but 123Doc will advance answers to clinical tutor subscribers so they can engage their students in the learning process. Each issue provides comprehensive clinical cases for trainees as well as practical teaching assessments for educators. Readers will benefit from:

- **MMC CURRICULAR-BASED CONTENT** to enhance understanding of the core competencies required from future leading doctors.
- **FOCUS ON SPECIALTY-SPECIFIC CLINICAL CASES** each month to form broad subject coverage.
- **ADDITIONAL IN-DEPTH** good clinical and acute care articles aligned with the case-based discussion assessments.
- **TRAINING GUIDE FOR FOUNDATION YEAR (FY)** educators with proposed clinical cases for teaching sessions.
- **PRACTICAL & INFORMATIVE** articles written by senior doctors & consultants.
- **EXTRA REVISION** with comprehensive assessment. Questions & Picture Quiz.

**Editorial Board**

## FOUNDATION YEARS JOURNAL 2011

Volume 5, Issue 2

### How to order Foundation Years Journal

Orders for subscriptions should be made by email (subscriptions@123doc.com) or with a credit card through 123Doc's website. (www.123doc.com). Or by returning the subscription form included in the Journal to:

123Doc Education
72 Harley Street
London
W1G 7HG

### How to advertise in Foundation Years Journal

Advertising orders and enquiries can be sent to sabine@123doc.com.
Tel: +44 (0)207 253 4363.

### Photocopying

Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale and all forms of document delivery.

### Electronic storage or usage

Permission of the Publisher is required to store or use electronically any material contained in this Journal, including any article or part of an article. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.

### Notice

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

# MICROSCOPIC HAEMATURIA

Bamidele Ajayi and Peter Topham



**Microscopic Haematuria.**
**Patient Management.**


## Abstract

Although not done frequently, urine dipstick testing is one of the common bedside tests, which a young doctor will be asked to do either in an acute clinical setting or in an outpatient clinic. Microscopic (non-visible) haematuria is a common incidental finding on such tests[1,3,4]. In this article, we present an interesting case of a young man who presented with non-visible haematuria associated with a systemic illness. This case has been used to illustrate the diagnostic approach that should be taken in patients with haematuria. A careful and logical approach will help in identifying the clinical relevance of such positive dipstick results and will determine whether further assessment is necessary.


## Case Study

A 22-year old man presented to the surgical admissions unit with a 2-week history of abdominal pain. The pain was peri-umbilical and intermittent in nature. He had no history of haematemesis, haematochezia or melaena stool. He also had a 4-month history of a generalized purpuric rash that was mainly on his extremities. He had no urinary tract symptoms. He denied any history of sore throat or joint pains. His medical history was not significant, and he was taking no medication.

Physical examination demonstrated a purpuric rash on the extensor aspect of his forearms and lower limbs in addition to para-umbilical abdominal tenderness. His blood pressure was 110/70 mm Hg, and all his other vital signs were normal. He looked well apart from episodes of obvious pain. As part of his initial evaluation, a urine dipstick showed 3+ blood and 1+protein. Three further urine dipstick tests were positive for blood.

On initial investigation, his plasma creatinine was found to be 60 µmol/L; estimated glomerular filtration rate (eGFR) >90 ml/min and urine protein/creatinine ratio (PCR) was 100 mg/mmol. A midstream urine culture revealed no evidence of infection. The serological immunology investigations (ANCA, ANA, C3, C4, anti-GBM antibody) were unremarkable. An abdominal X-ray was unremarkable and in particular demonstrated no calcification related to the urinary tract. A renal ultrasound scan revealed normal-size kidneys with no obstruction and no structural abnormality. A clinical diagnosis of Henoch-Schonlein purpura was made.

His abdominal symptoms settled after 2 days without any specific intervention. A planned oesophagogastroduodenoscopy was cancelled, and he was discharged to be followed in the nephrology outpatient clinic. A skin biopsy had also been arranged following a dermatology consult; but the rash settled before the biopsy could be arranged and therefore this was not undertaken.

On review by the nephrology service, persistent non-visible haematuria as well as significant proteinuria was noted. His blood pressure remained normal, and he remained clinically well overall.

Given the persistence of the urinary abnormalities, a renal biopsy was performed. This showed mesangial proliferative glomerulonephritis with mesangial deposition of IgA compatible with a diagnosis of IgA nephropathy. This is the typical glomerular abnormality in patients with Henoch-Schonlein purpura. His renal function remained normal, and he was being followed up in the renal outpatient clinic. He was not maintained on any medication.

## Discussion

This case describes a young man with non-visible haematuria that was identified when he presented with evidence of a multi-system disease. We will use this case to discuss the significance of haematuria and the approach to identifying its cause.

## What is non-visible haematuria?

According to the joint consensus statement from the Renal Association and the British Association of Urological Surgeons, non-visible haematuria is considered to be urine dipstick positive haematuria of 1+ or greater[2]. Trace haematuria should be considered negative, and there is no distinction in significance between non-haemolysed and haemolysed dipstick-positive haematuria.

# MICROSCOPIC HAEMATURIA

Bamidele Ajayi and Peter Topham



**Microscopic Haematuria.**
**Patient Management.**

Non-visible haematuria can be further subdivided according to the presence of urinary tract symptoms[2] (hesistancy, frequency, urgency and dysuria) into the following:

**1. Symptomatic non-visible haematuria**

**2. Asymptomatic non-visible haematuria**

## What is significant non-visible haematuria?

Non-visible haematuria is present in about 2.5%–20% of the general population, but most of these individuals have no significant pathology[1,3,4,5]. Hence there is a need to carefully select those patients who need further investigation, and to avoid subjecting the remainder to unnecessary testing and the anxiety associated with it. Non-visible haematuria is usually transient, and this needs to be excluded by repeat urine dipstick testing. Transient causes include vigorous exercise, sexual intercourse, urinary tract infection and menstrual contamination[1,3,4,5]. Significant non-visible haematuria according to the RA/BAUS guidelines is:

**1. Any single episode of symptomatic non-visible haematuria**

**2. Persistent asymptomatic non-visible haematuria (persistence is two out of three positive dipsticks)**

## What are the causes of significant non-visible haematuria?

The causes of significant non-visible haematuria can be broadly divided into urological and nephrological causes (Table 1). Urological causes include nephrolithiasis, urological cancers and benign prostatic hyperplasia. Nephrological causes can be further subdivided into glomerular and non-glomerular causes. The most common primary glomerular causes are IgA nephropathy and thin-membrane nephropathy[1,3,5,6]. Non-glomerular causes include polycystic kidney disease and papillary necrosis. In young people (<40 years) urological cancer is a very uncommon cause of haematuria, and a glomerular cause is much more likely. In contrast, in patients over 40 years of age with haematuria, urological cancer becomes increasingly more common and appropriate investigation must be undertaken[1,3,5,6].

| Urological Cause | Nephrological Cause |
|---|---|
| Renal stone disease | **Glomerular cause** |
| Bladder cancer | IgA nephropathy |
| Prostate cancer | Thin membrane nephropathy |
| Renal cell cancer | Hereditary nephritis |
| Cystitis, pyelonephritis, prostatis, urethritis | Acute glomerulonephritis |
| | Vasculitis |
| Polycystic kidney disease | Lupus nephritis |
| Radiation cystitis | Post infectious GN |
| Urethral and meatal strictures | Goodpasture's disease |
| Schistosoma infection | Chronic glomerulonephritis |
| Papillary necrosis | Diabetes |
| Renal artery thrombosis | |
| Arteriovenous malformation | **Non-glomerular** |
| Renal trauma | Polycystic kidney disease |
| Loin pain haematuria syndrome | Medullary sponge kidney |
| | Hypercalciuria |
| | Hyperuricosuria |

**Table 1. Causes of Haematuria**

## Investigations

Initial assessment should factor in the possibility of urological cancer as a cause of non-visible haematuria. Hence patients of 40 years and more or with significant non-visible haematuria will need a urological assessment. This will include, as a minimum, imaging of the renal tract and cystoscopy. All patients with microscopic haematuria will need the following investigations:

1. Plasma creatinine and estimated glomerular filtration rate (eGFR)
2. Urine protein/creatinine ratio
3. Blood pressure

**Further investigation will be necessary in these patients if:**

1. eGFR <60 ml/min
2. PCR ratio >50 mg/mmol
3. Blood pressure >140/90 mm Hg

# MICROSCOPIC HAEMATURIA

Bamidele Ajayi and Peter Topham

An algorithm for the evaluation of patients with haematuria is shown in Fig. 1.

The patient described in this article had significant asymptomatic non-visible haematuria. He was under 40 years of age, and hence urological cancer as a cause of his non-visible haematuria was unlikely. The presence of significant proteinuria was highly suggestive of glomerular disease, and further nephrological assessment was therefore necessary.

Furthermore he appears to have a systemic disease process given the evidence of multiple organ involvement, i.e., skin, gastrointestinal system and the kidneys. It is therefore important to test for the serological markers of immunologically-mediated disease. A definitive diagnosis is however usually made with the aid of a biopsy and histological examination of an affected organ. In this case, the skin, kidney or gastrointestinal system could be sampled. Since the abdominal symptoms had settled, the skin and kidney would be most likely to yield a diagnosis. A skin biopsy would however be the safer of the two however the rash resolved before this could be undertaken. The constellation of abdominal pain, purpuric skin rash, haematuria/proteinuria is compatible with a diagnosis of Henoch-Schonlein purpura. The renal biopsy finding of IgA deposition with mesangial proliferative changes supported this clinical diagnosis.

As defined by the International Consensus Conference on Nomenclature of Systemic Vasculitis, Henoch-Schonlein purpura is a vasculitis with IgA dominant immune deposits affecting small vessels and typically involving the skin, gut and glomeruli and associated with arthralgias or arthritis[5,6,7]. It is also described as the multisystem form of IgA nephropathy. It is most common in children between the ages of 5 and 15 years. However, it can occur at any age. Nephritis (renal involvement) affects adults more frequently than children. The classic tetrad of signs and symptoms includes rash, arthralgias, abdominal pain and renal disease[5,6,7].

In the majority of patients, Henoch-Schonlein purpura is self-limiting lasting between 1 and 6 weeks. In patients with normal renal function like the patient described, supportive treatment is usually all that is required. If however there is progressive kidney failure, immunosuppressive therapy (for example corticosteroids +/- cyclophosphamide) might be considered. However, in a minority of patients the disease can be recurrent and can result in progressive renal dysfunction and in extreme cases the development of end stage renal disease[5,6,7].

This case has been used to illustrate the approach to any patient presenting with non-visible haematuria. We have attempted to define non-visible haematuria and to describe significant non-visible haematuria. This approach should ease the mind of the reader when confronted with an abnormal urine dipstick result.




**Figure 1**

## Questions

**1. A 50-year old man presented to his general practitioner with a history of poor urinary stream, urgency and frequency of micturition. Dipstick urinalysis 2 weeks earlier had demonstrated non-visible haematuria, and he had been treated with antibiotics for a presumed urinary tract infection. Urine culture had however demonstrated no growth. His blood pressure was 120/75 mm Hg, and his renal function was normal. A further two urine dipstick tests had revealed 3+ blood with no protein, nitrite or leucocytes. His only medication was aspirin. What would be the most appropriate next step in his management?**

A. Arrange for further urine dipstick testing every 3 months
B. Commence an alpha blocker for his bladder outflow symptoms
C. Refer to nephrology for consideration of a renal biopsy
D. Refer to urology for further assessment
E. Stop his aspirin

# MICROSCOPIC HAEMATURIA

Bamidele Ajayi and Peter Topham



## Microscopic Haematuria.
## Patient Management.

**2. A 26-year old army sergeant presented to the emergency department having collapsed during a morning run. He had no significant medical history. A urine dipstick test undertaken during a routine medical examination 1 month earlier had been positive for blood. His blood pressure on arrival was 170/100 mm Hg. A urine dipstick in the emergency department revealed 3+ protein and 2+ blood. What is mostly likely cause of these findings ?**

A. Bladder cancer
B. Exercise-induced haematuria
C. IgA nephropathy
D: Renal stone disease
E: Urinary tract infection

## Answers

**1. Correct answer: D.**
The patient has significant haematuria as evidenced by three positive dipsticks. Arranging further urine dipsticks would not add any more information. He is above 40 years and with symptomatic non-visible haematuria. Paramount in his work up is the need to rule out urological cancers. Treating his symptoms with an alpha blocker might actually mask a significant underlying disease and therefore would not be recommended. A nephrology referral at this point would not be appropriate, as a urological cause needs to be ruled out. Stopping his aspirin would not stop his haematuria. Anticoagulation or antiplatelet therapy is never the cause of haematuria.

**2. Correct answer: C.**
Two urine dipsticks positive for blood indicates significant haematuria. He is under 40 years which makes cancer unlikely. Exercise-induced haematuria is transient; therefore, the persistence of the haematuria and the concomitant presence of proteinuria makes that explanation unlikely. His proteinuria and hypertension suggests a nephrological cause of his kidney disease. In this case, IgA nephropathy is statistically the most likely diagnosis. He has no symptoms that might suggest renal stone disease or urinary tract infection.

## References

1. J.D. Kelly, D.P. Fawcett, and L.C. Goldberg. Assessment and management of Non-visible Haematuria in primary care. *BMJ* 2009, 338: a3021.

2. Renal Association and British Association of Urological Surgeons. Joint Consensus Statement on the Initial assessment of Haematuria. 2008.

3. R.A. Cohen and R.S. Brown. Microscopic Hematuria. *N Engl J Med* 2003, 348: 2330–8.

4. P.K. Rao and J.S. Jones. How to evaluate 'dipstick hematuria': What to do before you refer. *Clev Clin J Med;* 75:3:227–33.

5. R.J. Johnson and J. Feehally. Comprehensive Clinical Nephrology. 2nd edn. Mosby.

6. J. Barratt, K. Harris, and P. Topham. Oxford Desk Reference Nephrology, Oxford University Press.

7. E.V. Lerma, J.S. Berns, and A.R. Nissenson. Current Diagnosis and Treatment: Nephrology and Hypertension. McGraw Hill Medical. 2009.

## Authors

**Bamidele Ajayi ST3 LAT in Nephrology,**
East Midlands School of Medicine.

**Peter Topham,**
Honorary Consultant Nephrologist,
John Walls Renal Unit,
Leicester General Hospital.

# CHRONIC KIDNEY DISEASE - MINERAL BONE DISEASE

Matthew Graham-Brown, David Bennett-Jones and Mohamed Thahir

**Chronic Kidney Disease - Mineral Bone Disease.**
**Patient Management.**




## Abstract

The development of secondary hyperparathyroidism and characteristic high-turnover bone disease are invariably associated with the onset of sustained reduction in renal function seen in patients with chronic renal failure (CRF). The drivers to hyperparathyroidism include phosphate retention, failure of renal bioactivation of vitamin D and hypocalcaemia. Some patients — particularly those being treated for renal bone disease — develop a low-turnover bone disease, which results from a relative suppression of parathyroid hormone (PTH). There is considerable morbidity and mortality associated with development of these conditions. These patients are also predisposed to soft-tissue and vascular calcification. Treatment aims to maintain bone integrity, by keeping phosphate, calcium and PTH within well-defined target ranges. It is hoped that these measures will reduce cardiovascular events in these patients, although this has not (yet) been proven.


## Case Study

A 59-year old female, with end-stage renal failure (ESRF) secondary to polycystic kidney disease (APKD) on continuous ambulatory peritoneal dialysis (CAPD), was seen as part of a routine follow-up in outpatients. She complained of tingling around her mouth, as well as numbness and tingling in her fingers. She had been diagnosed with APKD in 1987 and had had 18 months of CAPD before a deceased donor renal transplant in 1992 which failed after 15 years, necessitating her return to CAPD. Her medication consisted of an ACE-inhibitor, a calcium channel blocker, levothyroxine, an active vitamin D analogue and a calcium containing phosphate binder. Her only other medical conditions were hypertension, hypothyroidism and previous partial parathyroidectomy.

## Initial Approach to Investigation and Management

Our patient is known to have ESRF and displays classical symptoms associated with hypocalcaemia; although this is a frequently observed complication of renal failure, it is rarely symptomatic. Initial investigations should be to confirm hypocalcaemia via corrected calcium or direct measurement of ionised calcium, if available, and to measure levels of phosphate and PTH, as well as ensuring that there are no immediate risks to the patient from immediate complications of hypocalcaemia. In this case the total calcium was found to be low at 1.76 mmol/L (range 2.2–2.6 mmol/L), and PTH was confirmed as being high at 98.9 mmol/L (range 10–55 mmol/L), with phosphate levels also being raised at 2.56 mmol/L (range 1.1–1.8 mmol/L). This is the classical biochemical picture of one form of chronic kidney disease-mineral bone disease (CKD-MBD). CKD-MBD is a broad term used to describe the clinical syndrome that affects bone, minerals and calcific cardiovascular complications that develop as a result of CRF[1] (Table 1).

| KDIGO classification of CKD-MBD and renal osteodystrophy |
|---|
| **Definition of CKD-MBD**<br>A systemic disorder of mineral and bone metabolism due to CKD, manifested by either one or a combination of the following:<br>1. Abnormalities of calcium, phosphorous, PTH or vitamin D metabolism<br>2. Abnormalities in bone turnover, mineralization, volume, linear growth or strength<br>3. Vascular or other soft-tissue calcification |
| **Definition of renal osteodysrtophy**<br>1. An alteration of bone morphology in patients with CKD<br>2. It is one measure of the skeletal component of the systemic disorder of CKD-MBD that is quantifiable by histomorphometry of bone biopsy |

**Table 1. Chronic Kidney Disease.**

# CHRONIC KIDNEY DISEASE - MINERAL BONE DISEASE

Matthew Graham-Brown, David Bennett-Jones, and Mohamed Thahir

## Chronic Kidney Disease - Mineral Bone Disease. Patient Management.



The decrease in glomerular filtration rate (GFR) leads to progressive phosphate retention, and there is failure of renal bioactivation of vitamin D, both of which lead to hypocalcaemia. The resultant powerful stimulation of parathyroid glands leads to high levels of circulating PTH[3]. In a variant of this condition, PTH fails to rise; resulting in a low bone turnover form of CKD-MBD. In terms of immediate risk to the patient, major complications are rare but can include prolonged QT interval, laryngospasm and papilloedema. In this patient, however, an ECG was normal, there were no signs of upper airway obstruction and, on fundoscopy, optic discs were normal.

Initial management was centred around restoring biochemical parameters to normal levels. Treatment strategies in management of renal bone disease are centred around the following three fundamental principles:

**1. Replacing deficient active vitamin D (calcitriol)**

**2. Increasing serum calcium**

**3. Lowering circulating levels of phosphate**

To that end, the dose of activated vitamin D was increased, with advice to the patient to increase further if symptoms persisted. Her dose of calcium containing phosphate binder was also increased, not only further to decrease phosphate, but also as a source of calcium. She was started on the phosphate binder lanthanum carbonate, one of the newer generation (non-calcium containing) phosphate binders. The importance of a low phosphate diet was also reinforced (Table 2). After 1 week of increasing her tablets, her bloods were rechecked, and adjusted calcium had increased to 2.08 mmol/L. PTH had also fallen, and later it returned to 13.8 mmol/L, confirming that this patient had predominantly secondary hyperparathyroidism, responding to calcium level, as opposed to tertiary hyperparathyroidism with autonomous PTH production, due to parathyroid hyperplasia.

Table taken from KDIGO (kidney disease improving global outcomes) guidelines. Definitions adapted from Moe et al[2].

| Sodium | | Potassium | | Phosphate | |
|---|---|---|---|---|---|
| **Low** | **High** | **Low** | **High** | **Low** | **High** |
| 'White' cheese | Cured Meats | Cucumber | Clams | 'Light' coloured 'soda' drinks | Cola drinks |
| Unprocessed meat | Pickles | Asparagus | Avocado | Shortbread | Dairy products |
| Unprocessed fish | Cheese | Green/ waxed beans | Potato | Boiled sweets | Bran/barley |
| Fresh fruit | Soy sauce 'Chinese food' | Corn | Kiwi | White fish | Nuts |
| Fresh veg | Tinned fish | Cauliflower | Dry fruit | Tuna | Coconuts |
| | Smoked salmon | Water chestnut | Dry cereal | Water biscuits | Peas |
| | Shellfish | Lemonade | Dry beans | Plain chocolate | Beans |
| | | | Dry lentils | | Organ meats |
| | | | | | Oysters |

**Table 2. Non-exhaustive list of examples of foods important to renal patients. A well-constructed diet may contain any or all of the above in the correct amounts and the importance of dietician input in the management of renal patients should not be underestimated. The consideration of protein content is also important: Generally speaking pre-dialysis protein content should be low, and after starting dialysis protein content should increase. Adapted from suggestions made by National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC).**

# CHRONIC KIDNEY DISEASE - MINERAL BONE DISEASE

Matthew Graham-Brown, David Bennett-Jones, and Mohamed Thahir

## Biochemistry, Renal Bone Disease and Extra-Skeletal Calcification

The biochemical picture described above—that develops in CRF—has a direct effect on the skeleton. In health, PTH release is under tight homeostatic controls, mediated in part by the calcium-sensing receptor (CaR) in the parathyroid gland (Fig. 1). Physiological PTH secretion is pulsatile and has an anabolic effect, maintaining healthy bone turnover. However, when PTH is consistently elevated, as in untreated CRF, its effect is catabolic. High PTH levels increase osteoclast and osteoblast activity, causing resorptive bone damage. This is known as hyperparathyroid (high turnover) bone disease[4]. A second type of bone disease develops in some renal patients; particularly in those who have been exposed to high levels of calcium from calcium replacement or in dialysate fluid, or who have been treated with active vitamin D metabolites. The high level of circulating calcium causes PTH suppression and the anabolic effects that PTH has in normal physiology are lost: osteoclast and osteoblast activity is reduced, and pathological low bone turnover (adynamic bone disease) develops[3].




**Figure 1. The calcium-sensing receptor is responsible for regulation of PTH secretion, based on minute-by-minute changes in calcium levels. Chronic states of low-calcium, high-phosphate or low-calcitriol increase the amount of PTH secreted per cell and cause parathyroid hyperplasia.**

Both types of renal bone disease lead to increased skeletal morbidity. However, hyperphosphataemia also causes extra-skeletal calcification—particularly in the vascular media of large arteries—by causing precipitation of circulating calcium. Deposition is in the vascular media, which differentiates this form of arterial calcification from the intimal calcification typically seen in atheromatous disease. This vascular calcification is strongly associated with the increased cardiovascular morbidity and mortality seen in CRF patients[5]. Interestingly there is currently some debate as to the significance of high serum phosphate in the development of cardiovascular disease in non-renal patients.

From the biochemical picture seen above (particularly the high level of PTH), it is most likely that our patient is at risk of developing high turnover bone disease. This is likely to have developed from sub-therapeutic doses of active vitamin D and phosphate binder or possible evidence of the progression of her renal failure. The way her biochemical parameters responded were encouraging, but further optimization is essential to limit development of renal bone disease, and further investigations are required to ascertain the extent of disease. Caution must be exercised not to overtreat with vitamin D analogues and calcium supplementation, otherwise low-turnover bone disease could develop.

## Further Investigation and Optimization

Our patient has had renal disease for many years and had a DEXA bone scan in 2003, which showed a normal spine and normal hips, with a T-score >1, and a Z-score >1.5. Given her hypocalcaemic symptoms and the time since her last scan, a DEXA scan was repeated. This showed a decrease in bone density of 7.7% in the spine in 6 years and a decrease of 2.6% in her hips. Her T-score of −1.2 and a Z-score of −1.6 suggested she had become osteopenic, although interpretation of these scores is difficult in patients with CKD-MBD. Bone biopsy remains the only way to definitively define what is going on in a patients bones, but is often declined by patients (as in this case) due to the invasive nature of the procedure. Treatment with bisphosphonates in CKD-MBD is an interesting and much debated area, but beyond the scope of this article.

Other contributing causes of osteopenia were considered: importantly our patient was menopausal, with her last menstrual period 9 years previously, and she had not received any hormone replacement therapy since. She had previously taken long-term steroids when she had her renal transplant, but had not been on any immunosuppressive therapies in the last 2 years. She lived an active life, with plenty of exercise and had only occasionally drunk alcohol. She was a non-smoker, and her BMI was 27. No other modifiable risk factors for bone disease were found.

Attempts were therefore made to optimize the patient's medical therapy in line with KDIGO guidelines to slow the rate of renal bone disease[1]. The effectiveness of these therapies is measured by directly recording biochemical markers:

**1. Calcium should be maintained within the normal range**

**2. Hyperphosphataemia should be minimized by the use of phosphate binders[6] and a low phosphate diet**

**3. Finally, PTH should be maintained at a level of 2–9 times the upper limit seen in normal physiology**

This final point is based on a number of observational studies, showing that PTH within this target range is associated with the highest probability of bone turnover being normal[4]. PTH below 16 mmol/L is associated with low-turnover (adynamic) bone disease, whereas PTH >32 mmol/L is associated with high turnover (hyperparathyroid) bone disease[7].

# CHRONIC KIDNEY DISEASE - MINERAL BONE DISEASE

Matthew Graham-Brown, David Bennett-Jones, and Mohamed Thahir



## Chronic Kidney Disease - Mineral Bone Disease. Patient Management.

The above therapies are, for the most part, effective in controlling secondary hyperparathyroidism—but may contribute to vascular calcification by causing hypercalcaemia. More recently there has been a substantial move away from calcium-based phosphate binders which are less prone to cause hypercalcaemia and vascular calcification. Newer active vitamin D compounds have been developed which have greater selectivity for parathyroid glands, and cause less calcium uptake from intestines and bone. An alternative approach, which has not yet been used in our patient, is to use calcimimetic agents. These drugs work by binding the CaR on parathyroid cells[8], and reducing secretion of PTH.

## Conclusions

The disturbances in our patient's mineral and bone metabolism are common to the majority of patients with CRF, who are at risk of developing renal bone disease. The challenges in managing progression of bone disease vary between patients but are founded on the basic principles outlined above. The pathogenesis of renal bone disease is clearly linked to the development of the accelerated vascular disease seen in CRF, furthering the importance of tight control of biochemical parameters.

## Renal Bone Disease Assessment Questions

**1. ECG changes associated with hypocalcaemia include:**

a. Sine wave
b. Prolonged QT interval
c. Shortened P-R interval
d. Absent T waves
e. Third-degree heart block

**2. With regards to biochemical changes that occur in renal bone disease, which of the following are correct?**

a. Decrease in GFR stops calcium excretion, accounting for the rise in serum calcium
b. Loss of renal bioactivation of vitamin D3 means calcium is not absorbed efficiently from the intestines, contributing to the hypocalcaemic picture that develops in CRF
c. Hyperphosphataemia develops due to loss of excretory function and plays a direct role in extra-skeletal calcification
d. High levels of circulating PTH result from loss of homeostatic control by calcitriol (active vitamin D3)
e. PTH is normally excreted by the kidneys and accumulates as excretory function diminishes

**3. High turnover bone disease**

a. is caused by overactivity of osteoclasts and osteoblasts
b. is a consequence of low levels of circulating PTH, which develops secondary to CRF
c. is commonly seen in patients receiving treatment for renal bone disease
d. high levels of circulating PTH have a catabolic effect on bone
e. results from the pulsatile release of PTH

**4. Which of he following is most useful in leading to a definitive diagnosis of CKD-MBD**

a. DEXA bone scan
b. Biochemical picture on blood results
c. Plain film X-ray of hand
d. MRI of thoraco-lumbar spine
e. Bone biopsy

**5. In terms of treatment of renal bone disease:**

a. All biochemical parameters should be maintained within normal range
b. Aluminium containing phosphate binders are commonly used to lower circulating phosphate levels
c. Treating renal bone disease not only prevents skeletal mortality, but also delays cardiovascular calcification
d. Actively treating renal bone disease can lead to adynamic (low turnover) bone disease
e. Calcimimetic agents are commonly used as first line agents in the treatment of mineral bone disease

# CHRONIC KIDNEY DISEASE - MINERAL BONE DISEASE

Matthew Graham-Brown, David Bennett-Jones, and Mohamed Thahir

## Renal Bone Disease Assessment Answers

**1. ECG changes associated with hypocalcaemia include:**

b. Prolonged QT interval

If signs of hypocalcaemia are present on ECG, this should be confirmed by measuring adjusted calcium as soon as possible and serum calcium replaced immediately.

**2. With regards to biochemical changes that occur in renal bone disease, which of the following are correct?**

a. Loss of renal bioactivation of vitamin D3 means calcium is not absorbed efficiently from the intestines, contributing to the hypocalcaemic picture that develops in CRF

b. Hyperphosphataemia develops due to loss of excretory function and plays a direct role in extra-skeletal calcification

High levels of phosphate cause calcificium precipitation in tissues, which is part of the reason calcium levels fall in renal failure, but also the reason calcium gets deposited in tissues. Active vitamin D3 has no direct affect on PTH control. PTH is a polypeptide hormone not directly excreted by kidneys, but is broken down.

**3. High turnover bone disease**

a. is caused by overactivity of osteoclasts and osteoblasts

b. high levels of circulating PTH have a catabolic effect on bone

High bone turnover disease results from secondary hyperparathyroidism—where low serum calcium is the driving stimulant. Persistently high levels of PTH stimulate osteoblasts and osteoclasts, causing increased bone resorption. In normal physiology, pulsatile secretion of PTH has an anabolic effect on bone.

**4. Which of he following is most useful in leading to a definitive diagnosis of CKD-MBD**

a. Bone biopsy

A precise diagnosis of CKD-MBD still relies on a bone biopsy. Most patients refuse this procedure due to its invasive nature.

**5. In terms of treatment of renal bone disease**

a. Treating renal bone disease not only prevents skeletal morbidity, but also delays cardiovascular calcification

b. Actively treating renal bone disease can lead to adynamic (low turnover) bone disease

Calcium and phosphate should be maintained at physiological levels, but PTH should be maintained at a level 2–9 times greater than normally seen in health. Close control of these biochemical parameters is associated with reduced skeletal morbidity and mortality and improved cardiovascular outcomes. Aluminium-containing phosphate binders are no longer in widespread use due to side effects of aluminium toxicity.

## References

1. KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder. *Kidney Int* 2009, 76 ( 113): s1–132.

2. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006, 69: 1945–53.

3. Cunningham J. Renal Bone Disease. Medicine 2007, 35:8: 450–52.

4. Malluche H, Faugere M. Renal Bone Disease 1990: an unmet challenge for the nephrologist. *Kidney Int* 1990, 38: 193–211.

5. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. Kidney Int 2005, 94: S120–127.

6. Fan LS, Cunningham J. Hyperphosphataemia management. *Semin Dial* 2002,15: 1–3.

7. Naional Kidney Foundation. K/DoQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. *Am J Kidney Dis* 2003, 42 (suppl. 4): S1–S201.

8. Steddon SJ, Cunningham J. Calcimimetics and calcilytics – fooling the calcium receptor. *Lancet* 2005, 365: 2237–39.

## Authors

**Matthew Graham-Brown**
FY1 – University hospital Coventry and Warwickshire
email: MattGB@doctors.org.uk

**David Bennett-Jones**
Consultant Renal Physician
University hospital Coventry and Warwickshire

**Mohamed Thahir**
Specialist registrar Medicine
University hospital Coventry and Warwickshire

# THE NEPHROTIC SYNDROME

Gang Xu, Peter Topham

**The Nephrotic Syndrome.**
**Patient Management.**




## Abstract

A 30-year old man presented with ankle swelling and progressive weight gain. He was subsequently found to have heavy proteinuria for which a diagnosis of nephrotic syndrome was made. This case discussion describes the process of diagnosing nephrotic syndrome, the management of the consequences of the nephrotic syndrome and the process for identifying the underlying cause.


## Case Study

A 30-year old man presented to the emergency department with a 2-week history of ankle swelling and progressive weight gain. Further questioning revealed that he suffered from facial swelling particularly in the early morning, and lower limb oedema that worsened throughout the day. He had a distant history of traumatic injury to his left kidney which resulted in unilateral loss of renal function. He had no other medical history, and he took no recreational or prescribed medications. He consumed 20 units of alcohol per week.

## Examination and initial investigations

Initial examination revealed a young man with severe leg oedema extending up to his sacrum. His blood pressure was 130/60 mm Hg, and both cardiac and abdominal examinations were normal. Initial blood testing demonstrated normal haemoglobin, a reduced albumin concentration (19 g/L), normal liver function tests, an elevated cholesterol (7 mmol/L) , an elevated serum creatinine (200 µmol/L) and an estimated glomerular filtration rate of 40 ml/min. Dipstick urinalysis showed 3+ protein, and no blood. The urine protein/creatinine ratio (PCR) was 700 mg/mmol (which approximates to 7 g of proteinuria per day). A renal ultrasound scan demonstrated a 11.9 cm right kidney measured, and the left kidney was small measuring 7 cm with evidence of previous trauma.

## The clinical problem

This patient had previous good health and no obvious cause of the oedema was identified during the initial evaluation (see Table 1). A diagnosis of nephrotic syndrome was made based upon the history of oedema (particularly periorbital oedema), proteinuria, hypoalbuminaemia, and hypercholesterolaemia (see Table 2). He was referred to the renal team and transferred to the nephrology ward for further management.

Once the diagnosis of nephrotic syndrome was made, the next step was to establish the cause (see Table 3). Normally in an adult who presents with nephrotic syndrome of uncertain cause, a renal biopsy is warranted to provide a diagnosis, and to guide treatment and prognosis. However, given the patient effectively had a single functioning kidney, a kidney biopsy would be technically challenging, more risky than normal, and any complications arising as an result of a renal biopsy would have severe consequences (see Fig. 1). Therefore, it was decided that the risks associated with a renal biopsy outweighed the benefits, and an empiric trial of treatment was commenced.

- **Heart failure**
- **Hypoalbuminaemia**
- **Cirrhosis**
- **Renal failure**
- **Lymphatic obstruction**
- **Venous obstruction**
- **Previous deep vein thrombosis**
- **Hypothyrodism (myxoedema)**

**Table 1. Common Causes of Peripheral Oedema.**

- **Heavy proteinuria (>3.5 g/day)**
- **Hypoalbuminaemia (<35 g/L)**
- **Peripheral oedema**
- **Hyperlipidaemia**

**Table 2. Clinical Features of the Nephrotic Syndrome.**

# THE NEPHROTIC SYNDROME

Gang Xu, Peter Topham

| Children | Adults |
|---|---|
| Minimal change disease | Diabetic nephropathy |
| Focal segmental glomerulosclerosis | Minimal change disease |
| Other proliferative glomerulonephritis | Membranous nephropathy |
| | Other conditions, e.g., Focal segmental glomerulosclerosis, Amyloidosis, HIV, SLE |

**Table 3. The Common Causes of the Nephrotic Syndrome.**




**Figure 1: Renal biopsy under ultrasound guidance.**

## Management

The initial aim of treatment was to deal with the consequences of the nephrotic syndrome.

**Oedema:** oedema results from renal salt and water retention and when severe can be very debilitating. The treatment of nephrotic oedema usually involves loop diuretic therapy combined with dietary salt and water restriction. The patient was therefore initially started on Furosemide 80 mg twice a day intravenously. Moreover, a fluid restriction up to 1.5 L/day was imposed. The effectiveness of the treatment was monitored by weighing daily and strict fluid input/output measurement. Given his already impaired renal function, his renal function and electrolytes were closely monitored.

**Thromboembolic risk:** Patients with nephrotic syndrome are at much higher risk of venous and arterial thrombosis compared to the normal population. The risk of venous thrombolic events (VTE) in this patient was further increased by being immobile due to his severe oedema. This demanded the patient to be started on VTE prophylaxis.

**Hyperlipidaemia:** Hypercholesterolaemia associated with the nephrotic syndrome usually responds well to treatment with HMG CoA reductase inhibitors (statins). However, the patient declined statin treatment, and the plan was to monitor his lipid profile on a regular basis.

The next aim is to provide disease-specific treatment, which clearly depends on identifying the underlying cause. In the absence of a pathological diagnosis from a kidney biopsy, this patient was empirically started on a course of corticosteroids (prednisolone 40 mg o.d.) on the basis that the most common glomerular diseases which can cause nephrotic syndrome (minimal change nephropathy, focal segmental glomerulosclerosis, membranous nephropathy) can be responsive to steroid treatment. Unfortunately the patient suffered a number of side effects associated with high dose steroid use, including worsening facial swelling, weight gain and personality changes (see Fig. 2). He was therefore weaned off the steroids rapidly. As his renal function had deteriorated and he had ongoing severe nephrosis, therefore treatment with immunosuppressive agents was considered. In light of this, the risk/benefit balance of the renal biopsy was reassessed. In the end an expert operator carried out a renal biopsy without complications, and a diagnosis membranous nephropathy was made.




**Figure 2: Complications of steroid therapy.**

## Discussion

### Diagnosis of nephrotic syndrome

Nephrotic syndrome is a clinical syndrome characterized by heavy proteinuria (3.5 g >24 hr), hypoalbuminaemia, peripheral oedema and hyperlipidaemia. In the evaluation of patients with nephrotic syndrome other causes of peripheral oedema (see Table 1) and hypoalbuminaemia (long-term illness, liver disease and poor nutrition) need to be considered and excluded.

# THE NEPHROTIC SYNDROME

Gang Xu, Peter Topham

## Investigations

The identification of proteinuria is essential in making a diagnosis of nephrotic syndrome. Urine dipsticks are a useful bedside screen for proteinuria. If there is any evidence of proteinuria on dipstick (1+ or greater) the urine should be sent for quantification of the proteinuria. A 24 hr urine collection is the 'gold standard' method of proteinuria quantification. This is however time-consuming and inconvenient for patients, and therefore measurement of the PCR (mg protein/mmol creatinine) in an early morning spot urine sample has become increasingly popular. The normalization of the protein concentration by the creatinine concentration adjusts for the effects of patient hydration status. The PCR has been shown to correlate well with 24 hr urine collections. Furthermore, because the average daily creatinine excretion is 10 mmol, the PCR result can be multiplied by 10 to give an estimate of the 24 hr protein excretion (e.g., a urine PCR of 700 mg/mmol is roughly equivalent to 7 g proteinuria in 24 hr). Normally physiological proteinuria does not exceed 150 mg/24 hr for an adult. Proteinuria in excess of 300 mg/day (urine PCR >30 mg/mmol) is abnormal and is suggestive of glomerular disease. Proteinuria of this level can be associated with a wide range of conditions. Nephrotic range proteinuria is defined as more than 3.5 g of proteinuria in 24 hrs (urine PCR >350 mg/mmol).

## Pathophysiology

The pathogenesis of the nephrotic syndrome is disease affecting primarily the glomerulus (see Fig. 3). Damage to the podocytes causes increased filtration of various plasma proteins, which are lost in the urine. Albumin is the primary protein lost in urine. While hepatic synthesis of albumin increases, this isn't enough to compensate, and hypoalbuminaemia results. The cause of oedema is thought to be as a result of reduced plasma oncotic pressure, and renal salt retention.








**Figure 3**

## Initial treatment

The oedema in nephrotic syndrome can be difficult to treat; often large doses of diuretics are needed. In this particular case intravenous diuretics were used to circumvent the effects of intestinal oedema on the absorption of oral diuretics. If patients fail to respond to loop diuretics alone, they can be combined with a thiazide diuretic such as metolazone. Rarely patients may have completely treatment-resistant oedema and mechanical ultra-filtration using a dialysis machine becomes the only treatment option.

Patients who are nephrotic are also at high risk of developing venous, and rarely arterial, thrombosis. A particular risk is the development of renal vein thrombosis, which can lead to loin pain, haematuria and acute kidney injury. It is therefore important to ensure patients who are nephrotic receive adequate VTE prophylaxis, especially when they are in hospital and are relatively immobile, and often volume deplete. Many experts believe that very high risk patients (proteinuria exceeding 10g/day, serum albumin <20 g/L and a diagnosis of membranous nephropathy) should be considered for full anticoagulation with warfarin to prevent thromboembolic disease. However, there is no randomized control trial data to support this. Therefore, the risks of bleeding associated with chronic warfarin therapy versus the risk of thromboemboic must be considered for each individual patient.

# THE NEPHROTIC SYNDROME

Gang Xu, Peter Topham

Hyperlipidemia is also commonly seen in patients with nephrotic syndrome. Lipid lowering agents such as HMG-CoA reductase inhibitors (statins) are useful in controlling hyperlipidemia, and there is also some evidence that they may reduce proteinuria.

**Specialist input**

Once a diagnosis of nephrotic syndrome is made, it is important nephrology advice is sought promptly so that further investigation, and disease-specific treatment can be arranged. In a child below the age of puberty, minimal change disease is by far the most common diagnosis, and empiric treatment with prednisolone without a renal biopsy is usual practice. In contrast, in adults further specific testing is necessary to establish the precise diagnosis. Useful investigations include urine testing for haematuria, a variety of serological immunology investigations (see Table 4) and renal ultrasonography. However, a renal biopsy is usually necessary to obtain a diagnosis. However, it is important to remember that there are risks associated with a renal biopsy; uncontrollable bleeding being the most serious, but fortunately rare, complication. Therefore, before a biopsy is carried out it is important to ensure that the benefits outweigh the potential risks.

| Test | Comments |
|---|---|
| Anti-double stranded DNA antibodies | Sensitive and specific marker of lupus nephritis |
| Complement levels (C3 and C4) | Reduced in various conditions such as systemic lupus erythematosus |
| Serum and urine protein electrophoresis | Abnormal in conditions such as multiple myeloma |
| Anti-nuclear antibody (ANA) | Elevated in various autoimmune conditions including systemic lupus erythematosus. Not specific |
| Virology | HIV can cause collapsing FSGS, hepatitis B and C, can be associated with membranous nephropathy |

**Table 4. Useful Tests in Patients with Nephrotic Syndrome.**

Once a diagnosis is made, the underlying renal disease can be treated accordingly, although discussion of this aspect of management is beyond the scope of this article.

## MCQ

**1) A 60-year old man with a 15-year history of type 2 diabetes mellitus presents with peripheral oedema. Clinically his jugular venous pressure was not elevated, with no evidence of pulmonary oedema, but did have pitting peripheral oedema up to his knees. Blood test showed a serum albumin of 16 g/dL, a serum cholesterol of 7 mmol/L and a serum creatinine of 200 µmol/L. How would you investigate this patient next?**

(a) Organize an immediate renal biopsy.
(b) Arrange for an early morning urine protein creatinine ratio (PCR).
(c) Put the patient on a high protein diet.
(d) Start the patient on diuretics therapy, discharge and arrange GP follow-up.
(e) Arrange an urgent echocardiogram.

## Answers

(a) **FALSE:** Sometimes a renal biopsy is not needed (e.g., in children or patients with long-standing diabetes mellitus). Remember any invasive procedure is associated with potentially serious complications.
(b) **TRUE:** Greater than 3.5 g of proteinuria in 24 hrs is essential in establishing a diagnosis of nephrotic syndrome.
(c) **FALSE:** This patient's hypoalbuminaemia is due to renal loss of albumin, and not malnutrition. Increasing his protein intake may worsen proteinuria.
(d) **FALSE:** This patient has impaired renal function, and a possible new diagnosis of nephrotic syndrome, it may be safe to discharge the patient, but only after specialist input and an plan made regarding future investigations and follow-up.
(e) **FALSE:** Though an echocardiogram may be useful given this patients history of diabetes, its important to remember there are many other causes of peripheral oedema, clinically he doesn't have any evidence of congestive cardiac failure so an non-cardiac cause of his oedema should be thought.

**2) The patient is found to have a urine PCR of 800, and a diagnosis of nephrotic syndrome is confirmed. His HbA1c was found to be 10.7%, and an echocardiogram showed mild left ventricular hypertrophy. What is the most appropriate next step in his management?**

(a) Steroids should be started immediately once nephrotic syndrome is confirmed.
(b) Diuretics should be started to treat his peripheral oedema.
(c) Patient should now be booked for a renal biopsy.
(d) His target blood pressure should be no more than 140/90 mm Hg.
(e) Statins are not indicated in this patient.

# THE NEPHROTIC SYNDROME

Gang Xu, Peter Topham

## Answers

(a) **FALSE:** Not all conditions that cause nephrotic syndrome warrant steroid therapy. Steroid therapy itself is associated with numerous complications and should only be started after careful consideration.

(b) **TRUE:** Patients should be initially started on oral diuretics, but often may need intravenous diuretics due to intestinal oedema.

(c) **FALSE:** Though a renal biopsy is often warranted in an adult, in this case, diabetic nephropathy is the likely underlying cause. The decision to carry out a renal biopsy always needs to be carefully discussed with a senior nephrologist.

(d) **FALSE:** Blood pressure control in all patients with proteinuria, a BP target of 130/80 mm Hg should be aimed for.

(e) **FALSE:** Statins are not only useful in controlling hyperlipidemia, but they also may reduce proteinuria.

## Suggested Future Reading

1. Stephan R., Orth, M.D. and Eberhard Ritz, M.D. The nephrotic sydrome. *N Engl J Med* 1998, 338:1202–11.

2. Topham P. Nephrotic syndrome. Barratt J., Harris K., Topham P (eds.). Oxford Desk Reference Nephrology, 1st edn. NewYork: Oxford University Press 2009, 80–5.

3. Renal association; CKD eGuide, proteinuria : **http://www.renal.org/whatwedo/InformationResources/CKDeGUIDE/Proteinuria.aspx**

4. British medical journal, Best practice; Overview of nephrotic syndrome: **http://bestpractice.bmj.com/best-practice/monograph/356.html**

## Authors

**Gang Xu ST3 nephrology**
EastMidlands school of medicine,

**Peter Topham**
Honorary Consultant Nephrologist
John Walls Renal Unit
Leicester General Hospital

**The Nephrotic Syndrome.**
**Patient Management.**

# ASSESSING RENAL FUNCTION - THE eGFR EXPLAINED

Sarah Leech, Richard Fish, Karen Anthony

**Assessing Renal Function - the eGFR Explained. Good Clinical Care.**



Mrs X is a 62-year old, white, non–insulin-dependent patient with diabetes. She was diagnosed with diabetes in 1992. Her medical history includes hypertension and asthma. She takes ramipril 5 mg daily. She is a non-smoker and does not drink alcohol. She is attending diabetic clinic for the first time. Your consultant asks you for a thorough review, including evaluation of her renal function.

## Which aspects of renal function can be assessed?

**Tubular Function**

Kidney tubules are involved with maintaining electrolyte and fluid balance.

## Hormonal Regulation

The kidneys play a vital role in vitamin D regulation, secrete erythropoietin to stimulate red blood cell production and are key organs in the renin-angiotensin-aldosterone system relating to blood pressure control.

## Acid-Base Balance

The kidney regulates bicarbonate and hydrogen ion balance by adjusting the extent to which these are excreted.

**Proteinuria**

Under normal conditions, less than 150 mg protein should appear in the urine during a 24-hr period, approximately 30 mg of which is albumin. Microalbuminuria refers to the appearance in the urine of between 30 mg and 300 mg albumin in 24 hrs with urinary concentrations exceeding this usually referred to as proteinuria. The term 'microalbuminuria' is somewhat confusing as it seems to imply an alteration in the size of albumin itself, when in fact all the term means is that slightly more albumin than normal is appearing in the urine.

A comprehensive overview of proteinuria is beyond the scope of this article. However, it is extremely important to evaluate as microalbuminuira is a marker of early renal disease and also correlates with increased cardiovascular risk[1].

Whilst a variety of techniques exist to measure all these aspects of renal function, the most important parameter to assess is the glomerular filtration rate (GFR). The rest of this article therefore concentrates on how this is achieved in the clinical setting.

**The GFR is the volume of plasma that is filtered per unit time by all of the functioning glomeruli put together. It can be used to estimate the amount of adequately functioning renal tissue and is usually expressed in millilitres per minute.**

## How can the GFR be assessed?

It is impossible to directly measure GFR. Instead we somehow need to find a way of indirectly measuring how much plasma is being filtered (crossing the glomerular filtration barrier into the urinary space) each minute. We use the idea of 'clearance'.

Clearance can be a difficult concept to grasp. It is defined as the volume of plasma 'cleared' of a substance per unit of time. Of course this is not an actual physical volume - rather a hypothetical amount (as the entire plasma concentration of a substance decreases as it gets progressively removed). However, if the only mechanism by which the plasma is cleared of a substance is by urinary excretion, clearance can be used to determine renal function.

Imagine that we can measure the plasma concentration of a substance or 'marker' and know that its production remains fairly constant. If the marker is eliminated from the body entirely by the kidneys, then we know that any alterations in its plasma concentration must be due to worsening renal function. Furthermore, if it is freely filtered at the glomerulus and travels along the nephron unchanged (i.e., it is not reabsorbed, secreted or metabolized by the tubules) then a rise in plasma concentration must mean a fall in the GFR. This is the basis behind using creatinine as a marker of renal function.

Creatinine is an end product of muscle catabolism (with some also being derived from the diet). It is released into the circulation at a constant rate and freely filtered at the glomerulus. It is not reabsorbed at all during its passage through the nephron. About 10% of the creatinine appearing in the urine is due to secretion from proximal tubular cells, and therefore urinary creatinine clearance is not identical to GFR (see below)[2]. However, because it is cheap and easy to measure, in most circumstances creatinine is reliable enough to give a crude indication of renal function.

# ASSESSING RENAL FUNCTION - THE eGFR EXPLAINED

Sarah Leech, Richard Fish, Karen Anthony

**Assessing Renal Function - the eGFR Explained. Good Clinical Care.**

There are various methods of using creatinine to assess GFR. The most straightforward is simply to look at the plasma concentration. Creatinine plasma levels and GFR demonstrate an inverse relationship (as you would expect given that nearly all creatinine clearance depends upon functioning glomeruli). However, there are many problems with this. As previously mentioned, creatinine comes from muscle and therefore subjects with more muscular builds will have naturally higher plasma creatinine concentrations (a male body builder could have the same renal function as a female gymnast, but the creatinine concentrations could differ by 100 umol/L). Another problem, as we have seen already, is that not all creatinine is filtered by the glomerulus. The amount secreted by the proximal tubular cells becomes more significant as the number of viable glomeruli decreases. Additionally a small amount is degraded by bowel flora (an effect which also increases in significance as GFR falls)[1]. A number of drugs can also interfere with these two mechanisms (see Table 1).

## Creatinine Clearance

An alternative technique is to calculate the urinary creatinine clearance over 24 hours by applying the following equation:

$$\text{Creatinine clearance} = \frac{[\text{Creatinine}]\ \text{Urine Volume}}{[\text{Creatinine}]^{\text{Plasma}}}$$

This involves knowing the mean plasma concentration of creatinine (usually one blood test will suffice during the collection in the steady state scenario) and collecting urine for 24 hrs. The main pitfall to this is that it requires a very accurate urine collection which is technically difficult and prone to inaccuracies. Also, renal tubular secretion of creatinine leads to more appearing in the urine than is filtered (giving an overestimation of GFR). For these reasons, coupled with the advent of new mathematical formulae to estimate GFR (see below), 24-hr urine collections are not performed very frequently in current practice any more.

## Estimated GFR (eGFR)

There has been much interest in recent years to develop mathematical equations based upon serum creatinine results, which also account for patient variables in order to estimate GFR. They require no urine collection whatsoever.

The most commonly used formula was developed using information from the Modification of Diet in Renal Disease (MDRD) study[3,4]. This looked at a large number of patients with renal impairment and the data obtained was analysed in order to devise a way to estimate the GFR based upon certain parameters. There are currently four variables included in the formula, namely the serum creatinine level, patient age, race and gender.

It is becoming normal practice throughout the UK now to report the eGFR alongside laboratory serum creatinine measurements. Although laboratories now readily provide an eGFR, it is still important to understand the factors involved in the calculation as this will aid interpretation of reported results and clinical situations in which they may not be so useful.

**The MDRD equation is given below:**

eGFR = 186.3 x Serum creatinine$^{-1.154}$ x Age$^{-0.203}$ x 1.210 (if black) x 0.742 (if female). This equation uses creatinine in units of mg/dL. It is usual practice in the UK to quote serum creatinine in units of umol/L. To convert umol/L into mg/dL you simply divide by 88.4.

**Mrs X has blood tests taken.**
**Her serum creatinine was measured at 178 umol/L.**



# ASSESSING RENAL FUNCTION - THE eGFR EXPLAINED

Sarah Leech, Richard Fish, Karen Anthony

## What is her eGFR based on the MDRD formula?

**For Mrs X:eGFR =**

$186.3 \times (178/88.4)^{-1.154} \times 62^{-0.203} \times 0.742 = 26.7$ ml/min

## Is there a more accurate way of measuring the GFR?

Isotopic techniques are generally considered to be the most accurate way available in clinical practice to measure GFR. The most widely used method involves a single injection of 51Cr-EDTA with regular venous sampling thereafter[1]. These are expensive and time-consuming procedures and are reserved for clinical circumstances when it is necessary to obtain an accurate measure of GFR (e.g., when a subject is being considered as a live organ donor).

Some weeks later, Mrs X was admitted to hospital having been unwell with diarrhoea and vomiting for a number of days. She had not been taking much orally and noticed she had been passing much less urine. Upon admission to hospital her serum creatinine concentration was 360 umol/L.

## How would you estimate her level of renal impairment now?

The methods of estimating GFR mentioned above are all dependent on the patient being in a 'steady state', i.e., their production of creatinine is balanced by their urinary clearance. However, they cannot be used in the setting of rapidly changing GFR.

To illustrate this, consider the hypothetical situation of both renal arteries suddenly becoming totally blocked. Actual GFR would be zero (no blood at all would physically be filtered as it couldn't pass the blockages). However, the serum creatinine concentration an hour after this insult would not be much higher than it was an hour before, and would simply increase over the coming days. You can see that to just apply the various formulae would give a very different estimation of GFR to the real situation (of zero).

In the setting of acute renal injury (or acute on chronic injury), the best guide is to look at the trend in the creatinine levels coupled with the urine output. Clearly a patient whose serum creatinine concentration doubles each day and is passing no urine, has very little being filtered at that point in time. Alternatively, a level rising by only a few points each day in a uric patient would imply some ongoing filtration. In these situations it is impossible to know exactly what the GFR is, but adopting this approach allows a reasonable estimate to be made and therefore permits appropriate clinical decisions (e.g., regarding drug dosing) to be reached.

## Are there any other problems with using the eGFR equation?

**Patients with near normal renal function**

One of the main criticisms of the eGFR calculation raised from the MDRD study was that the formula was inaccurate at calculating the eGFR when the actual renal function was near to normal. This could lead to slightly low GFR estimates being over-interpreted. A new recently published formula from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)[5] has tried to overcome this particular flaw and found that their equation is more accurate, especially when used in those patients with a higher GFR. This is likely to gain more recognition in the future.

**Remember—it's just an ESTIMATE!**

The formula is used purely to give an idea of a patient's renal function. Using this technique 90% of patients will have a 'true' GFR within 30% of their 'eGFR'[2].

**It isn't validated in all patient groups**

The eGFR formula is not validated for use in children (age <18) and in pregnant women. Also the original MDRD study was based on black and white American patients. Therefore it isn't strictly applicable to all ethnic groups (in practice this point usually gets forgotten!).

**Issues with body mass**

The calculation is still based around serum creatinine concentrations, and hence all the factors already mentioned which impact on this parameter will influence the eGFR result. Caution also needs to be applied when assessing very elderly patients for this reason.

| Factors that Increase or Decrease Serum Creatinine | |
|---|---|
| ↑ | ↓ |
| Younger age and male sex | Older age and female sex |
| Large muscle mass, vigorous exercise | Protein-restricted diets, e.g., vegetarian diets |
| Drugs that competitively inhibit creatinine secretion, e.g., trimethoprim, cimetidine, amiloride and spironolactone. | Amputations or muscle wasting diseases |

**Table 1. Factors Affecting Serum Creatinine Levels (adapted from Bagshaw SM and Gibney M6).**

# ASSESSING RENAL FUNCTION - THE eGFR EXPLAINED

Sarah Leech, Richard Fish, Karen Anthony



**Assessing Renal Function - the eGFR Explained. Good Clinical Care.**

Mrs X was diagnosed with viral gastroenteritis and recovered well with intravenous fluids and antiemetics. On discharge from hospital, her creatinine was 180 umol/L. She was followed up in clinic 4 weeks later.

You review her historical blood results and see her eGFR was 58 ml/min in 2002. In 2004 it had dropped to 46 ml/min and was 39 ml/min in 2006. By 2008 it had dropped to 29 ml/min. She asks you if she has CKD.

## What is chronic kidney disease?

CKD is the irreversible, progressive decline in renal function over a period of months to years. Diabetes is the most common cause in the UK[7]. It is now routinely classified into stages according to GFR estimates (see Table 2).

Patients with eGFR over 60 should not be classed as having CKD unless they have 'evidence of kidney damage'. Such evidence could include findings of haematuria or proteinuria, known genetic diseases such as polycystic kidney disease, histological abnormalities or structurally abnormal kidneys (on imaging).

After obtaining an 'abnormal' eGFR result, it is important to repeat the test within 2 weeks to ensure that it isn't an acute deterioration[8].

| CKD Stage Normal | eGFR (ml/min/ 1.73 m$^2$) | Additional Features |
|---|---|---|
| 1 | >90 | No evidence of kidney disease |
| 2 | >90 | Evidence of kidney damage |
| 3a | 60-89 | Evidence of kidney disease |
| 3b | 45–59 | |
| 4 | 30–44 | |
| 5 | 15–29 | |
| | <15 | Approaching end-stage disease. Established renal failure |

**Table 2. Classification of Chronic Kidney Disease According to eGFR (adapted from NICE guidelines[8]).**

Using eGFR in this way has several advantages. Patients with serum creatinine concentrations previously thought to be 'normal' are now being identified as having renal impairment much earlier. This leads to closer monitoring and permits more timely intervention and specialist referral. Secondly, plotting graphs of eGFR over time allows clinicians to estimate when renal replacement therapy may become necessary and thus enables planning to be undertaken well in advance.

Mrs X's eGFR is falling by approximately 4 ml/min/year. It is likely that she will reach CKD stage 5 in 2–3 years time. It will then be necessary to start planning for renal replacement therapy.

## Questions – True or false?

**1. The following would be expected to cause a rise in the plasma creatinine concentration:**

(a) Trimethoprim use
(b) Uncomplicated above knee amputation
(c) Weight training
(d) Becoming a vegan
(e) Cimetidine use

**2. Regarding the MDRD equation for estimating glomerular filtration rate:**

a. It takes into account the age of the patient
b. It doesn't require a serum creatinine value
c. It is validated in pregnancy
d. It can be used in the setting of acute kidney injury
e. It is used to define the stages of chronic kidney disease

**3. Regarding chronic kidney disease:**

a. Patients with a serum creatinine value within the normal reference range of the reporting laboratory cannot have CKD
b. A patient with an eGFR of 35 ml/min on two separate tests taken 3 months apart has CKD stage 3
c. Patients with CKD 3 need to have plans made for renal replacement therapy
d. Techniques used to estimate GFR tend to be more accurate at higher values
e. Patients with CKD 5 are reaching end-stage renal disease

# ASSESSING RENAL FUNCTION - THE eGFR EXPLAINED

Sarah Leech, Richard Fish, Karen Anthony

## Answers

**1A. TRUE.** 10–20% of creatinine excretion is due to proximal tubular cell secretion. Trimethoprim blocks this effect which causes a rise in serum creatinine concentration. Trimethoprim DOES NOT cause a change in GFR.

**1B. FALSE.** Provided the operation is uncomplicated (e.g., no infectious or haemodynamic consequences which could effect renal function) then by amputating a limb, the subject is losing a substantial amount of muscle. Therefore you would expect creatinine levels to fall.

**1C. TRUE.** Training will increase muscle bulk and hence serum creatinine levels.

**1D. FALSE.** As much as 25% of serum creatinine is as a result of dietary meat intake.

**1E. TRUE.** This is due to the same mechanism described for trimethoprim.

**2A. TRUE.** The equation is eGFR = 186.3 x serum creatinine$^{-1.154}$ x Age$^{-0.203}$ x 1.210 (if black) x 0.742 (if female). This equation uses creatinine in units of mg/dL. It is usual practice in the UK to quote serum creatinine in units of umol/L. To convert umol/L into mg/dl you simply divide by 88.4.

**2B. FALSE.** See 2A. As a serum creatinine value is required, factors effecting this parameter will influence the eGFR result.

**2C. FALSE.**
The equation is not validated in pregnancy. It is also not validated in the very young and certain ethnic groups.

**2D. FALSE.** Equations to estimate GFR assume a steady state. When creatinine levels are changing rapidly, GFR can only really be estimated clinically by looking at the trend in creatinine concentrations and assessing urine output.

**2E. TRUE.** CKD is classified into 5 stages according to eGFR results. See text for more details.

**3A. FALSE.** With the introduction of equations to estimate GFR an increasing number of patients with creatinine levels traditionally thought of as 'normal' are being recognised as having impaired function.

**3B. TRUE.** Assuming the blood results do not represent acute renal injury (and we are told here that things are stable over a number of months) then CKD stage 3 is defined as an eGFR between 30 and 59 ml/min.

**3C. FALSE.** Many patients with CKD stage 3 will remain stable at this level for many years. Renal replacement therapy plans are usually made as patients get close to CKD stage 5 (i.e., eGFR reaches around 15 ml/min).

**3D. FALSE.** Most equations devised thus far are more inaccurate at estimating GFRs in the 'normal' range. New improved formulae are being developed to try and address this issue.

**3E. TRUE.** These patients need to be counselled about the potential management options (dialysis, transplantation or supportive care).

## References

1. Steddon S., Ashman N., Chesser A. and Cunningham J. (eds.). Clinical Assessment of the Renal Patient. *Oxford Handbook of Nephrology and Hypertension,* 1st edn. New York : Oxford University Press 2006; Chapter 1 pages 18–48.
2. Gul A., Gilbert S.J. and Levey A.S. Assessment of Renal Function. In: Freehally J., Floege J. and Johnson R.J. (eds.). Comprehensive Clinical Nephrology, 3rd edn. Philadelphia : Mosby Elsevier 2007; Chapter 3, pp. 27 – 34.
3. Levey A.S., Bosch J.P., Brewer L. J., Greene T., Rogers N. and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. *Ann Int Med* 1999;130: 461–70.
4. Levey A.S., Coresh J., Greene T., et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Int Med* 2006;145: 247–254.
5. Levey A.S., Stevens L.A., Schmid C.H. et al. A new equation to estimate glomerular filtration rate. *Ann Int Med* 2009; 150:604–12.
6. Bagshaw S.M. and Gibney M. Conventional markers of kidney function. *Crit Care Med* 2006; 36(4): 152–58.
7. Feest T. Epidemiology and causes of chronic renal failure. *Medicine* 35(8): 438–41.
8. National institute of clinical excellence. Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (NICE clinical guideline 73) September 2008. Available at URL: **http://www.nice.org.uk/nicemedia/pdf/CG073FullGuideline.pdf Accessed December 9th 2009.**

## Authors

**Sarah Leech Foundation year 1 doctor**

**Richard Fish, ST4 in Nephrology**

**Karen Anthony Consultant in Diabetes and Endocrinology**

## Correspondence

**Sarah Leech**
The Whittington Hospital NHS Trust
Magdala Avenue, N19 5NF

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

**Nutrition in Kidney Disease.**
**Good Clinical Care.**

## Introduction

There is an increasing incidence of chronic kidney disease (CKD) worldwide [1]. Early identification and treatment of CKD is vital to help delay progression to end-stage renal disease (ESRD). This is because of he impact it can have on quality of life, survival outcomes and the financial implications for the NHS. Nutrition is an important but frequently overlooked aspect of the disease. Protein energy malnutrition is prevalent in 30%–70% of CKD patients [2] and predicts morbidity and mortality [3–4]. Nutritional status often starts to decline from CKD stage 4 (eGFR <30 ml/min) and becomes clinically significant by the time patients reach ESRD. Important nutritional considerations from CKD stage 4 onwards involve assessing protein and calorie intake and determining whether or not dietary restriction of potassium, phosphate, salt and fluid are indicated. Here, we provide a brief review of nutrition in CKD for Foundation Year Doctors.

## Malnutrition in Chronic Kidney Disease

At present, depending on the population studied and the methodology used, 30%–70% of patients with ESRD are malnourished [5]. Aetiology for malnutrition in renal disease is multi-factorial [6–7] (Table 1). Malnutrition in CKD is clearly associated with increased morbidity and mortality [8] [4]. In the 1960s when dialysis was not widely available, patients were often advised to restrict their protein intake in order to slow the progression of CKD [9] [10]. At present the value of such treatment remains controversial with some studies showing only a small benefit [11]. Although some studies have shown that low-protein diet is safe, clinicians are not willing to take chance to allow malnutrition by restricting protein intake [12]. A recent Cochrane review on the topic concluded that a nutritional intervention should be proposed to patients with moderate CKD, including a reduction in protein intake [13]. The authors also felt that the decision for or against protein restriction should be an individual choice [13].

| Aetiology | Contributory Factors |
|---|---|
| Inadequate nutritional intake | · Nausea, vomiting, anorexia (for example secondary to uraemia)<br>· Fatigue, psychosocial issues (depression, loneliness, poverty)<br>· Dietary restrictions<br>· Frequent hospitalisations<br>· Inadequate dialysis |
| Increased nutritional requirements and losses | · Protein losses (6 to 12 g of amino acid per HD session, 6 to 12 g protein through PD in a day)<br>· Catabolic and chronic inflammatory state due to dialysis<br>· Co- morbidities<br>· Chronic infection |

**Table 1. Factors Contributing to Malnutrition in Chronic Kidney Disease.**



**Fig. 1. Malnutrition in a CKD patient with polycystic kidney disease. Note muscle wasting over the chest and arm and swollen abdomen due to grossly enlarged native kidneys (published with written consent).**

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

**Dietetic interventions aim to maintain or improve the nutritional status of the patient by achieving recommended protein and calorie requirements. To avoid malnutrition, current guidelines recommend a daily intake of these as enlisted below:**

- For pre-dialysis patients: 35 kcal/kg ideal body weight (IBW)/day for those who are younger than 60 years old and 30 kcal/kg IBW/day for individuals who are 60 years of age or older plus 0.75–1.0g protein/kg IBW/day [14]

- For dialysis patients: 35 kcal/kg IBW/day for those who are younger than 60 years old and 30 kcal/kg IBW/day for individuals who are 60 years of age or older plus 1.2–1.5g protein/kg IBW/day [14]

If a patient is not meeting his/her estimated nutritional requirements, dietetic advice can be given to increase meal and snack frequency and fortify food. Nutritional supplements may also need to be considered if oral intake remains inadequate or if weight loss is clinically significant or continues. A huge variety of supplements are available. The choice of supplement will depend on the patient's biochemistry, personal preferences and co-morbidity, for example diabetes. Of note, supplements improve serum albumin and dietary intake but whether this translates into improved clinical outcomes is less clear [15]. If oral diet and supplementation is inadequate to meet requirements, then enteral feeding may be considered, especially in inpatients. Intradialytic parenteral nutrition [16] may also be considered in selected cases although there are no adequately powered studies to show that this treatment actually improves clinical outcomes [17].

Whilst malnutrition is a major concern in CKD, obesity should not be ignored. It is clear that, concurrent with the emerging epidemic of type II diabetes and CKD, patients who newly start dialysis are becoming more obese [18]. However, while the role of obesity as an independent risk factor in the general population remains undisputed, it is much less clear in renal patients. Several studies have demonstrated a survival advantage for dialysis patients with an high BMI compared to those with normal or low BMI [19–20]. However, high BMI has been shown to be associated with inferior outcomes after renal transplantation [21], and most centres now decline candidates with a BMI above 35 for renal transplantation and those above 30 for simultaneous kidney-pancreas transplantation [22]. At present, the optimum BMI of a patient on dialysis remains unknown. Weight management advice is usually offered to those not meeting the BMI cutoff for the transplant list [23] and those with type II diabetes or who are clinically obese.

## Nutritional Assessment in Chronic Kidney Disease

There is no single ideal nutritional marker or screening tool available to assess the nutritional status of patients with CKD [14]. Serum albumin has often been used as a nutritional guide. Moreover, several studies have shown that low albumin is strongly associated with increased cardiovascular disease and mortality [24] in the dialysis population. However, numerous other factors including inflammation, the degree of proteinuria and external protein losses (for example on dialysis) also influence the serum albumin levels [25], thus making it an unreliable marker of nutritional status when considered in isolation.

A variety of tools are available to help assess patients nutritional status in clinical practice. Simple measurements can include weight, height, body mass index and the percentage of weight loss over time. Additional anthropometric measurements may also be employed such as waist circumference, mid-arm muscle circumference, skin fold thickness and handgrip strength. The Malnutrition Universal Screening Tool (MUST) [26] is a simple validated screening tool increasingly being used in hospitals and the community to help identify patients at risk of malnutrition. The Subjective Global Assessment (SGA) [27] is another tool which less commonly used. It is also important when monitoring weight that fluid status (particularly pre- and post-dialysis weight) and the presence of large kidneys with multiple cysts (in adult polycystic kidney disease) are taken into account.

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

## Nutritional Requirements in Acute Kidney Injury

Acute kidney injury (AKI) is defined as the abrupt loss of kidney function that results in the retention of urea and other nitrogenous waste products and in the disturbance of extracellular volume and electrolytes. Several sets of criteria are in use concurrently, but the commonly used criteria diagnose AKI, for example, after a twofold increase in the serum creatinine [28]. In critically ill patients, intensivists and nephrologists have traditionally assumed that the presence of AKI increases energy requirements to 35 or even 40 kcal/kg/day. However, convincing studies with hard end point data are still lacking [29], and a less aggressive approach has been advocated more recently. In the absence of robust data a pragmatical approach in non-ICU patients would be to screen patients and refer to a renal specialist dietician if indicated. A protein intake up to 2.5 g/kg/d may be needed to achieve positive nitrogen balance in patients treated with continuous renal replacement [30]. Of course, dietary restrictions need to be observed as described below, particularly regarding potassium.

## Dietary Restrictions

### Phosphate

Chronic Kidney Disease-Mineral Bone Disorder (CKD-MBD) is a systemic disorder which usually presents from CKD stage 4 onwards. It is associated with disturbances in serum calcium and phosphate homeostasis, serum parathyroid hormone (PTH) and with abnormalities in bone turnover and growth. The main long-term consequence of an increased calcium-phosphate product is vascular and soft tissue calcification, leading to cardiovascular disease [31, 32]. Elevated serum phosphate therefore associates with morbidity and mortality in dialysis patients [33–35] and also, interestingly, with cardiovascular disease in individuals with normal renal function [36]. The serum phosphate is influenced by dietary intake, renal function and dialysis dose. The UK Renal Association guidelines on CKD-MBD have just been re-drafted and now suggest a target serum phosphate of 0.9 and 1.5 mmol/l in pre-dialysis and between 1.1 and 1.7 mmol/l in dialysis patients [37]. New international guidelines for CKD-MBD have also been published [38], which recommend maintaining the serum phosphate in the normal range in pre-dialysis patients and lowering elevated phosphate levels towards the normal range in patients on dialysis, without proposing specific target levels [38].

Phosphate control is usually achieved through a combination of dietary restriction (Table 2) and the use of oral phosphate binders. In dialysis patients, the dialysis adequacy may be checked and the dialysis dose can be increased as well. There are two main types of binders: calcium-based binders (e.g., calcium acetate, calcium carbonate) and calcium-free binders (e.g., sevelamer and lanthanum carbonate). The choice of binder will depend on a combination of factors, including biochemistry, associated medical conditions, patient tolerance and preference, meal pattern and the cost (calcium-free binders tend to be more expensive). It is crucial to maintain adjusted serum calcium levels in the normal range [38]. Compliance with phosphate binders is notoriously difficult, and it is often influenced by tolerance, side effects, timing and dosage. Patients may require anything from 1 to 18 tablets daily and must remember to take with each phosphate containing meal or snack. In addition, as many patients are asymptomatic of a high-serum phosphate it is difficult for them to realise the importance of taking phosphate binders.

Most of the phosphate rich foods (Table 2) are naturally high in protein. Dietary advice has to be carefully balanced in order to ensure optimum protein intake whilst restricting phosphate particularly in dialysis patients who have a higher protein requirements. Therefore strict phosphate restriction will not be indicated if a patient is severely malnourished as it can siginificantly limit their protein intake.

| Foods High in Potassium | Foods High in Phosphate | Foods High in Salt |
|---|---|---|
| Potatoes, chips, potato crisps, jacket potatoes | Milk, milky puddings, milk shakes, condensed / evaporated / dried milk | Tinned foods |
| Spinach, tomatoes, bananas, oranges, grapes, kiwi fruit | Eggs, cheese | Crisps and salted nuts |
| Fruit juices and coffee | Meat, oily fish / shellfish | Cheese |
| Pulses | Chocolate, fudge, nuts | Soups |
| All dried fruits and nuts | Malted and chocolate drinks | Ready meals, takeaways |
| Chocolate | Pulses | Processed, smoked or cured meats and fish |
| Milk, milky puddings, milkshakes, condensed / evaporated / dried milk | | Condiments, e.g., bottled sauces, Bovril, Marmite, soya sauce, stock cubes, monosodium glutamate, Worcester sauce. |
| | | Note: All salt substitutes should be avoided, e.g., Lo-Salt, Selora, Ruthmol |

**Table 2. Foods Rich in Potassium, Phosphate and Salt**

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

### Potassium

As renal function declines, the ability of the kidneys to maintain normal serum potassium is reduced, leading to hyperkalemia. Severe hyperkalemia is associated with cardiac arrhythmias and death [39–41] and will usually require prompt medical intervention. Other causes of hyperkalaemia include inadequate dialysis, metabolic acidosis, medications (angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor antagonists and spironolactone), blood transfusions, poor glycaemic control and constipation. These factors should always be considered before initiating dietary potassium restriction as a low-potassium diet can compromise patients vitamin, mineral and fibre intakes and can be difficult to adhere to. Potassium-binding resins (Kayexalate™, Resonium™) can be used as a temporary measure in inpatients with severe hyperkalemia. If a low potassium diet is indicated, patients will be advised on ways to reduce their intake of potassium rich foods (Table 2), use suitable cooking methods, whilst encouraging a well-balanced diet and promoting the inclusion of appropriate fruit and vegetables.

Hypokalaemia although less common, can occur for several reasons, including losses on dialysis, inadequate dietary intake, medications (e.g., diuretics), diarrhoea and vomiting. A recent study has shown that hypokalemia increases mortality in patients with CKD and heart failure [42]. Treatment of hypokalaemia will depend on the severity and cause; medical management is usually indicated when serum levels fall below 3.0mmol/l whereas dietary intervention may be more appropriate if serum levels are between 3.0 and 3.5 mmol/l.

**Fig. 2. Potassium-rich food items.**

### Salt and water

Hypertension is prevalent in more than 80% patients with CKD [43] and accelerates the progression towards ESRD in addition to increasing the risks of cardiovascular disease [44]. Sodium retention is a major contributing factor for the development of hypertension in CKD and also blunts the response to antihypertensive agents [45]. The average western diet contains 9–12 g of salt per day, while current guidelines recommend an intake of less than 6 g per day. This involves avoidance of salt at the table, gradually reducing salt to a minimum in cooking and limiting salt-rich foods (Table 2). Instead of using salt, patients are encouraged to use herbs, spices and seasonings to flavour food. Salt substitutes should be avoided for they usually contain Potassium.

Fluid restrictions may be indicated in some renal patients, particularly those on dialysis if the urine output declines or ceases. A high salt intake is associated with increased thirst and leads to poor compliance with fluid restrictions. Therefore, salt and fluid restrictions should always be considered together. Non-compliance with these restrictions can lead to acute pulmonary oedema and emergency dialysis. Fluid allowances in CKD patients are usually based on 500–750 ml (insensible losses) plus the previous day's urine output. Fluid intakes should take into account the contribution of fluids not only from drinks, but also from supplements, food and medications.

## The Role of the Renal Dietician

Renal dietician work with CKD patients to assess their nutritional status and dietary intakes on an individual basis, using subjective and objective tools. Patients are often reviewed and monitored at multidisciplinary renal clinics. The aim is to ensure nutritional requirements are met whilst preventing or treating complications such as CKD-MBD, electrolyte disturbances, hypertension, fluid overload, malnutrition and obesity.

Initial dietetic asessement involves gathering relevant anthropometric, medical, social and dietary information with specific consideration given to energy, protein, potassium, phosphate, salt and fluid intakes. Relevant medications such as phosphate binders, vitamin D, diuretics, anti-hypertensive agents, proton pump inhibitors and patient symptoms such as nausea, vomiting, constipation or reflux are also taken into account.

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

An individualized care plan is set in agreement with the patient which should be achievable, specific, measurable and realistic, taking into account social,cultural and religious factors (e.g. ,the fasting period in Abrahmic patients). Patients are offered practical advice, tips and a variety of leaflets and online resources are available with suggestions on recipes, meal ideas, snacks and guides to eating out. Monitoring and regular review are extremely important as the patient's clinical condition and the priorities of medial and dietetic treatment may change over time.

It is vital that patients understand the reasons for dietary interventions, the advantages of compliance and most importantly the dangers of non-compliance. Education and patient empowerment is fundamental and in our experience more motivated patients benefit greatly from having access to their own laboratory results.

## Conclusion

Malnutrition is highly prevalent in our increasingly elderly patients with CKD and the presence of malnutrition predicts morbidity as well as mortality. Nurses and doctors working with CKD patients should screen for malnutrition as well as for obesity and the patient should be referred to a renal dietician when indicated. Screening can help to identify, prevent and treat malnutrition or obesity. In addition, many patients with advanced CKD require restrictions as to their daily intake of potassium, phosphate, salt and fluid. Phosphate restriction and treatment with phosphate binders are crucial in the treatment of CKD-MBD, which is a major factor in the development of vascular calcification and cardiovascular disease in these patients. Patients often find long-term compliance with what can be a complex dietary regimen difficult to sustain and often report that it impacts on their quality of life. The nutritional needs of patients may also change over time as their CKD progresses or improves, and dietary restrictions are advised only when necessary. In addition, all dietary restrictions must be balanced against the risk of malnutrition. National CKD guidelines emphasize the multidisciplinary approach to the disease, of which specialist renal dieticians are an integral part as they are best placed to conduct a nutritional assessment, offer dietetic advice and create individual nutritional care plans. Regular dietetic review, monitoring and encouragement is essential to help patients to adhere to their nutritional care plans. Finally, it is noteworthy that evidence on many aspects of nutrition in CKD is lacking. Adequately powered studies with outcome data should therefore be encouraged.

## References


1. Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. *Am J Kidney Dis* 2005, 45(1): 201–08.
2. Aparicio M, Cano N, Chauveau P, et al. Nutritional status of haemodialysis patients: A French national cooperative study. French Study Group for Nutrition in Dialysis. *Nephrol Dial Transplant* 1999, 14(7): 1679–86.
3. Fung F, Sherrard DJ, Gillen DL, et al. Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients. *Am J Kidney Dis* 2002, 40(2): 307–14.
4. Owen WF, Jr., Lew NL, Liu Y, et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. *N Engl J Med* 1993, 329(14): 1001–06.
5. Thunberg BJ, Swamy AP, Cestero RV. Cross-sectional and longitudinal nutritional measurements in maintenance hemodialysis patients. *Am J Clin Nutr* 1981, 34(10): 2005–12.
6. Mitch WE, Maroni BJ. Factors causing malnutrition in patients with chronic uremia. *Am J Kidney Dis* 1999, 33(1): 176–79.
7. Chazot C, Laurent G, Charra B, et al. Malnutrition in long-term haemodialysis survivors. *Nephrol Dial Transplant* 2001, 16(1): 61–9.
8. Germain M, Harlow P, Mulhern J, et al. Low protein catabolic rate and serum albumin correlate with increased mortality and abdominal complications in peritoneal dialysis patients. *Adv Perit Dial* 1992, 8: 113–5.
9. Kluthe R, Quirin H, Oechslen D. On the prognosis of advanced chronic kidney insufficiency under a strict low protein special diet ("potato-egg diet"). *Arch Klin Med* 1968, 214(3): 273–85.
10. Giovannetti S, Maggiore Q. A low-nitrogen diet with proteins of high biological value for severe chronic uraemia. *Lancet* 1964, 1(7341): 1000–03.
11. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med* 1994, 330(13): 877–84.
12. Aparicio M, Chauveau P, De Precigout V, et al. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet. *J Am Soc Nephrol* 2000, 11(4): 708–16.
13. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. In: Cochrane Database of *Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd; 2009.
14. Kopple JD. National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. *Am J Kidney Dis* 2001, 37(1 Suppl 2): S66–70.
15. Stratton RJ, Bircher G, Fouque D, et al. Multinutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kidney Dis* 2005, 46(3): 387–405.
16. Dukkipati R, Kalantar-Zadeh K, Kopple JD. Is there a role for intradialytic parenteral nutrition? A review of the evidence. Am J Kidney Dis 2010, 55(2): 352–64.
17. Bossola M, Tazza L, Giungi S, et al. Artificial nutritional support in chronic hemodialysis patients: A narrative review. *J Ren Nutr* 2010, 20(4): 213–23.

# NUTRITION IN KIDNEY DISEASE

Cheralathan Arunachalam, Jenny Stopford, Julia Ireland, Alexander Woywodt

18. Mau LW, Liu J, Qiu Y, et al. Trends in patient characteristics and first-year medical costs of older incident hemodialysis patients, 1995-2005. *Am J Kidney Dis* 2010, 55(3): 549–57.
19. Leavey SF, McCullough K, Hecking E, et al. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2001, 16(12): 2386–94.
20. Chazot C, Gassia JP, Di Benedetto A, et al. Is there any survival advantage of obesity in Southern European haemodialysis patients? *Nephrol Dial Transplant* 2009, 24(9): 2871–76.
21. Cheung CY, Chan YH, Chan HW, et al. Optimal body mass index that can predict long-term graft outcome in Asian renal transplant recipients. *Nephrology (Carlton)* 2010, 15(2): 259–65.
22. Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. *Am J Kidney Dis* 2010, 56(1): 143–56.
23. MacLaughlin HL, Cook SA, Kariyawasam D, et al. Nonrandomized trial of weight loss with orlistat, nutrition education, diet, and exercise in obese patients with CKD: 2-year follow-up. *Am J Kidney Dis* 2010, 55(1): 69–76.
24. Beddhu S, Kaysen GA, Yan G, et al. Association of serum albumin and atherosclerosis in chronic hemodialysis patients. *Am J Kidney Dis* 2002, 40(4): 721–27.
25. Kaysen GA, Rathore V, Shearer GC, et al. Mechanisms of hypoalbuminemia in hemodialysis patients. *Kidney Int* 1995, 48(2): 510–16.
26. Stratton Rj Fau - King CL, King Cl Fau - Stroud MA, Stroud Ma Fau - Jackson AA, et al. 'Malnutrition Universal Screening Tool' predicts mortality and length of hospital stay in acutely ill elderly. (0007–1145 (Print)).
27. Enia G Fau - Sicuso C, Sicuso C Fau - Alati G, Alati G Fau - Zoccali C, et al. Subjective global assessment of nutrition in dialysis patients. (0931–0509 (Print)).
28. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8(4):R204–12.
29. Gervasio JM, Cotton AB. Nutrition support therapy in acute kidney injury: distinguishing dogma from good practice. Curr Gastroenterol Rep 2009, 11(4): 325–31.
30. Brown RO, Compher C, Parenteral ASf, et al. A.S.P.E.N. Clinical Guidelines. *JPEN-Parenter Enter* 2010, 34(4): 366–77.
31. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006, 69(11): 1945–53.
32. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis* 2004, 44(5 Suppl 2): 34–8.
33. Ketteler M, Gross ML, Ritz E. Calcification and cardiovascular problems in renal failure. *Kidney Int Suppl* 2005(94):S120–27.
34. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol* 2004, 15(8): 2208–18.
35. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. *J Am Soc Nephrol 2005,* 16(2): 520–28.
36. Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. *Arch Intern Med 2007,* 167(9): 879–85.
37. UK Renal Association Guidelines on CKD-Mineral and Bone Disorders (CKD-MBD). Final draft (September 2010) [**http://www.renal.org/Clinical/GuidelinesSection/CKD-MBD.aspx]**
38. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). *Kidney Int Suppl* 2009(113):S1–130.
39. Kovesdy CP, Regidor DL, Mehrotra R, et al. Serum and dialysate potassium concentrations and survival in hemodialysis patients. Clin J Am Soc Nephrol 2007, 2(5): 999–1007.
40. Unruh ML, Evans IV, Fink NE, et al. Skipped treatments, markers of nutritional nonadherence, and survival among incident hemodialysis patients. *Am J Kidney Dis* 2005, 46(6): 1107–16.
41. Noori N, Kalantar-Zadeh K, Kovesdy CP, et al. Dietary potassium intake and mortality in long-term hemodialysis patients. *Am J Kidney Dis* 2010, 56(2): 338–47.
42. Bowling CB, Pitt B, Ahmed MI, et al: Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. *Circ Heart Fail* 2010, 3(2): 253–60.
43. Toto RD. Treatment of hypertension in chronic kidney disease. S*emin Nephrol* 2005, 25(6): 435–39.
44. London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. *Semin Dial* 2003, 16(2): 85–94.
45. Boudville N, Ward S, Benaroia M, et al. Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. *Am J Hypertens* 2005, 18(10): 1300–05.

## Authors

**Cheralathan Arunachalam MBChB MRCP**
Renal Registrar

**Jenny Stopford**
Renal Dietician

**Julia Ireland**
Renal Dietician

**Alexander Woywodt MD FRCP**
Consultant Nephrologist

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt

**Radiology Risks and Renal Disease.**
**Good Clinical Care.**

## Introduction

Chronic kidney disease (CKD) is a world-wide public health problem[1] that is strongly associated with cardiovascular morbidity and mortality. It affects between 5 and 10% of the population in developed countries and approximately 4.9% of the adult population in the UK. However, these procedures carry specific risks for renal function. Here, we review contrast-induced nephropathy (CIN), cholesterol embolism and risks associated with magnetic resonance imaging in patients with renal disease, with an emphasis on practical points for Foundation Year Doctors.

## Contrast-Induced Nephropathy

### Definition, pathogenesis and risk factors

Contrast-induced nephropathy (CIN) is an important and largely preventable cause of iatrogenic acute kidney injury (AKI) and also carries significant mortality[2]. There are numerous definitions for CIN[3,4]. The incidence varies, depending on the definition and the study population used. A rise in serum creatinine of >0.5 g/dL or >25% rise in serum creatinine from base line at 48 hours is widely used[5]. Prospective studies have found that a small rise in the plasma creatinine concentration is common after contrast exposure, whereas the incidence of CIN varies with the clinical setting, ranging from 3 to 7%[6].

Mechanisms of CIN remain poorly understood, not least due to the fact that the diagnosis is made clinically, leading to a paucity of renal biopsy data. Current concepts therefore stem mainly from animal models. Contrast media can have direct cytotoxic effects and generate free radicals, which induce apoptosis in tubular and glomerular cells[7]. This effect is believed to be exacerbated by defective anti-oxidant mechanisms[8] and ameliorated by N-acetylcysteine. In addition, contrast media induce changes in renal haemodynamics[9], probably mediated by nitric oxide[10]. There is initial vasodilatation, followed by vasoconstriction and medullary hypoxia with tubular damage. It has been speculated that increased susceptibility in some renal diseases may relate to these haemodynamic changes.

There are a number of factors that increases the risk of CIN[11,12] (Table 1). Some of them are non-modifiable, such as the underlying form of renal disease. In this regard diabetes as well as renal disease due to paraproteins (myeloma kidney, light chain deposition disease) carry a higher risk than others[13]. The risk in poorly controlled diabetes is even higher and hyperglycemia itself may play a role[14]. High age and concomitant congestive heart failure also carry a risk, as do dehydration and shock[15]. It is also very clear that the risk of severe or even dialysis-dependent CIN relates to the degree of renal impairment prior to the procedure, whereby the risk is highest with a baseline serum creatinine above 350 µmol/L[6]. It is worthwhile to remember that serum creatinine and estimated glomerular filtration rate (eGFR) are unreliable markers of renal function[16], particularly at the extremes of age and body mass. Hence a cachectic 80-year old with a serum creatinine of 180 µmol/L may well have a GFR around 20 ml/min and thus have a high risk of CIN.

| Non-Modifiable Risk Factors | Modifiable Risk Factors |
|---|---|
| Age | Amount of contrast media |
| Degree of renal impairment and proteinuria | Type of contrast media |
| Diabetic nephropathy | Concomitant use of other nephrotoxic drugs (NSAIDs, aminoglycosides) |
| Renal disease associated with paraprotein (myeloma, light chain deposition disease) | Concomitant use of ACE inhibitors, angiotensin receptor blockers, spironolactone, loop diuretics |
| Shock and need for immediate intervention (for example rescue PCI in cardiogenic shock due to myocardial infarction) | Dehydration and peri-procedural hypotension |
| Concomitant peripheral vascular disease | Coexisting de-compensated congestive heart failure (investigation may be delayed until patient stable) |
| Liver cirrhosis | Poorly controlled diabetes (investigation may be delayed until better control obtained) |

**Table 1. Risk Factors for Contrast-Induced Nephropathy[12]**

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt

Common sense and most, but not all, data suggest that the amount of contrast correlates with the risk of severe, dialysis-dependent CIN[17,18]. The type of contrast media seems to be important as well. Contrast agents are either ionic or non-ionic and of variable osmolality[19] depending on the iodine content[20]. First generation agents are ionic monomers, which are highly hyper-osmolal compared to plasma. These are no longer routinely used, not least because they cause more side effects overall. Second generation agents, such as iohexol, are nonionic monomers with a lower osmolality; however, they still have an increased osmolality (500–850 mosmol/kg) compared with plasma[20]. New nonionic contrast agents, such as iodixanol, are iso-osmolal, being dimers with an osmolality of approximately 290 mosmol/kg[20]. The nephrotoxic properties of these agents seem to vary and high osmolality has been associated with a higher risk of CIN[21]. A prospective trial involving 300 patients undergoing coronary angiography showed that the incidence of CIN was significantly lower with iso-osmolar contrast media (7.9%) than with low-osmolar contrast media (17.0%; p = 0.021)[22]. The ionic content in contrast media also has some effect and non-ionic contrast media, such as Iodixanol, are felt to be superior[6, 23, 24]. A meta-analysis of 16 randomized control trials involving 2,727 patients also showed lower rates of CIN in the Iodixanol group (1.4% vs. 3.5%, p <0.001)[25]. However, a multi-centre, randomized, double-blinded trial involving 414 patients did not show any clinically significant difference[26]. Most centres, including our own, apply a rationale of using low-osmolar contrast in healthy patients with no risk factors, and iso-osmolar in those with risk factors[27].

## Clinical Characteristics, Diagnosis and Treatment of CIN

CIN usually occurs within 12–24 hours of contrast media exposure[28]. The serum creatinine will then peak and recovery occurs within 3–5 days. Some patients, particularly those with risk factors and high serum creatinine at baseline, will require temporary dialysis. Some patients remain permanently dialysis-dependent. In one large study among 1,826 patients receiving contrast for coronary angiography, dialysis-dependent AKI occurred in 0.8%[2]. The 2-year survival in the group requiring dialysis was only 19%[2]. The poor prognosis probably reflects substantial co-morbidity in this population, rather than the effects of renal failure or dialysis.

The differential diagnosis of CIN includes ischemic acute tubular necrosis, acute interstitial nephritis and cholesterol embolism (see below). The former two require additional insults such as sepsis or hypotension, or medication exposure. Renal biopsy is rarely performed in these cases, and the diagnosis is usually made on clinical grounds alone. It should be noted that contrast media can cause false positives in the measurement of urine protein[29]. Once CIN is established, there is no specific treatment. Treatment involves supportive measures and dialysis when indicated as in all other forms of AKI[30].

## Prevention of CIN

Without an effective treatment for fully established CIN, prevention is essential. The first step should be to consider alternative imaging modalities, such as ultrasound, non-contrast CT and magnetic resonance imaging. Contrast-enhanced magnetic resonance imaging is an alternative but should be viewed in the context of the risk of nephrogenic systemic fibrosis (NSF) (see below). Carbon dioxide angiography has been used, although as a method of reducing, but not replacing, contrast administration[31]. If administration of iodinated contrast is required in patients at risk of CIN, the possibility of deferring the investigation or procedure should be explored, to allow correction of reversible factors (Table 1). Prophylactic post-procedure dialysis is not currently recommended[32,33], although earlier studies had been promising[34]. However much of the risk-benefit assessment relates to the risk incurred by placing a temporary haemodialysis access. Many clinicians would therefore consider post-procedural dialysis only in patients who already have functioning dialysis access.

| Establish risk profile |
|---|
| eGFR and measure proteinuria (spot proteine creatinine ratio) |
| Alert the interventionalist/radiologist to presence and severity of renal impairment to limit the amount of contrast media and choose appropriate, newer-generation contrast agent. |
| Consider alternative imaging modalities (ultrasound, non-contrast CT, MRI). Discuss risk and benefit between interventionalist/radiologist, clinician and patient and prioritise. Include renal risk in written consent. |
| Consider deferring contrast investigation to address modifiable risk factors (Table 1). |
| Consider reducing/stopping ACE inhibitor, angiotensin receptor blocker, and diuretics. Stop NSAID. An individual assessment is mandatory in congestive heart failure and severe hypertension; consider seeking an opinion from nephrologist and cardiologist. |
| Admit if severe risk of CIN and/or congestive heart failure or compliance problems. |
| Hydrate intravenously with normal saline prior to the procedure. Avoid volume overload in patients with congestive heart failure. Oral hydration can be considered if low risk. |
| Prescribe N-acetylcysteine 1,200 mg twice daily orally, starting prior to the procedure |
| Establish fluid chart and reassess the patient clinically after the procedure. Watch for signs of fluid overload and consider intravenous diuretics. |
| In emergency patients (e.g., rescue PCI in myocardial infarction, CT in aortic dissection) consider an intravenous bolus of 500 ml saline prior to the procedure followed by 1 litre in the succeeding 12 hours (if no signs of congestive heart failure or volume overload). |
| Repeat serum creatinine the day after the procedure and the following day. |

**Table 2. Prevention of CIN in Patients at Risk[20]**

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt



### Hydration, Mannitol and Diuretics

It is now widely accepted that hydration is effective in the prevention of CIN although the optimum hydration strategy remains disputed. Historically, half-isotonic saline has been advocated[35] although more recent studies have found that normal saline is superior[36]. Mannitol is not currently recommended[37]. Excessive use of diuretics should also be avoided[35]. Many clinicians would also reduce or stop ACE inhibitors, angiotensin receptor antagonists and spironolactone, depending on an individual assessment of the patient. The value of stopping these drugs is currently unproven, and a large study to evaluate the benefit of stopping ACE inhibitors is expected to be published in 2011[38]. Small studies have shown that oral hydration is inferior to intravenous[39]. Care has to be taken in patients with severely reduced left ventricular function, since overzealous hydration may lead to volume overload and pulmonary oedema. In such patients even minor overload can cause problems during the investigation itself, as many radiological investigations and procedures require the patient to lie flat for a prolonged period of time. Patients with high risk and/or congestive heart failure should be admitted to permit optimum preparation and avoid overload.

### Sodium Bicarbonate

Treatment with sodium bicarbonate has been suggested as an additional reno-protective approach for CIN[40,41]. However a randomized double-blinded clinical trial involving 265 patients did not show any significant difference between the use of sodium bicarbonate with normal saline and just intravenous hydration with normal saline alone[42]. Another recent randomized trial compared the use of sodium bicarbonate and half isotonic saline with half isotonic saline alone and showed no significant difference between the two groups in the prevention of CIN[43]. A third randomized trial involving 353 patient showed that hydration with sodium bicarbonate is not superior when compared to normal saline[44]. A recent meta-analysis emphasized substantial heterogeneity in the studies[45], and another recent review found evidence of benefit only in smaller, methodologically inferior, studies[46]. In summary, we believe there is at present no good evidence to support the routine use of sodium bicarbonate in preventing CIN.

### N-Acetyl-Cysteine

N-Acetyl-Cysteine (NAC) has been extensively investigated in the prevention of CIN following the study by Tepel in 2000[47]. This paper has been criticized, not least because it seemed to show an improvement of GFR in the NAC group. Subsequent studies have demonstrated that NAC itself reduces serum creatinine levels without changes in GFR[48]. Since then evidence for NAC administration has remained equivocal with some studies showing a clinical benefit[49,50,] while other studies did not show such an effect[51]. Several meta-analyses have been conducted[52,53,] some of which showed a benefit of NAC[54,55,] while others did not[52–54]. The mechanism by which NAC works is not entirely clear although removal of oxygen free radicals and increased vaso-dilatatory effect of nitric oxide have been proposed. The use of NAC is currently widely recommended at a dose of 1,200 mg orally twice daily[20], due to its low risk and negligible cost. The routine use of intravenous NAC is not advised, because of the risk of allergic reactions[20]. Table 1 summarizes our approach to preventing CIN, based on current evidence-based recommendations[20]. It may be worthwhile to emphasize that even patients at high risk of CIN can be safely investigated with contrast studies as long as current recommendations for prevention are followed.

## Cholesterol Embolism

Cholesterol embolism is a rare but feared complication of endo-vascular intervention[56]. The pathogenesis involves rupture of an atherosclerotic plaque in the aorta or its major branches as a sequel to injury with an intra-vascular catheter or device[56,57]. Cholesterol embolism can also occur spontaneously[56,57]. Good epidemiological data is lacking but one large study in patients undergoing cardiac catheterisation diagnosed cholesterol embolism in 1.4% with an in-hospital mortality rate of 16%[58]. Another study of 221 patients with cholesterol embolism reported a long-term mortality of 80%[59].

The clinical manifestations of cholesterol embolisation may be subtle and nonspecific, or sudden and dramatic, depending on the amount of dislodged embolic debris. The effects are specific to the end-organ damaged, and AKI is a common and devastating feature of the disease. Typical findings on examination include digital or skin ischemia, with blue toes (Fig. 1A) and Livedo. Often these signs become evident in 1–2 days, following endo-vascular intervention. Severe cases may feature mesenteric and spinal ischemia, and stroke. Laboratory features include a decrease in serum complement as well as eosinophilia although the diagnosis is usually made on clinical grounds alone. Skin or kidney can be biopsied and histology shows the typical cleft-like cholesterol crystals (Fig. 1 B).

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt




**Fig. 1. Cholesterol embolism. (A) Right foot with discoloration, resulting from petechiae arranged in a reticulated pattern. Note the blue discoloration of the small toe (Adapted with permission from eMedicine75. (B) Renal histology. Cholesterol embolus in the arcuate renal artery with foreign-body type reaction. Jones silver stain (Courtesy of Dr Jan Becker, Department of Pathology, Hannover Medical School, Hannover, Germany).**

There is essentially no established therapy for cholesterol embolism beyond supportive treatment[57]. A "no-touch approach" and embolic protection devices[60] used during endo-vascular intervention may prevent cholesterol embolism although large studies are lacking[57]. Anecdotal reports have described successful treatment with steroids[61] and statins[62]. Anti-platelet agents are used while thrombolysis is not currently recommended[56]. Some authors suggest the reduction or withdrawal of anticoagulation[57] but others disagree[56]. Further studies are clearly needed to establish the best strategy for anticoagulation.

## Nephrogenic Systemic Fibrosis

This is a rare and recently identified fibrosing disorder in patients with renal failure, which was first described in 1997[63]. The disease was first compared to scleromyxedema[64], but it soon became clear that NSF is a disease in its own right. As of October, 2010, 335 cases had been reported to the international NSF registry at Yale University[65]. NSF is currently not known to have occurred in patients with GFR>60 ml/min, and most patients have advanced CKD or are dialysis-dependent. NSF carries a 30% mortality and is a disabling and debilitating disorder[66].

The clinical presentation of NSF is variable although it predominantly involves the skin. The lesions are characterised by dark or red patches and hardening of skin which give a peau d'orange appearance (Fig. 2). Patients can present with swelling, itching, pain or with a burning sensation. The skin can have a woody texture and there may be joint and muscle involvement, leading to stiffness. Limbs (Fig. 2) and the trunk are predominantly involved. Other manifestations include breathlessness, paraesthesia and pericardial effusion[67]. The diagnosis is based on deep biopsy of an involved site. Light microscopy will show proliferation of dermal fibrocytes and immuno-histochemistry reveals abundant CD34+ cells.



**Fig. 2. NSF affecting the arms. Note the pinkish plaques that are so characteristic of the disease (Courtesy of Prof. Anne Laumann, Feinberg School of Medicine, Northwestern University, Chicago, USA).**

The aetiology of NSF is not quite clear although most patients have a history of magnetic resonance imaging with gadolinium-based contrast media. Thus, current concepts favour gadolinium as the main etiological factor of the disease[68]. The pathophysiology of NSF is not fully understood but patients with normal renal function do not develop NSF[66]. Studies in rats suggest that the toxic effect is indeed due to deposition of Gadolinium itself[69].

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt

There is very little evidence available for the treatment of NSF[70]. All cases should be reported not only to the Medicines and Healthcare products Regulatory Agency (MHRA) but also to the international NSF registry. The main emphasis is on prevention and alternative imaging modalities should be considered. The MHRA currently recommends to avoid gadodiamide in patients with a GFR below 30 ml/min and to consider the other gadolinium-based agents very carefully[71]. There is reason to believe that the risk of NSF is lower with newer contrast agents[72], and some authors suggest giving other gadolinium preparations, such as gadoteridol[73]. Local guidelines are in place in many NHS Trusts in the UK. The Royal College of Radiologists has also issued comprehensive guidance[74].

## Conclusion

Investigations with contrast media, intra-vascular interventions and magnetic resonance imaging all carry important risks for renal function. Foundation Years doctors should be aware of these risks. They need to make sure that the interventionalist or radiologist is aware of the presence and severity of renal impairment. Current evidence-based strategies of prevention should be followed. The risks and benefits associated with a particular procedure need to be carefully balanced and priorities need to be determined. This discussion should also involve the patient and Foundation Years Doctors must appreciate the risks when taking consent for these procedures.

## References

1. Nwankwo E, Bello AK, El Nahas AM. Chronic kidney disease: stemming the global tide. Am J Kidney Dis 2005; 45: 201–8.
2. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368–75.
3. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. Am J Cardiol 2008; 101: 812–9.
4. Toprak O. What is the best definition of contrast-induced nephropathy?: Ren Fail 2007;29(3):387–8.
5. Kagan A, Sheikh-Hamad D. Contrast-induced kidney injury: focus on modifiable risk factors and prophylactic strategies. Clin Cardiol 2010; 33: 62–6.
6. Rudnick MR, Goldfarb S, Wexler L, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: a randomized trial. The Iohexol Cooperative Study. Kidney Int 1995; 47: 254–61.
7. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14–22.
8. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008–15.
9. Persson PB, Tepel M. Contrast medium-induced nephropathy: the pathophysiology. Kidney Int Suppl 2006; 100: S8–10.
10. Agmon Y, Peleg H, Greenfeld Z, et al. Nitric oxide and prostanoids protect the renal outer medulla from radiocontrast toxicity in the rat. J Clin Invest 1994; 94: 1069–75.
11. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006; 100: S11–5.
12. Toprak O, Cirit M. Risk factors and therapy strategies for contrast-induced nephropathy. Ren Fail 2006; 28: 365–81.
13. McCarthy CS, Becker JA. Multiple myeloma and contrast media. Radiology 1992; 183: 519–21.
14. Stolker JM, McCullough PA, Rao S, et al. Pre-procedural glucose levels and the risk for contrast-induced acute kidney injury in patients undergoing coronary angiography. J Am Coll Cardiol 2010; 55: 1433–40.
15. Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc 2004; 79: 211–9.
16. Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16: 763–73.
17. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009; 150: 170–7.
18. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol 2002; 90: 1068–73.
19. Lautin EM, Freeman NJ, Schoenfeld AH, et al. Radiocontrast-associated renal dysfunction: A comparison of lower-osmolality and conventional high-osmolality contrast media. AJR Am J Roentgenol 1991; 157: 59–65.
20. Prevention of contrast-induced nephropathy. 2010. (Accessed October 22, 2010, 2010, at http://www.uptodate.com/online/content/topic.do?topicKey=renlfail/14655&view=print.)
21. Andrew E, Berg KJ. Nephrotoxic effects of X-ray contrast media. J Toxicol Clin Toxicol 2004; 42: 325–32.
22. Jo SH, Youn TJ, Koo BK, et al. Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: The RECOVER study: a randomized controlled trial. J Am Coll Cardiol 2006; 48: 924–30.
23. Berg KJ. Nephrotoxicity related to contrast media. Scand J Urol Nephrol 2000; 34: 317–22.
24. Adolph E, Holdt-Lehmann B, Chatterjee T, et al. Renal Insufficiency Following Radiocontrast Exposure Trial (REINFORCE): A randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. Coron Artery Dis 2008; 19: 413–9.
25. McCullough PA, Bertrand ME, Brinker JA, et al. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48: 692–9.
26. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 2007; 115: 3189–96.
27. Aspelin P, Aubry P, Fransson SG, et al. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003; 348: 491–9.

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt

**Radiology Risks and Renal Disease.**
**Good Clinical Care.**



28. Rudnick MR, Berns JS, Cohen RM, et al. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24: 713–27.
29. Morcos SK, el-Nahas AM, Brown P, et al. Effect of iodinated water soluble contrast media on urinary protein assays. BMJ 1992; 305: 29.
30. Renal replacement therapy (dialysis) in acute kidney injury (acute renal failure): Indications, timing, and dialysis dose. Uptodate, 2010. (Accessed October 23, 2010, at http://www.uptodate.com.)
31. Liss P, Eklof H, Hellberg O, et al. Renal effects of CO2 and iodinated contrast media in patients undergoing renovascular intervention: a prospective, randomized study. J Vasc Interv Radiol 2005; 16: 57–65.
32. Rodby RA. Preventing complications of radiographic contrast media: Is there a role for dialysis? Semin Dial 2007; 20: 19–23.
33. Klarenbach SW, Pannu N, Tonelli MA, et al. Cost-effectiveness of hemofiltration to prevent contrast nephropathy in patients with chronic kidney disease. Crit Care Med 2006; 34: 1044–51.
34. Marenzi G, Marana I, Lauri G, et al. The Prevention of Radiocontrast-Agent Induced Nephropathy by Hemofiltration. N Engl J Med 2003; 349: 1333–40.
35. Solomon R, Werner C, Mann D, et al. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416–20.
36. Mueller C, Buerkle G, Buettner HJ, et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 2002; 162: 329–36.
37. Visweswaran P, Massin EK, Dubose TD, Jr. Mannitol-induced acute renal failure. J Am Soc Nephrol 1997; 8: 1028–33.
38. Angiotensin Converting Enzyme Inhibitors & Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization (NCT00317252). 2006. (Accessed October 30, 2010, at http://clinicaltrials.gov/ct2/show/NCT00317252.)
39. Trivedi HS, Moore H, Nasr S, et al. A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. Nephron Clin Pract 2003; 93: C29–34.
40. Merten GJ, Burgess WP, Gray LV, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: A randomized controlled trial. JAMA 2004; 291: 2328–34.
41. Tamura A, Goto Y, Miyamoto K, et al. Efficacy of single-bolus administration of sodium bicarbonate to prevent contrast-induced nephropathy in patients with mild renal insufficiency undergoing an elective coronary procedure. Am J Cardiol 2009; 104: 921–5.
42. Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate plus isotonic saline versus saline for prevention of contrast-induced nephropathy in patients undergoing coronary angiography: a randomized controlled trial. Am J Kidney Dis 2009; 54: 610–8.
43. Vasheghani-Farahani A, Sadigh G, Kassaian SE, et al. Sodium bicarbonate in preventing contrast nephropathy in patients at risk for volume overload: a randomized controlled trial. J Nephrol 2010; 23: 216–23.
44. Brar SS, Shen AY, Jorgensen MB, et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300: 1038–46.
45. Kunadian V, Zaman A, Spyridopoulos I, et al. Sodium bicarbonate for the prevention of contrast induced nephropathy: A meta-analysis of published clinical trials. Eur J Radiol.
46. Brar SS, Hiremath S, Dangas G, et al. Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4: 1584–92.
47. Tepel M, van der Giet M, Schwarzfeld C, et al. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000; 343: 180–4.
48. Hoffmann U, Fischereder M, Kruger B, et al. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004; 15: 407–10.
49. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA 2003; 289: 553–8.
50. Briguori C, Colombo A, Violante A, et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity: Eur Heart J. 2004 Feb;25(3):206–11.
51. Thiele H, Hildebrand L, Schirdewahn C, et al. Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. J Am Coll Cardiol; 55: 2201–9.
52. Zagler A, Azadpour M, Mercado C, et al. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 2006; 151: 140–5.
53. Kshirsagar AV, Poole C, Mottl A, et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 2004; 15: 761–9.

# RADIOLOGY RISKS AND RENAL DISEASE

Maharajan Raman, Alistair Craig, Alexander Woywodt

**Radiology Risks and Renal Disease.**
**Good Clinical Care.**

54. Gonzales DA, Norsworthy KJ, Kern SJ, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007; 5: 32.
55. Nallamothu BK, Shojania KG, Saint S, et al. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med 2004; 117: 938–47.
56. Kronzon I, Saric M. Cholesterol embolization syndrome. Circulation 2010; 122: 631–41.
57. Scolari F, Ravani P. Atheroembolic renal disease. Lancet 2010; 375: 1650–60.
58. Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 2003; 42: 211–6.
59. Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987; 38: 769–84.
60. Thatipelli MR, Misra S, Sanikommu SR, et al. Embolic protection device use in renal artery stent placement. J Vasc Interv Radiol 2009; 20: 580–6.
61. Nakayama M, Nagata M, Hirano T, et al. Low-dose prednisolone ameliorates acute renal failure caused by cholesterol crystal embolism. Clin Nephrol 2006; 66: 232–9.
62. Woolfson RG, Lachmann H. Improvement in renal cholesterol emboli syndrome after simvastatin. Lancet 1998; 351: 1331–2.
63. Fibrosing skin condition among patients with renal disease--United States and Europe, 1997-2002. MMWR Morb Mortal Wkly Rep 2002; 51: 25–6.
64. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000; 356: 1000–1.
65. The International Center for Nephrogenic Systemic Fibrosis Research (ICNSFR). (Accessed October 25, 2010, at http://www.icnsfr.org/.)
66. Canavese C, Mereu MC, Aime S, et al. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness. J Nephrol 2008; 21: 324–36.
67. Perez-Rodriguez J, Lai S, Ehst BD, et al. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. Radiology 2009; 250: 371–7.
68. Kay J. Nephrogenic systemic fibrosis: A gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008; 67: iii66–9.
69. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: A possible role for gadolinium-based contrast media. Invest Radiol 2008; 43: 65–75.
70. Marckmann P, Skov L. Nephrogenic systemic fibrosis: clinical picture and treatment. Radiol Clin North Am 2009; 47: 833–40.
71. MHRA guidance: Gadolinium-containing MRI contrast agents and Nephrogenic Systemic Fibrosis (NSF). 2007. (Accessed October 25, 2010, at http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2030229.)
72. Thomsen HS. Nephrogenic Systemic Fibrosis: History and Epidemiology. Radiol Clin North Am 2009; 47: 827–31.
73. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure., 2010. (Accessed October 25, 2010, at http://www.uptodate.com.)
74. Royal College of Radiologists: Gadolinium-containing MRI contrast agents and Nephrogenic Systemic Fibrosis (NSF). 2007. (Accessed October 25, 2010, at http://www.rcr.ac.uk/docs/radiology/pdf/BFCR0714_Gadolinium_NSF_guidanceNov07.pdf.)
75. eMedicine: Cutaneous Manifestations of Cholesterol Embolism. Updated: Feb 23, 2009. (Accessed October, 16, 2010, at http://emedicine.medscape.com/article/1096593-media.)

## Authors

**Maharajan Raman MBChB MRCP**
Renal Registrar

**Alistair Craig**
Consultant Radiologist

**Alexander Woywodt MD FRCP**
Consultant Nephrologist

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde

**A Raised Troponin: Are the Kidneys to Blame? Good Clinical Care.**


## Abstract

Troponins (cTn) are protein elements of the cardiac sarcomere, fundamental to myocardial contractility. The current assays of cTn are very sensitive and specific to cardiac damage and have replaced the relatively non-specific creatine kinase (CK-MB). cTn are detected in the blood following a myocardial necrosis reaching maximum after 6–12 hours, and has revolutionized the diagnosis of myocardial infarction (MI) in the last 10 years. The value of the troponin following a coronary event has significant prognostic value and guides the physician in their management.

However, there are large number of differentials that cause a raised cTn from myocyte damage that does not include coronary arterial occlusion and these need to be considered within the clinical context of any patient with a raised cTn. These include myocarditis, arrthythmias, pulmonary embolism (PE), cardiac contusions, congestive cardiac failure, sepsis and renal failure.

Although still under investigation, many falsely belief that cTn is raised in renal failure due to reduced clearance by the kidneys. First, in order for troponin to be raised, cTn must be released from cardiac muscle. This can include silent micro infarctions, left ventricular hypertrophy, uraemic skeletal myopathy, increasing incidence of congestive cardiac failure, inflammation and abnormal protein metabolism. Secondly, cTn has a large molecular weight and their clearance is not renally dependent.

Increased cTnT in end-stage renal disease (ESRD) has significant prognostic value and is approved for appropriate risk stratification; bearing in mind that ESRD patients' have significant prevalence of coronary arterial disease.


## What Are Cardiac Troponins?

The basic unit of myocardial contraction is made up of the sarcomere. Each sarcomere is comprised of thick and thin filaments(2) Myosin is a complex molecule which helps make up the thick filaments and functions as the site for ATPase as well as a bridge between actin and myosin(1–3). Myosin helps regulate the level of molecular movement(4). The thin filaments are composed of actin, tropomyosin and troponin(4). The thin filament has a helical appearance which is held in place by tropomyosin as demonstrated in Fig. 1.

**Troponin is a group of regulatory proteins which control the calcium mediated interaction of actin and myosin(5, 6). Troponin consists of three subunits;**

- Troponin T; 37kDa protein which binds to tropomyosin and caused muscle contraction(7).
- Troponin I; 22 kDa This binds to actin and inhibits actin-myosin interaction(7).
- Troponin C—which binds to calcium ions. This troponin isoform is also shared by smooth muscle(2, 7).

Cardiac Tn are found as structural bound proteins and a small free pool exists in the cytosol (around 6%–8% of CTn) (7).




**Fig. 1(8) Demonstrating a cardiac myofibrillar thin filament. cTn I and T exist in a structurally bound form to both actin and tropomyosin. The free cTn protein exist in the cytosolic free pool.**

(Reproduced with permission from Differential diagnosis of elevated troponins, susanne Korff, Hugo A Katus and Evangelos Giannitsis, 92, 987–93, 2006] and from BMJ Publishing Group Ltd.)

The cardiac enzymes troponin T (TnT) and I (TnI) are only expressed in cardiac troponins by muscle (2). However, cardiac troponin C is identical to troponin C expressed from skeletal muscle (1, 9). Studies have shown cardiac troponins to be more sensitive to myocardial damage than CK(10). Following acute myocardial infarction (AMI), cTn is released from the myocyte after 2–4 hours and may persist for up to 14 days(11).

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde

## A Raised Troponin: Are the Kidneys to Blame? Good Clinical Care.

In September 2000, the Joint European Society of Cardiology (ESC)/ American College of Cardiology introduced the use of troponin T and troponin I (cardiospecific enzymes), to define MC—a positive Tn rise signifying myocardial necrosis(6–8). The Committee decided that a positive troponin should be defined as an elevation of troponin which exceeds the 99th percentile of a reference control group(9). Since 2000, cardiac troponin has replaced creatine-kinase-MB (CK-MB) as the preferred biochemical marker for AMI (1, 7). Introduction of these new guidelines has led to a greater number of patients being diagnosed with AMI, who have presented initially with atypical symptoms with an uncharacteristic electrocardiogram (ECG)(1, 4).

The first-generation cTn assay utilized a capture and detection antibody (12). For cTn to be detected, the two antibodies bind to cTn molecule, forming a sandwich complex(13). The first generation of cTnT assays generated large numbers of false positives due to cross reactions with cTnT isoforms (≈2%) released in response to injury (e.g., from skeletal muscle) (12, 14). A second-generation assay was developed in 1997 which used a cardiac troponin specific detection antibody(12, 13). The troponin assay is in its third generation of development, which has a similar principal but with a greater specificity, with cross reactivity of less than <0.01% (8, 15, 16). In patients with normal renal function, the sensitivity of most cTnI assays is 92% (5–12 hours) with a specificity of 94% (1–2 days).

The type of assay used will vary in different hospitals. Some will use cTnI, and others will detect cTnT(2). cTnI and cTnT both make up the same part of the ternary complex within the myocyte(2, 7, 17). It has been hypothesized that free cytoplasmic cTnT is more abundant than cTnI (9). The lower incidence of cTnI is an indicator of irreversible myocyte damage as opposed to transient leakage of cytolasmic cTnT(7).



Troponin I and T assays have similar diagnostic power, although some studies have shown cTnT detection to be superior (7). Analyses have shown TnI assays to be less precise at the lower end of the reference range than cTnT assays. This may render cTnT detection more advantageous for detecting smaller amounts of myocardial necrosis. cTnI—when released in to the circulation—is more biochemically unstable and prone to modifications (including proteolysis and oxidation) which in turn can affect recognition of the molecule by monoclonal antibodies, affecting assay performance(18). TnI elevation does, however, appear to be more specific than cTnT in patients with ESRD (30%–85%) as elevations above the cut off are seen more frequently in asymptomatic patients with ESRD than cTnI (<5%–18%) (9).

### Cardiac Troponins in Acute Coronary Syndrome

It is clear that the implementation of the ESC/American College of Cardiology guidelines has increased the number of patients diagnosed with AMI(5). For instance, a study involving 2,181 patients presenting to tertiary centres demonstrated a 195% increase in the diagnosis of AMI based on elevated cTn as opposed to CK-MB (19). The same study also implied that mortality at 30 days was 5.2% higher for those patients who had a raised cTn (odds ratio 7.9) compared to those only had raised CK-MB markers only (odds ratio 1.7) (7, 13, 20).

Multiple randomized studies have since gone on to show that there is an adverse prognostic risk associated with elevated cTn (15). Ottani et al compared the 30-day mortality in the cTn-positive chest pain group versus cTn negative group. They concluded that the odds ratio for death and AMI was 3.44 higher in the cTn positive group(8, 19).

Whilst it is apparent that cTn is a sensitive marker of myocardial damage, it is only a powerful test if it leads to change in therapy which improves outcome (1). Recent advances including administration of IIb/IIIa antiplatelet inhibitors and routine PCI has been shown to be effective in patients with cTn elevations (4, 6).

The ESC Task Force Report on acute coronary syndrome without ST elevation commented that cTn measurements were vital in the diagnosis of AMI and the decision of further management(8, 21). Better risk stratification is achieved if a baseline cTn is done on admission followed by a repeat cTn done 6–12 hours later (17).

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde

## A Raised Troponin Following Cardiac Procedures

In addition to raised troponin following AMI, troponin release is also observed after elective percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (7). A large meta-analyses reported that 24%–48% of patients after PCI demonstrated a raised cTn level (22). In this study, none of the patients with a raised cTn had a rise in CK-MB which supports the statement that cTn are more sensitive to myocardial damage (5, 17).

In addition, a study looking at 316 post-PCI patients found that those with a troponin rise had a statistically significant increased risk of major adverse cardiac events within 18 months (odds ratio 3.28, 95% CI 1.7–6.4) compared to those patients who did not have an elevated cTn (23).

Following open heart surgery, studies have shown that almost all patients demonstrate a rise in cTn (24). This is attributed to incomplete cardioprotection, reperfusion and injury as well as direct surgical trauma.

In these situations the cardiac origin of the troponin release is obvious although the exact mechanism of the troponin leak is not clearly understood. Possible reasons include transient ischaemia secondary to bulky devices, coronary dissection, micro-emboli or side branch occlusion (25). One must always remember that peri-procedural or post-procedure AMI uncommon but can occur and must be considered, especially in the context of chest pain(26).

Direct current cardioversion (DCCV) is often used in patients with compromising arrythmias (7). There is an increase in CK-MB following a DCCV which likely originates from the skeletal chest wall (secondary to high voltages) as opposed to myocardial damage as demonstrated by Rao et al showed no increase in either cTnI and cTnT in any patient undergoing elective DCCV for atrial fibrillation(27). DCCV does not lead to myocardial damage.

## Cardiac Troponin Release Unrelated to Acute Coronary Syndormes

In patients with suspected ACS (even those with a raised cTn), it is not uncommon to find normal coronary arteries on angiography(8). We have already discussed that a raised cTn alone is an adverse prognostic factor. Treating a patient for ACS in whom the raised cTn is secondary to another condition may lead to inappropriate management (28, 29)

Khan et al studied 102 consecutive patients and found that 35% of those with a raised cTn had normal coronary arteries on angiography. It is important to be aware of other conditions which cause troponin release (30). Table 1 lists some of the documented conditions in which a rise of non-ACS-related cTn can occur.

| |
|---|
| Congestive heart failure |
| Pericarditis |
| Myocarditis |
| Iatrogenic (ablation, pacing, defibrillation discharge, cardiac surgery) |
| Arrythmias |
| Trauma (cardiac contusions) |
| Thermal injury |
| Rhabdomyolysis with cardiac injury |
| Critical Illness (sepsis) |
| Stroke |
| Acute intercerebral bleed |
| Renal Failure |
| Pulmonary embolism |
| Lobar pneumonia |
| Cirrhosis |
| Human immunodeficiency virus (HIV) |
| Endocrine disorders (hypothyroidism) |

**Table 1. Possible Etiologies for Troponin Elevation in Non-ACS States**

## Sepsis

In the setting of sepsis, myocardial oxygen demand is increased as a consequence of fever and tachycardia (7, 8). Additionally, there is a reduction in the myocardial oxygen supply because of a shortened diastolic phase, which is when most of the myocardial perfusion occurs (31). This concept is know as "demand ischaemia" whereby increased myocardial oxygen consumption along with reduced perfusion pressure and oxygen delivery results in troponin release(8, 32).

Many studies have been performed in intensive care units involving septic patients. Ammann et al recently looked at 20 patients admitted to the ICU with sepsis or septic shock; 85% had a raised cTn. A total of 6 patients died, and of those 5 had an elevated cTn. In the majority of those who died significant coronary artery disease (CAD) was ruled out at autopsy (33, 34). Patients with sepsis and raised troponin value have increased mortality rate 83% versus 38% in those whose troponin value was below <0.2 µ/l(35).



# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde



## Arrythmias

Other cause of "demand ischaemia" with normal coronary arteries include tachycardias or tachyarrythmias(8). Bakshi et al looked at 21 patients with a raised cTn and found the cause of the troponin leak to be tachycardia in 21% of patients (36).

## Pulmonary Embolism

A total of 50% of cases with acute PE have a raised cTn (8). The mechanism of troponin elevation is unclear, however, a number of theories have been proposed. It is thought that acute increase in pulmonary artery pressure leads to sudden right ventricle dilatation (37). As a direct result of damage, the right ventricle then releases cTn (38). The concept of "demand ischaemia" concept is also recognized as a hypothesis whereby a perfusion defect within the pulmonary circulation causes myocardial perfusion injury (39, 40).

Recent studies by Giannitsis et al have shown that the cTn persisted for a shorter time compared to those with AMI (37). The most likely explanation for this is that the source of troponin is the free cytoplasmic cTn which leaks secondary due to right ventricular strain as opposed to irreversible myocardial damage (39). Again, if a patient has a raised cTn, with all-cause mortality associated with the PE is higher (hazard ratio 9.1, 95% CI: 3.3–26.1)(41). Conversely, normal troponin values are associated with a better outcome (37, 39).

## Congestive Heart Failure

Congestive heart failure can lead to cardiac troponin release without myocardial ischaemia. The release of cTn correlates to the severity of heart failure as well as being an indication of prognosis, (42) but the studies often used small sample sizes(7).

A large study by Latini et al looked at over 4,000 patients in the Valsartan Heart Failure Trial (Val-HeFT) (43, 44). They assessed the association between baseline troponin concentrations, all-cause mortality and hospitalisation for heart failure. Cardiac troponin was detected in 92% of patients using a highly sensitive cTnT assay. These patients were also prone to more clinical risk factors such as atrial fibrillation(7, 8, 45).

Volume and pressure overload of both the right and left ventricle result in "myocardial strain". This is defined as the percentage change of a structure from its initial length after the application of stress (7, 9). This theory has been supported by the close relationship between B-type natruiretic peptide (BNP), a marker of ventricular strain, and cTn elevation in heart failure patients (46).

Heart failure describes ongoing cardiomyocyte injury which is reflected by troponin release (46). This could be due to reversible cardiac injury from ventricular strain may result in transient cytoplasmic release of cTn. Additionally, myocardial necrosis and apoptosis is continuously occurring even in stable heart failure patients providing continuous cTn release (44, 45).

## Exercise

cTnI and cTnT appear in athletes following strenuous exercise such as marathons (47). These elevations are only transient and resolve within 24 hours of exercise, leading us to believe that the raised cTn is due to release of the cytoplasmic pool of cTn, not irreversible cardiac damage(8). On the other hand, the incidence of underlying structural cardiac disease in apparently young and healthy athletes raises the possiblity that elevated cTn may be secondary to subclinical mechanisms (47).

## Pericarditis/Myocarditis

Along with AMI and PE's, both pericarditis and myocarditis are the next most commonly diagnosed condition in those patients presenting with chest pain and a raised cTn; in a third of patients with pericarditis (8, 48). Studies by Homma et al looked at 231 patients diagnosed with pericarditis who subsequently underwent coronary angiography to exclude CAD, 78% of these patients had completely normal coronary arteries. It is thought that cTn release is due to inflammation of the epicardium, as the pericardium does not contain cTn (49).

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde



**A Raised Troponin: Are the Kidneys to Blame? Good Clinical Care.**

## Cardiac Contusions

Traumatic or inflammatory damage to the myocardium can result in elevated cTn. Velmahos et al demonstrated a high negative predictive value of cTn in those with blunt thoracic trauma, concluding that a negative cTn following cardiac trauma can virtually exclude cardiac contusions (50). This is vital as cardiac contusions can result in fatal arrythmias (8, 50).

## Subarachnoid Haemorrhage

Around 25% of patients with an acute stroke or intracranial haemorrhage with ECG changes will have a raised cTn (51). Again the exact mechanism of troponin release is not clear; there may be a disturbance in autonomic function causing increased sympathetic function and catecholamine release. The excess catecholamine release is thought to cause myocardial cell damage resulting in cTn release (52).

## Cardiac Transplantation

Case reports from the 1990s have highlighted the persistent elevation in cardiac transplant recipients (53). Further studies namely by Labarrere et al go on to demonstrate that nearly all cardiac transplant recipients will have a rasied cTn for at least 1 month following surgery . However, those who have a raised cTn at around 12 months following transplantation are at increased risk of developing further CAD or even graft failure (54). On the other hand, if cTn is negative in this subset of patients one can be reassured that they are at low risk for further cardiac disease or allograft rejection (54, 55).

## Renal Insufficiency

Troponin is known to be elevated even in mild degrees of renal failure(7, 8). An elevated troponin in the context of renal failure is a subject we shall return to later as it is highly controversial(3). The interpretation of a raised cTn with or without clinical indication of ACS has posed huge difficulty for cardiologists as well as general physicians(3, 56).

## Cardiac Troponins and Chronic Kidney Disease

A meta-analysis of 26 studies was carried by Zhang et al to assess the prevalence of chronic kidney disease (CKD). Using the Modification of Diet in Renal Disease equation, the prevalence of CKD was 7.2% amongst those aged 30 or above and at least 23.4% in those aged 64 or above(57).

It has been reported that amongst 50% of those with CKD stage 4 or above, cardiovascular disease is the leading cause of death, 73% of which is attributable to CAD(58). These figures reflect the increased risk of silent ischaemia amongst patients with renal failure. The risk ratio of all-cause mortality following MI in patients' with creatinine clearance of <40 ml/min–1 was 2.0 (95% CI: 1.6–2.4), whereas the risk in those with CrCl >80 ml/min–1was 1.1 (95%: 0.9–1.3)(59). Therefore, there is doubling of the risk of mortality following MI in those with severely impaired renal function.

Few studies exist looking at the relationship between cTn and CKD, with the majority using patients' with ESRD. The GUSTO IV (Global Use of Strategies to Open Occluded Coronary Arteries IV) trial found that the prevalence of a raised cTn in those with CKD is around 53%. Additionally, the same trial found cTn to be the best predictor of death or MI amongst those with all degrees of renal impairment. They showed a 20% chance of death or MI in patients who had a raised troponin (≥0.1 ng/ml) with worst renal function as opposed to 9% in the same group but without a raised troponin (<0.1 ng/ml)(60).

## Troponin T versus Troponin I

There are number of differences in the cellular biology between TnT and TnI. Firstly, there over twice the number of cTnT exists freely within the myocyte cytoplasm as cTnI (7% vs. 3.5%) (61). The actual content of TnT is twice the amount TnI within the myocyte as well. The free cytoplasmic cTn are released early in cardiac necrosis and detected by their relative assays (18) .

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde

The above differences may help to explain why cTnT (up to 53%) is more likely to be elevated in patients with ESRD compared to cTnI (up to 19%). Patients with ESRD show a fall cTnI level by 86% post dialysis, whereas cTnT level remains static or increases (16). Troponin T is very useful prognostic marker in ESRD. In a large study of 733 patients, an elevated cTnT was associated with increased death in the first 3 years of follow-up, with mortality 2–5 times higher in those with an elevated cTnT(13).

As a result, cTnT has been approved by the Food and Drug Administration as marker assessing the prognosis in patients with ESRD about to start dialysis (3).

## So, Is Troponin Cleared Renally?—It's a Myth or Is It?

Troponin is often presumed to be renally cleared, nevertheless, for the detection of cTn in renal impairment there must be cTn release even in the absence of an obvious cardiac ischaemic event. A number of theories have been proposed to explain this phenomenon in CKD: silent micro-infarcts, heart failure, left ventricular hypertrophy and uraemia.

1) Silent micro-infarcts within the myocardium(15). The existence of micro infarcts has been demonstrated in histological samples in patients with a raised cTn (62). The high incidence of CAD in patients' with CKD maybe predisposing them to recurrent episodes of micro infarcts (18). A study in dialysis patients has shown close correlation between raised cTn and severity of CAD on angiography (17). The value of cTn is also associated with the extent of calcification of the coronary arteries in dialysis patients (63).

2) Heart failure. The incidence of heart failure is proportional to worsening renal function(64). There is data to support the rise in cTn in heart failure in the absence of acute ischaemia (65, 66). Del Carlo et al have shown an association in the severity and prognosis of heart failure with the rise in cTn (45).

3) Left ventricular hypertrophy (LVH)(67). The cTn release could be due to subendocardial ischemia as a result of impaired blood supply to the hypertrophied muscle. Laboratory studies have demonstrated a paucity of capillary growth in areas of myocyte hypertrophy, leading to mismatch in oxygen supply and demand (68). There are also changes in the expression of cTn in hypertrophied muscle. Ricchiuti et al showed a decrease in intracellular cTn level in left ventricular remodelling and suggested that this might due to loss of free cTn into the circulation (69).

4) Uraemia. This may induce skeletal myopathy, thus promoting the re-expression of cTnT. Studies have shown the expression of cTnT in skeletal muscles of ESRD patients (70) as well as a detectable serum rise cTnT in inflammatory myopathies in the absence of myocardial ischaemia (18). However, there is lack of correlation betweem cTnT and the severity of skeletal myopathy in patients with ESRD (71). This theory remains very speculative.

The are other explanations being considered by researchers, including endothelial dysfunction due to inflammation and oxidative stress (72), calcium deposition within the myocardium, leading to injury and hypotensive episodes following dialysis (12) .

The most misconception is that cTnT has renal clearance. This is unlikely given both forms of free and bound cTnT molecules are large, (37 kDa and 77 kDa, respectively). There is no change in cTnT level in patients with ESRD undergoing renal transplantation despite an improvement in renal function (73). The elimination rate constant and half-lives of cTn do not change significantly in patients with or without renal failure (74). The clearance may well occur through the reticuloendothelial system (2, 18) but has not been conclusively proven.

**Intrepreting a Raised Troponin in Chronic Kidney Disease**

- The clinician should revisit the initial presenting complaint the patient came to hospital with.
- Current and admitting ECGs need to be evaluated and compared against old ECGs.
- The differential diagnosis of a raised cTn as discussed earlier should always be borne in mind.
- Always compare the current cTn level to a baseline cTn.

The physician should not forget that patients with CKD—especially with ESRD—have a high prevalence of coronary arterial disease with multiple risk factors including hypertension and diabetes. These high risk factors should be used for appropriate risk stratification of the patient with chest pain.(1)

## Self-Test Questions

**1. What are the three forms of troponins in the cardiac myocyte?**
**2. How long do troponin levels remain elevated after an acute ischaemic event?**
**3. What pathologies within the heart muscle can lead to elevated troponins?**
**4. What is the difference between troponin T and I?**
**5. What are the theories to explain the raised troponin in chronic kidney disease?**

## Answers

1. Troponin T, I and C
2. They can remain elevated up to 14 days following an acute event.
3. Myocarditis, cardiac contusions, pericarditis, iatrogenic (bypass surgery, DC cardioversion, pacing and ablation), arrhythmias and myocardial infarction.
4. Troponin T is present freely in the cytoplasm at a higher amount than cTnI (7% vs. 3.5%). The weight of free cTnT and cTnI is 37 kDa and 22 kDa, respectively. cTnT is more likely to be elevated in ESRD and dialysis seems to have no effect on its measurement value, whereas cTnI value falls post-dialysis. As a result, there is clear evidence to use cTnT as a prognostic marker in ESRD.
5. The elevated troponin value could be due to silent micro-infarctions, uraemic skeletal myopathy, increase prevalence of congestive cardiac failure and left ventricular hypertrophy.

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde



**A Raised Troponin: Are the Kidneys to Blame? Good Clinical Care.**

## References


1. Balamuthusamy S, Khosla S, Meka S, et al. Clinical utility of cardiac troponin I in the diagnosis of acute coronary syndrome in patients with renal failure. Am J Ther 2007;14(4):356–60.
2. Bozbas H, Yildirir A, Muderrisoglu H. Cardiac enzymes, renal failure and renal transplantation. Clin Med Res 2006;4(1):79–84.
3. Lauer MS. Cardiac troponins and renal failure: The evolution of a clinical test. Circulation 2005;112(20):3036–7.
4. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 2001;38(2):478–85.
5. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med 2005;142(9):786–91.
6. Kelley WE, Januzzi JL, Christenson RH. Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. Clin Chem 2009;55(12):2098–112.
7. Dewantoro O, Harun S. Troponin in heart disorder and chronic renal failure. Acta Medica Indonesiana 2005;37(4):218–23.
8. Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins. Heart 2006;92(7):987–93.
9. Wang AY, Lai KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008;19(9):1643–52.
10. Needham DM, Shufelt KA, Tomlinson G, et al. Troponin I and T levels in renal failure patients without acute coronary syndrome: A systematic review of the literature. Can J Cardiol 2004;20(12):1212–8.
11. Diris JH, Hackeng CM, Kooman JP, et al. Impaired renal clearance explains elevated troponin T fragments in hemodialysis patients. Circulation 2004 6;109(1):23–5.
12. Babuin L, Jaffe AS. Troponin: the biomarker of choice for the detection of cardiac injury. Can Med Assoc J 2005;173(10):1191–202.
13. Apple FS, Murakami MM, Pearce LA, et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002;106(23):2941–5.
14. Grewal J, Gin K. Troponin: Marks the Spot! Perspec Cardiol. 2004:35–40.
15. Ooi DS, Isotalo PA, Veinot JP. Correlation of antemortem serum creatine kinase, creatine kinase-MB, troponin I, and troponin T with cardiac pathology. Clin Chem 2000;46(3):338–44.
16. Wayand D, Baum H, Schatzle G, et al. Cardiac troponin T and I in end-stage renal failure. Clin Chem 2000;46(9):1345–50.
17. deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003;290(3):353–9.
18. Freda BJ, Tang WH, Van Lente F, et al. Cardiac troponins in renal insufficiency: review and clinical implications. J Am Coll Cardiol 2002;40(12):2065–71.
19. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 2000;140(6):917–27.
20. Rao SV, Ohman M, Granger CB, Armstrong, et al. Prognostic Value of Isolated Troponin Elevation Across the Spectrum of Chest Pain Syndromes. Am J Cardiol 2003;91:936–40.
21. Abbas NA, John RI, Webb MC, et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005;51(11):2059–66.
22. Ricciardi MJ, Davidson CJ, Gubernikoff G, et al. Troponin I elevation and cardiac events after percutaneous coronary intervention. Am Heart J 2003;145(3):522–8.
23. Nageh T, Sherwood RA, Harris B, et al. Prognostic role of cardiac troponin I after percutaneous coronary intervention in stable coronary disease. Heart 2005;91:1181–5.
24. Lehrke S, Steen H, Sievers HH, et al. Cardiac troponin T for prediction of short- and long-term morbidity and mortality after elective open heart surgery. Clin Chem 2004;50(9):1560–7.

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde

25. Kannankeril PJ, Wax DF, Pahl E. Elevations of troponin I after interventional cardiac catheterization. Cardiol Young 2001;11(4):375–8.
26. Herrmann J, Von Birgelen C, Haude M, et al. Prognostic implication of cardiac troponin T increase following stent implantation. Heart 2002;87(6):549–53.
27. Rao AC, Naeem N, John C, et al. Direct current cardioversion does not cause cardiac damage: evidence from cardiac troponin T estimation. Heart 1998;80(3):229–30.
28. Lim W, Qushmaq I, Devereaux PJ, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Int Med 2006;166(22):2446–54.
29. Wu TT, Yuan A, Chen CY, et al. Cardiac troponin I levels are a risk factor for mortality and multiple organ failure in noncardiac critically ill patients and have an additive effect to the APACHE II score in outcome prediction. Shock 2004;22(2):95–101.
30. Khan IA, Wattanasuwan N, Mehta NJ, et al. Prognostic value of serum cardiac troponin I in ambulatory patients with chronic renal failure undergoing long-term hemodialysis: a two-year outcome analysis. J Am Coll Cardiol 2001;38(4):991–8.
31. Spies C, Haude V, Fitzner R, et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998;113(4):1055-63.
32. Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993;328(20):1471–7.
33. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001;27(6):965–9.
34. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003;41(11):2004–9.
35. Spies C, Haude v, Fitzner R. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998;113:1055–63.
36. Bakshi TK, Choo MK, Edwards CC, et al. Causes of elevated troponin I with a normal coronary angiogram. Int Med J 2002 Nov;32(11):520–5.
37. Giannitsis E, Muller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000;102(2):211–7.
38. Goldman L, Lee L. Evaluation of the patient with chest pain. N Engl J Med 2000;342:1187–95.
39. Muller-Bardorff M, Weidtmann B, Giannitsis E, et al. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002;48(4):673–5.
40. Yalamanchili K, Sukhija R, Aronow WS, et al. Prevalence of increased cardiac troponin I levels in patients with and without acute pulmonary embolism and relation of increased cardiac troponin I levels with in-hospital mortality in patients with acute pulmonary embolism. Am J Cardio 2004;93(2):263–4.
41. Kostrubiec M, Pruszczyk P, Bochowicz A, et al. Biomarker-based risk assessment model in acute pulmonary embolism. Eur Heart J [Research Support, Non-U.S. Govt] 2005;26(20):2166–72.
42. Aksoy N, Ozer O, Sari I, et al. Contribution of renal function impairment to unexplained troponin T elevations in congestive heart failure. Ren Fail 2009;31(4):272–7.
43. Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106(19):2454–8.
44. Reed SD, Friedman JY, Velazquez EJ, et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2004;148(1):122–8.
45. Del Carlo C, O'Connor C. Cardiac Troponins in congestive heart failure. Am Heart J 1999;138:646–53.
46. La Vecchia L, Mezzena G, Zanolla L, et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. J Heart Lung Transplant 2000 Jul;19(7):644–52.
47. Neumayr G, Gaenzer H, Pfister R, et al. Plasma levels of cardiac troponin I after prolonged strenuous endurance exercise. Am J Cardiol 2001;87(3):369–71.
48. Fromm R. Cardiac Troponins in the intensive care unit: Common causes of increased levels and interpretation. Crit Care Med 2007;35(2):584–88.
49. Smith SC, Ladenson JH, Mason JW, et al. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 1997;95(1):163–8.
50. Velmahos GC, Karaiskakis M, Salim A, et al. Normal electrocardiography and serum troponin I levels preclude the presence of clinically significant blunt cardiac injury. J Trauma-Inj Infect Crit Care 2003;54(1):45-50; discussion 1.
51. Tung P, Kopelnik A, Banki N, et al. Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke 2004;35(2):548–51.
52. Homma S, Grahame-Clarke C. Editorial comment--myocardial damage in patients with subarachnoid hemorrhage. Stroke 2004;35(2):552–3.
53. Hossein-Nia M, Holt DW, Anderson JR, et al. Cardiac troponin I release in heart transplantation. Ann Thorac Surg 1996;61(1):277–8.
54. Labarrere CA, Nelson DR, Cox CJ, et al. Cardiac-specific troponin I levels and risk of coronary artery disease and graft failure following heart transplantation. JAMA 2000;284(4):457–64.
55. Mullen JC, Bentley MJ, Scherr KD, et al. Troponin T and I are not reliable markers of cardiac transplant rejection. Eur J Cardiothorac Surg 2002;22(2):233–7.
56. Desai AA, Nissenson A, Chertow GM, et al. The relationship between laboratory-based outcome measures and mortality in end-stage renal disease: A systematic review. Hemodial Int 2009;13(3):347–59.

# A RAISED TROPONIN: ARE THE KIDNEYS TO BLAME?

Anamika Bakshi, Sasiharan Sithamparanthan, Antonia Scobie, Michael Wilde





57. Zhang Q-L, Rothenbacher d. Prevalence of chronic kidney disease in population-based studies: Systematic review. BMC Public Health 2008;8(117).
58. Watnick S, Perazella MA. Cardiac troponins: utility in renal insufficiency and end-stage renal disease. Semin Dial 2002;15(1):66–70.
59. Sorensen CR, Brendorp B, Rask-Madsen C,et al. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur Heart J [Clinical Trial Comparative Study Randomized Controlled Trial] 2002;23(12):948–52.
60. Aviles RJ, Askari AT, Lindahl B, et al. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. New Engl J Med 2002;346:2047–52.
61. Wu AH, Feng YJ. Biochemical differences between cTnT and cTnI and their significance for diagnosis of acute coronary syndromes. Eur Heart J 1998;19 Suppl N:N25–9.
62. Antman EM, Grudzien C, Mitchell RN, et al. Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J 1997;133(5):596–8.
63. Jung HH, Ma KR, Han H. Elevated concentrations of cardiac troponins are associated with severe coronary artery calcification in asymptomatic haemodialysis patients. Nephrol Dial Transplant 2004;19(12):3117–23.
64. Harnett JD, Foley RN, Kent GM, et al. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors. Kidney Int 1995;47(3):884–90.
65. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997;96(9):2953–8.
66. Sato Y, Taniguchi R, Makiyama T, et al. Serum cardiac troponin T and plasma brain natriuretic peptide in patients with cardiac decompensation. Heart 2002;88(6):647–8.
67. Iliou MC, Fumeron C, Benoit MO, et al. Factors associated with increased serum levels of cardiac troponins T and I in chronic haemodialysis patients: Chronic Haemodialysis And New Cardiac Markers Evaluation (CHANCE) study. Nephrol Dial Transplant 2001;16(7):1452–8.
68. Amann K, Breitbach M, Ritz E, et al. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 1998;9(6):1018–22.
69. Ricchiuti V, Zhang J, Apple FS. Cardiac troponin I and T alterations in hearts with severe left ventricular remodeling. Clin Chem1997;43(6 Pt 1):990–5.
70. McLaurin MD, Apple FS, Voss EM, et al. Cardiac troponin I, cardiac troponin T, and creatine kinase MB in dialysis patients without ischemic heart disease: evidence of cardiac troponin T expression in skeletal muscle. Clin Chem 1997;43(6 Pt 1):976–82.
71. Zumrutdal A, Bakinen O, Ucan H, et al. Relationship between uremic myopathy and false-positive cardiac troponin T test. Nephron 2000;86(4):522–3.
72. Roppolo LP, Fitzgerald R, Dillow J, et al. A comparison of troponin T and troponin I as predictors of cardiac events in patients undergoing chronic dialysis at a Veteran's Hospital: a pilot study. J Am CollCardiol 1999;34(2):448–54.
73. Fredericks S, Chang R, Gregson H, et al. Circulating cardiac troponin-T in patients before and after renal transplantation. Clin Chim Acta2001;310(2):199–203.
74. Ellis K, Dreisbach AW, Lertora JL. Plasma elimination of cardiac troponin I in end-stage renal disease. South Med J 2001;94(10):993–6.

## Authors

**Anamika Bakshi BSc MBBS MRCP**
Core Medical Trainee 2
East Surrey Hospital
Redhill

**Sasiharan Sithamparanthan BMedSci BMBS MRCP**
Core Medical Trainee 2
East Surrey Hospital
Redhill

**Antonia Scobie BSc MBBS MRCP**
Core Medical Trainee 2
East Surrey Hospital
Redhill

**Michael Wilde BSc MRCP**
Consultant Respiratory Physician
East Surrey Hospital

## Correspondance

**Dr Anamika Bakshi**
anamikabakshi@hotmail.co.uk

# ANAPHYLAXIS AND VENOM IMMUNOTHERAPY

Dr Elizabeth Waldegrave, Dr Jessica Gale

## Anaphylaxis and Venom Immunotherapy Good Clinical Care.


## Abstract

We describe the case of a patient who had an anaphylactic reaction to a wasp sting and elicit the typical features of anaphylaxis. We go onto discuss the underlying immunology looking specifically at the role of IgE. We review appropriate emergency management, and subsequent investigation of anaphylaxis. Finally, the role of venom immunotherapy is explored.


## Case Study

A 57-year-old female gardener, usually fit and well, was stung by a wasp on her left ankle, and immediately afterwards started to cycle the 5 miles home. Approximately 15 min later, she developed an intense generalized itch affecting her whole body. This progressed into a widespread itchy rash and swelling of her lips and face.

She immediately presented to her GP where it was noted that in addition to a generalized urticarial rash and facial angioedema her speech was also slurred. She was hypotensive at 67/40 but did not have any signs of respiratory distress. She had no medical history of note and was on no regular medications. She had previously been stung by a wasp a number of years earlier which caused only a mild localized reaction. She had no known allergies.

The GP diagnosed an anaphylactic reaction and gave 500 mcg intra-muscular adrenaline with immediate response. Her blood pressure normalized and her symptoms resolved. She was subsequently given 4 mg chlorphenamine and monitored for 2 hours at the GP surgery. She was given an adrenaline auto-injector and referred to an allergy out patient clinic.

## Did This Patient Have Typical Features of Anaphylaxis?

Anaphylaxis is defined as 'a severe, life-threatening, generalized or systemic hypersensitivity reaction'[1].

Several target organs are affected by anaphylaxis; including skin (90% of presentations), respiratory tract (70%), GI tract (30%–40%), cardiovascular system (10%–45%) and CNS (10%–15%). The clinical presentation varies with which organs are affected. By definition anaphylaxis is systemic and therefore will involve more than one system[2].

Common clinical features include urticaria, pruritis, angiodema, nausea, vomiting, abdominal pain, syncope and flushing. The features that are life-threatening are airway obstruction and hypotension.

The presentation in this case involved urticaria, angiodema and hypotension which are considered 'typical' of anaphylaxis. The time period from sting to onset of symptoms was also typical in that her symptoms developed approximately 15 min after being stung. However her CNS involvement with slurred speech, and absence of respiratory symptoms are less common features.

## Was Exercise a Contributing Factor?

Exercise itself can induce anaphylaxis either alone or in combination with an allergen such as foods or drugs[3]. This patient was exercising during the onset of the symptoms, and therefore it could be argued that her anaphylaxis may have been exercise induced. However, the history of the wasp sting and the elevated specific IgE to wasp venom makes this less likely.

Currently there are no documented cases in the literature of exercise induced anaphylaxis associated with venom allergy.

## What Is the Underlying Immune Mechanism?

There are four types of hypersensitivity reactions; all mediated by the adaptive immune system. They occur in individuals with prior exposure and sensitisation to a particular allergen. The different types are characterized by the mechanism and speed of onset. Anaphylaxis is a type 1, immediate hypersensitivity reaction mediated by IgE, occurring within an hour of exposure of an allergen.

IgE is a monomeric immunoglobulin[4], its key roles are in allergy and fighting parasitic infections. IgE is the least abundant of the five immunoglobulin isotypes in serum; normal ranges vary with age but are generally <300 kU/l in adults[5].

Total serum IgE is not diagnostically specific; elevated levels can be seen in parasitic infections, and can vary from season to season in atopic individuals. It has a limited clinical role. Of more relevance are specific IgE levels which can pinpoint which allergen has induced IgE production. Serum can be tested for specific IgE to many different food substances, drugs, pollens and insect venom. It therefore has an important role in determining which allergen is responsible for the type 1 allergic reaction, and hence future avoidance.

# ANAPHYLAXIS AND VENOM IMMUNOTHERAPY

Dr Elizabeth Waldegrave, Dr Jessica Gale

Skin prick testing is an in vivo method of testing IgE responses to specific allergens. This can be performed in combination with specific IgE testing, or alone.

## How Is IgE Produced?

IgE is produced by plasma cells. Activation, differentiation and proliferation of naïve B cells to memory B cells and antibody producing plasma cells occurs when naïve B cells are stimulated by allergens through either T–cell-dependent or T–cell-independent mechanisms. IgM is the first immunoglobulin isotype to be produced by plasma cells in the primary immune response. In the secondary response other isotypes with an ability to bind to the antigen are produced. This process is known as class switching. Class switching to IgE is mediated by Th2 cells and their related cytokines (eg IL4, IL5 and IL6). Many factors are thought to play are role in promoting class switching to IgE, including both genetic and environmental factors as this occurs to a much greater degree in some individuals than others. Generally, these individuals will show clinical features of atopy. IgE produced by plasma cells binds to basophils in the blood and mast cells in tissues by high affinity receptors. Individuals are thus sensitised. Atopic individuals with higher levels of IgE will have up to five times the amount of IgE bound to cells compared with the normal population[6].

## What Happens in Anaphylaxis?

Allergy and anaphylaxis occur when a sensitized individual is next presented with the allergen. The allergen induces cross-linking between IgE molecules bound to mast cells and basophils and results in degranulation of the mast cell, releasing pre-formed mediators (e.g., histamine, heparin) as well as synthesis of arachidonic acid metabolites (e.g., leukotrienes, prostaglandin, thromboxanes). The pre-formed mediators are stored secretory granules; the major protein component of the granules is tryptase.

The major physiological effects of these various substances are: increased capillary permeability; mucosal oedema and smooth muscle contraction. These physiological changes explain the range of clinical features described earlier, and those seen in our patient.

## Was the Immediate Management Appropriate?

The UK resuscitation guidelines[7] outline the essential aspects of immediate management as shown in Fig. 1. Management includes:

- Adrenaline (non-selective adrenoreceptor agonist, increases blood pressure by vasoconstriction and increasing cardiac contractility as well as causing bronchial dilatation. It also stabilizes mast cells and inhibits further histamine release)
- Fluid resuscitation (to restore losses from increased vascular permeability and vasodilatation causing pooling of blood)
- Anti-histamines, steroids and bronchodilators.




**Fig. 17. Guidelines for immediate management of anaphylaxis.**

## How Should Adrenaline Be Given?

Adrenaline for anaphylaxis should be given intra-muscularly. The adult dose is 500 mcg (0.5 mL of 1:1000).[8]

## How Long Does It Take to Work?

Adrenaline has a rapid onset of action and the plasma half-life is about 2.5 min. During the initial stages of anaphylaxis the absorption of IM adrenaline is very good due to the vasodilation. However if the patient develops peripheral vasoconstriction seen in the later stages of anaphylaxis the onset of action is delayed[9]. Multiple doses may often be required and should be given after 5 min if clinically appropriate.

## Are There Other Investigations which Should Be Done at This Stage?

If possible, samples should be taken for serial tryptase measurement. Ideally three samples with the initial sample taken as soon as possible after stabilising the patient, repeated at 1–2 hours after onset of symptoms (when levels peak) and a third sample at more than 24 hours after onset. A total of 5 ml of serum or clotted blood should be sent with the times clearly recorded.[7] As mentioned earlier tryptase is a component of the mast cell granules from which mediators such as histamine are released in anaphylaxis. The half-life of histamine is 2–3 min so measuring histamine levels acutely is not possible. Tryptase has a half-life of 2 hours, its decay curve can therefore be observed over 24 hours (compared with 20 min for histamine). Normal levels of serum tryptase are <11.4 µg/L, so in a patient with anaphylaxis we may expect elevated/normal levels in the first sample; a peak in the second and normal baseline levels after more than 24 hours[10].

# ANAPHYLAXIS AND VENOM IMMUNOTHERAPY

Dr Elizabeth Waldegrave, Dr Jessica Gale

## Further Investigations

At the allergy clinic investigations revealed this patient's specific-IgE to wasp to be moderately elevated at 2.9 ku/L (see box 1). This is significant in supporting the diagnosis of wasp venom anaphylaxis. Specific-IgE to bee venom was negative. As tryptase levels were not sent during the initial presentation, there is no benefit to requesting them afterwards as they will have normalized.

**Normal Ranges for Specific IgE:**

<0.35 kUA/l no specific IgE antibody detected

0.35–0.70 kUA/l weak positive

0.70–3.50 kUA/l positive

**Box 1. Normal Ranges for Specific IgE[11]**

This patient was advised to avoid wasps as much as possible, and to always carry an adrenaline auto-injector for use should she sustain another wasp sting and develop another systemic reaction. However, as she is a gardener, trying to avoid exposure to the allergen is impracticable. Therefore, she was referred to an allergist for consideration of wasp venom desensitization.

## Who Is Eligible for Referral to an Allergist?

The resuscitation council guidelines[7] state that every patient with anaphylaxis should be referred to an allergist. At the allergy clinic it is the role of the doctor to determine the likely causes of anaphylaxis from the history and investigations such as specific IgE and skin prick testing. They ensure that the substance the patient is allergic to is communicated clearly to the patient and the GP for future avoidance, and they also further educate the patient on how to the use their adrenaline auto-injector.

For a small number of causes of IgE hypersensitivity, desensitization can be offered, and it is up to the immunologist to determine those who would be appropriate for this.

## What Advice Do You Give Alongside the Prescription of an Adrenaline Auto-Injector?

One clinical review12 published an algorithm to help identify those who would benefit from an adrenaline auto-injector (see Fig. 2). For all patients that are prescribed adrenaline, it is essential that they are taught how to use it accurately. Patients should be shown how to deliver the IM injection safely using a training injector, as one risk of incorrect administration, is that the adrenaline is accidently injected into the patient's thumb causing vasoconstriction and potentially ischaemia13. As shown in Fig. 1 autoinjectors contain 300 mcg of adrenaline. This is primarily for safety reasons, should the medications be administered incorrectly or given to a child.

Patients should be taught to inject the adrenaline prior to calling an ambulance, this ought to avoid the patient injecting after only a minor reaction and exposing themselves to potential side effects. Adrenaline side effects include vomiting, tachycardia, arrhythmias, tissue necrosis at the site of injection, dizziness and dyspnoea[8].

Adrenaline acts very quickly; the time from intramuscular injection to maximum plasma concentration is 8 min12. It has a short half-life of a number of minutes, and therefore it is appropriate to repeat the IM injection after 5 min if the clinical response is not maintained14. Therefore the patient will always need to call an ambulance after having delivered their adrenaline, as they may require subsequent doses.




**Image 1. Instructions for use of two different auto-injectors[12]**

# ANAPHYLAXIS AND VENOM IMMUNOTHERAPY

Dr Elizabeth Waldegrave, Dr Jessica Gale




**Figure 2. Algorithm to detect those who would benefit from an auto-injector.[12]**

## Desensitization Course

In the UK, the most common insects capable of stinging humans and producing a hypersensitivity reaction are of the hymenoptera order, and include bees and wasps. Bees release approximately 50 µg per sting, whereas wasps inject around 2–20 µg per sting[15].

## Who Should Be Referred for Desensitization?

A patient with a clear history of anaphylaxis with either a positive specific IgE testing to the offending insect, or positive skin prick testing to the specific venom, is then eligible for desensitization therapy. Desensitization is more likely to be considered for patients, like our case study, where avoidance of the allergen would be difficult. It is also only recommended for patients likely to be compliant and cooperative[16]. Venom immunotherapy is estimated to decrease the incidence of anaphylaxis induced by stings from a pre-treatment level of 50% to <5%.[17]

## What Does the Course Involve?

Initially the patient goes through induction during which they are given subcutaneous injections of gradually increasing strengths of diluted venom. The time period that this is delivered over varies greatly between centres from 1 to 3 days, to 8 weeks. Once the patient has reached maintenance dose (100 mcg), they need to continue receiving this on a regular basis, though the period of time in between injections can be gradually increased[18]. The whole process lasts between 3 and 5 years depending on the centre.

This patient has agreed to commence wasp venom desensitization, and she is currently in her induction phase. She continues to carry her adrenaline auto-injector with her at all times and is vigilant in avoiding wasps.

## MCQs

**1. A 22-year-old student comes into your GP surgery with unmanageable hay fever. He is being managed with regular antihistamines, steroid nasal spray and eye drops and finds that his symptoms are affecting his daily activities. He asks you about pollen desensitizsation and how effective it is.**

a) The longer the duration of immunotherapy, the more effective it is
b) The oral route is more efficacious than sublingual
c) There is a 70% reduction in symptoms and 50% reduction in medication requirement.
d) There is an 80% reduction in symptoms, but the medication requirement stays the same.
e) There is a 50% reduction in symptoms, and an 80% reduction in medication requirement.

**2. A 12-year old girl attends your GP surgery with difficulty breathing. The symptoms came on suddenly at school during lunchtime and have been present for an hour. She is normally fit and well.**

On examination she is in respiratory distress with tachypnoea and using her accessory muscles of respiration. Her blood pressure is 85/60, and heart rate is 115. There are extensive wheals all over her body. Her lips and eyes are puffy and swollen.

**In management of this patient, your first priority is:**

a) To take blood for tryptase levels and specific IgE as this will be important in avoiding the trigger in future.
b) Administer 4 mg chlorphenamine orally
c) Administer 0.5 mg IM adrenaline
d) Give 5 mg of nebulized salbutamol
e) Administer high flow oxygen

# ANAPHYLAXIS AND VENOM IMMUNOTHERAPY

Dr Elizabeth Waldegrave, Dr Jessica Gale

## Answers

**Answer E.**

Extending the maintenance course to greater than 12 months is not thought to be associated with any increase in efficacy.

The preferred route is sublingual rather than oral, as there is greater absorption. There is a 50% reduction in the symptom scores, and an 80% reduction in medication requirement[19].

**Answer C.**

This patient has anaphylaxis and is clinically unstable. She needs immediate treatment with IM Adrenaline. In a GP surgery setting up high flow oxygen is likely to be time consuming, and will not ultimately reverse the disease process. Chloramphenamine may be useful once the patient is stable, but should not delay administration of adrenaline. Taking blood for tryptase level should only be commenced after the patient has been stabilized.

Salbutamol may transiently help her breathing, but would not treat the laryngeal oedema that is likely to occlude her airway.

## References


1. Johansson SGO et al. A Revised Nomenculture for Allergy. Allergy 2001;56:813–24.
2. Simons ER. Anaphylaxis. J Allergy Clin Immunol 2010;125(2 suppl 2):S161–81.
3. Nolte K, van Rensburg CJ. Exercise-induced anaphylaxis. Current Allergy & Clinical Immunology 2010; 23(2):78–80.
4. Hamilton RG. Clinical laboratory assessment of immediate-type hypersensitivity. J Allergy Clin Immunol 2010;125:284–96.
5. Mediarty A, Neuber K. Total and specific serum IgE decreases with age in patients with allergic rhinitis, asthma and insect allergy but not in patients with atopic dermatitis. Immun Ageing 2005;2(1):9.
6. Sturm GJ et al. Influence of total IgE levels on the severity of sting reactions in Hymenoptera venom allergy. Allergy 2007;62: 884–89.
7. Soar J et al. Emergency Treatment of Anaphylactic Reactions-Guidelines for Healthcare Providers. Resuscitation 2008;77:157–69.
8. British National Formulary. London: BMJ Group and RPS Publishing; 2008:173–4.
9. Brown A. Therapeutic controversies in the management of acute anaphylaxis. J Accid Emerg Med 1998;15:89–95
10. Kucharewicz I, Bodzenta-Lukaszyk A, Szymanski W, et al. Basal serum tryptase level correlates with severity of hymenoptera sting and age. J Investig Allergol Clin Immunol 2007;17(2):65–9.
11. Phadia. ImmunoCAP 1000 Specific IgE Procedure. http://www.phadia.us/upload/US/Product_information/Files/CLSI-NCCLS%20Docs/ImmunoCAP%201000%20CLSI/CLSI_%20ImmunoCAP_1000_Specific_IgE.doc (accessed 15.10.10).
12. McLean-Tooke APC, Bethune CA, Fay AC, et al. Adrenaline in the Treatment of Anaphylaxis: What is the Evidence. BMJ 2003;327:1332–5.





13. I Velissariou, S Cottrell, K Berry, et al. Management of Adrenaline (Epinephrine) Induced Digital Ischaemia in Children After Accidental Injection from an EpiPen. Emerg Med J 2004;21:387–388.
14. Simons FER, Roberts JR, Gu X, et al. Epinephrine Absorption in Children with a History of Anaphylaxis. J Allergy Clin Immunol 1998;101(1):33–7.
15. Freeman TM. Hypersensitivity to Hymenoptera Stings. N Eng J Med 2004;351:1978–84.
16. James et al. Allergen immunotherapy: a practice parameter. Annals of Allergy, Asthma and Immunology. 2003;90.
17. Diwakar L, Noorani S, Huissoon AP, et al. Practice of Venom Immunotherapy in the United Kingdom: A National Audit and Review of Literature. Clin Exp Allergy 2008;38:1651–58.
18. Cavallucci E, Ramondo S, Renzetti A, et al. Maintenance Venom Immunotherapy Administered at a 3-Month Interval Preserves Safety and Efficacy and Improves Adherence. J Investig Allergol Clin Immunol 2010;20(1):63–8.
19. Wilson D, Torres-Lima M, Durham S. Sublingual Immunotherapy for Allergic Rhinitis (Review). The Cochrane Library 2009;1.


## Authors


**Dr Elizabeth Waldegrave, MBBS**
Rheumatology FY2
Wycombe General Hospital
Buckinghamshire Hospitals Trust

**Dr Jessica Gale, MBChB**
Accident & Emergency F2
Wycombe General Hospital,
Buckinghamshire Hospitals Trust

**Professor Helen Chapel, MD, FRCPath, FRCP**
Consultant Immunologist
Nuffield Department of Medicine
University of Oxford and Oxford Radcliffe Hospitals NHS Trust


## Address for correspondence


**Dr Jessica Gale**
176 Green Ridges, Headington, Oxford, OX3 8LZ

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi

**Important AIDS-Defining Illnesses in the UK.**
**Patient Management.**


## Abstract

Human Immunodeficiency Virus (HIV) presents to the clinician in a number of ways, and it is important to consider this diagnosis particularly in people who are from at-risk groups. Untreated HIV infection progresses through different stages. Primary HIV infection applies to the first 6 months of infection and may present as a non-specific viral illness. During the asymptomatic phase, most patients remain healthy and symptom free. This phase may last on average for 7 years. Severe immuno-suppression that results in Acquired Immunodeficiency Syndrome (AIDS) follows the asymptomatic phase of infection if patients are left untreated. AIDS is characterized by the onset of indicator diseases.

This article aims to discuss important AIDS-defining illnesses in the UK pertaining to all doctors to improve detection of HIV, as earlier detection confers a more favourable prognosis.


## Case Study

A 32-year-old Somalian lady was admitted to hospital with a 2 week history of feeling unwell with a dry cough, fever, lethargy, reduced appetite, weight loss and mouth sores. On examination her chest was clear, she had reduced oxygen saturations, mouth sores were consistent with oral candidiasis.

A total of 3 months prior to admission, she had visited her general practitioner and was treated for bacterial pneumonia. She had a medical history of cervical intraepithelial neoplasia III picked up on smear 5 years ago and shingles 2 years prior to admission.

She was originally treated for atypical pneumonia. An HIV test was performed and was found positive. After broncho-alvelor lavage samples were obtained, she was subsequently diagnosed with *Pneumocystis jiroveci* Pneumonia (PCP).

## Introduction

The introduction of highly active antiretroviral therapy (HAART) in 1996 saw a reduction in the incidence of AIDS-defining illnesses and deaths[1]. Despite this they are an important cause of morbidity and mortality with two million AIDS-related deaths globally in 2008[2]. A proportion of these deaths would have been prevented with early diagnosis of HIV and start of HAART. In developed countries nearly a third of people are unaware of their HIV status[3]. It is therefore important to have a high index of suspicion for these events and consider HIV testing.

HAART aims to suppress viral replication, working on a number of different stages of the HIV life cycle; cell entry (entry inhibitors), generation of viral DNA chains (reverse transcription), prevention of integration of viral DNA into the host cell's genome (integration) and prevention of maturation of new viral particles (viral protease).

Between 1994 and 2007, the number of AIDS-related deaths had fallen by 69%[4]. This reduction was mostly related to HAART. In addition, prophylaxis with co-trimoxazole—when CD4 counts fall below 250 cells/mm$^3$—has helped reduce incidence of the most common fatal AIDS-defining illness in the UK—Pneumocystis jiroveci pneumonia[5].

## *Pneumocystis jiroveci* Pneumonia

Pneumocystis jiroveci pneumonia is a fungal infection whose incidence has declined with HAART and chemoprophylaxis[6]. The majority of cases occur in patients unaware of their HIV status or who are poorly adherent to medication[7]. Despite its decline it is still one of the most important opportunistic infections being a common indication for ITU admission in HIV patients. Furthermore, of those requiring ITU admission it has an associated poor prognosis with mortality rates as high as 80%[8].

Exertional dyspnoea and interstitial infiltrates on chest radiograph are key markers for PCP[9]. Perihilar shadowing is another radiological finding. In addition, non-productive cough, chest tightness, fever and reduced oxygen saturation on air can be seen. A CT thorax may also show patchy ground glass changes[10].

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi

**Important AIDS-Defining Illnesses in the UK.**
**Patient Management.**

Diagnosis is based on performing PCP polymerase chain reaction (PCR) on broncho-alveolar lavage samples or sputum. Once PCP is diagnosed, treatment with a 21-day course of high dose co-trimoxazole is recommended. If the patient is hypoxic the addition of steroids should be considered.

## Mycobacterium Tuberculosis

The World Health Organisation estimated Mycobacterium tuberculosis (TB) is responsible for 13% of deaths in patients with AIDS[11]. Cases of TB are due to either active infection soon after exposure or reactivation of latent infection. Annual risk of reactivation in latent TB is much higher in HIV patients[12]. In Sub-Saharan Africa, a large percentage of patients with extra-pulmonary TB have HIV[13]. Extra-pulmonary disease is also more common in advanced HIV.

TB is a multi-system infection with a particular pattern of progression. In immunocompetent individuals, it initially forms a Ghon focus or primary complex which then goes on to produce active infection, or alternatively progress to latent infection. In HIV patients there may not be such a focus or complex. Clinical features of acute active infection include persistent cough, dyspnoea, night sweats, fever, pleuritic chest pain and haemoptysis. In addition, systemic symptoms such as weight loss, lymphadenopathy and malaise may also be present. All HIV patients with pyrexia of unknown origin should be screened for TB. Symptoms can be non-specific, and the diagnosis requires a high degree of suspicion. Conversely latent TB is asymptomatic, and these patients are not infectious but at risk of re-activation. It is important to remember that reactivation can occur particularly with increasing levels of immunosuppression or after the initiation of HAART due to immune reconstitution inflammatory syndrome. Restoration of the immune system leads to an inflammatory process against the offending pathogen which may produce symptoms.

Diagnosis is made from the growth of Mycobacterium tuberculosis from respiratory secretions in pulmonary TB[9]. Three early morning sputum samples for culture and microscopy in addition to early morning urine and multiple TB blood cultures should be obtained. Cultures will also provide important information on drug sensitivities. Chest radiographs can also be helpful especially with the characteristic appearance of upper zone shadowing, often bilateral and associated with cavitation in addition to miliary shadowing[14].

In HIV chest radiographic changes are less characteristic. In suspected latent TB, a Mantoux test can be performed however results should be treated with caution in HIV patients due to high false-positive and false-negative results. The interferon gamma-releasing assays QuantiFERON-tuberculosis Gold and T-SPOT have been shown to supercede the Mantoux test in detecting TB in HIV infected individuals[15].

Standard treatment for active TB consists of 6 months of isoniazid and rifampicin plus pyrazinamide and ethambutol for the first 2 months[16]. Infections involving the CNS are treated for 12 months. Patients with multi-drug resistant TB have high level resistance to isoniazid and rifampicin and ideally should be managed in a specialised centre[17].

It is important to treat latent TB to minimise or prevent the risk of reactivation of TB occurring in the future. In HIV patients the recommended regime is 6 months of isoniazid[16].

## Mycobacterium Avium Complex

Mycobacterium Avium Complex (MAI) typically occurs in patients with CD4 cell counts less than 50 cells/mm$^3$. It is also associated with high plasma levels of HIV RNA.

It can affect any organ, and the majority of patients present with disseminated disease. Prior to HAART a triad of features were often seen; raised alkaline phosphatase, anaemia and fever. In addition features such as night sweats, weight loss, lymphadenopathy and GI symptoms such as diarrhoea and abdominal pain may also be present.

Diagnosis is made by culture and staining of affected often extra-pulmonary sites such as bone marrow, liver and lymph nodes. PCR testing is also a useful diagnostic tool.

Treatment of MAI has its difficulties due to a combination of inherent resistance to isoniazid and a protracted drug course. In addition, there are a number of drug interactions with anti-retroviral drugs which adds further complications. The mainstay of treatment is with ethambutol, rifabutin and clarithromycin.

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi

## Bacterial Pneumonia

The incidence of bacterial pneumonia is higher in those with HIV infection[18]. It is a common cause of morbidity in the general population and may be the first manifestation of HIV. In addition, there is an increased mortality in HIV patients[19].

The organisms are the same as for non–HIV-infected persons and include Streptococcus pneumonia, Haemophilus influenza and Pseudomonas aeruginosa[20].

Presentation is often similar to non–HIV-infected individuals. However, immunocomprimised persons are more likely to have recurrent episodes. Chest radiographs often show lobar infiltrates[9]. To help guide treatment, blood and sputum samples should be sent for culture. In addition, an atypical pneumonia screen should be performed which should include testing for legionella urine antigen.

## Candidiasis

Oro-pharyngeal candidiasis is one of the most common opportunistic infections[13]. Immunocompromised subjects have frequent recurrences and the episodes are often more severe and ought to prompt the clinician to screen for HIV.

Candida albicans is the commonest causative agent. It presents with symptoms such as soreness of the mouth and commonly white plaque like lesions on the buccal and oropharyngeal mucosa or tongue that can be easily scraped off (Fig. 1). Oesophageal candidiasis can cause odynophagia and weight loss and may be diagnosed with gastroscopy.



**Figure 1: Classical features of pseudomembranous candidiasis with plaques affecting the mouth and pharynx[21].**

Candidiasis infections respond to anti-fungal agents such as fluconazole and will improve after commencing anti-retroviral therapy. It is important not to use anti-fungal agents long term due to the risk of developing resistance.

## Malignancy

The presence of HIV doubles the risk of malignancy[13]. In addition, cancer in immunocompromised patients often follows a more aggressive course and is often associated with a poorer prognosis.

## Kaposi's Sarcoma

Human herpes virus-8 has been identified as the causative organism in kaposi's sarcoma, which is the most common malignancy, affecting HIV patients. It is usually a late manifestation of AIDS and often follows an aggressive course[22].

It is mainly a cutaneous disease but can also affect visceral organs, including lymph nodes. In addition, patients may also present with non-pitting peripheral oedema. The face is the most common part of the body affected. Lesions usually begin as macular or papular eruptions progressing to plaques or nodules [23] (Fig. 2). Colour varies from pink to deep purple with a yellow or green halo characteristically surrounding them[13]. In darker skinned people lesions are usually brown or black. Large painful plaques may appear, usually on soles of feet and thighs[13]. About a third of people will have deep coloured purple plaques in the mouth, usually the hard palate which are often asymptomatic (Fig. 3).



**Figure 2: Typical brown cutaneous lesions found in kaposi's sarcoma[24].**

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi



**Important AIDS-Defining Illnesses in the UK.**
**Patient Management.**



**Figure 3: Appearance of kaposi's sarcoma lesion affecting the oral cavity with overlying candidiasis[25].**

Definitive diagnosis is made by histological exam ination of the lesions. In the majority of cases the introduction of HAART significantly improves kaposi's sarcoma particularly if there is systemic involvement however chemotherapy may also be required.

## B-Cell Lymphoma

The second commonest malignancy in HIV patients is high grade B-cell lymphoma[23] whose incidence has not decreased following the introduction of HAART[26].

Patients usually present with widespread disease and B symptoms such as night sweats, fever, weight loss and lymphadenopathy. Routine blood tests might show anaemia and deranged liver function tests. In HIV, extranodal involvement of the central nervous system and gastrointestinal tract is more commonly seen.

Diagnosis is made by lymph node biopsy, staging CT scan and bone marrow biopsy. Management involves the use of chemotherapeutic agents.

## Cryptococcal meningitis

Cryptococcus neoformans is the most common fungal pathogen affecting the CNS. In developing countries where HIV prevalence is high, cryptococcus is the most common cause of meningitis and should be considered in HIV patients.

Symptoms can be mild and may have been present for months prior to initial presentation[27]. Headache is usually the predominant presentation often with an associated fever. Meningism, which is often the defining symptom in bacterial meningitis is uncommon with Cryptococcus. In addition, other neurological manifestations include confusion, weakness, altered sensation and cranial nerve palsies.

If lumbar puncture is performed cerebrospinal fluid opening pressure is usually high. Diagnosis is made by identification of the organism in cerebral spinal fluid or with a positive India Ink stain. In addition, a serum cryptococcal antigen latex agglutination test can be performed. CT/MRI scans are often normal but may show ring enhancing lesions in the brain when cryptococcomas are present.

Management involves HAART, intravenous amphotericin B and flucytosine followed by long-term oral anti-fungal agents such as fluconazole. In addition, therapeutic lumbar punctures are performed to prevent raised intracranial pressure which can lead to cranial nerve palsies.

## Summary

Most AIDS-defining illnesses develop in patients with immunosuppression. It is therefore important to identify patients with HIV before they become immunosuppressed. Administration of HAART at the right time often helps preserve the immune status and leads to a reduction in progression to AIDS. Identifying HIV patients early on may prevent the often debilitating effects of AIDS-defining illnesses.

We have demonstrated the important clinical presentations of AIDS-defining illnesses that present to clinicians in the UK. This list is by no means exhaustive and Table 1 illustrates other AIDS-defining illnesses and diseases where HIV testing should be considered.

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi



| | AIDS-Defining Illness | Conditions Where HIV Testing Should Be Considered |
|---|---|---|
| Respiratory | Pneumocystis | Bacterial pneumonia |
| | Tuberculosis | |
| Gastroenterology | Oesophageal candidiasis | Oral hairy leukoplakia |
| | Cryptosporidiosis | Persistent/recurrent oral candidiasis |
| | Isosporiasis | Chronic diarrhoea of unknown cause |
| | | Hepatitis B infection |
| | | Hepatitis C infection |
| Malignancy | Kaposi Sarcoma | Anal cancer |
| | Non-Hodgkins lymphoma | Castleman's disease |
| | Cervical Carcinoma | |
| Neurology | Cerebral toxoplasmosis | Cerebral abscess |
| | Cryptococcal meningitis | Herpes zoster (shingles)- recurrent or |
| | Primary Cerebral lymphoma | involving >1 dermatome |
| | Progressive multifocal | |
| | leukoencephalopathy | |
| Ophthamology | CMV retinitis | |
| Dermatology | | Recurrent/persistent seborrhoeic dermatitis |
| | | Recurrent/persistent psoriasis |
| Haematology | | Idiopathic thrombocytopenic purpura |
| Others | Mycobacterium avium | Recurrent or persistent herpes simplex |
| | complex | Pyrexia of unknown origin |
| | | Lymphadenopathy of unknown cause |
| | | Any sexually transmitted infection |

**Table 1. Clinical Indicator Diseases for Adult HIV Infection[28]**

## Useful Websites

**www.bhiva.org**
British HIV Association

## References

1. Manfredi R., Chiodo F. Features of AIDS and AIDS defining diseases during the highly active antiretroviral therapy (HAART) era, compared with the pre-HAART period: A case control study. Sex Transm Infect 2000; 76:145–46.
2. UNAIDS Global facts and figures fact sheet 09. [Updated 2009 November; cited 2010 June 28th]. Available from: http://data.unAID's.org/pub/FactSheet/2009/20091124_FS_global_en.pdf
3. UNAIDS Fact sheet 09; North America and Western and Central Europe. [Updated 2009 November; cited 2010 June 28th]. Available from: http://data.unaids.org/pub/FactSheet/2009/20091124_FS_nawce_en.pdf
4. UNAIDS AIDS epidemic update. [Updated 2009 November; cited 2010 June 28th] Available from: http://data.unaids.org/pub/Report/2009/JC1700_Epi_Update_2009_en.pdf
5. Furrer H., Egger M., Opravil M., et al. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study. N Engl J Med 1999; 340:1301–6.
6. Phair J., Munoz A., Detels R., et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990; 322:161–5.
7. Lundberg B.E., Davidson A.J., Burman W.J. Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contri¬bution of non-adherence and drug failure. AIDS 2000; 14:2559–66.
8. Morris A., Wachter R.M., Luce J., et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17: 73–80.
9. Selwyn P.A., Pumerantz A.S., Durante A., et al. Clinical predictors of Pneumocystis carinnii pneumonia, bacterial pneumonia and tuberculosis in HIV-infected patients. AIDS 1998; 12: 885–93.
10. Hidalgo A., Falco V., Mauleon S., et al. Accuracy of high-resolution CT in distinguishing between Pneumocystis carinii pneumonia and non-Pneumocystis carinii pneumonia in AIDS patients. Eur Radiol 2003; 13:1179–84.
11. Global tuberculosis control; surveillance, planning, financing. WHO report 2007. Geneva, World Health Organisation.
12. Horsburgh C.R. Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350:2060–7.
13. Pattman R., Snow M. , Handy P., et al (eds.). Oxford Handbook of Genitourinary Medicine, HIV and AIDS. New York. Oxford University Press 2005.
14. Campbell I.A., Bah-Sow O. Pulmonary Tuberculosis: diagnosis and treatment. BMJ 2006; 332:1194–7.

# IMPORTANT AIDS-DEFINING ILLNESSES IN THE UK

Emma Clarke, Kaveh Manavi


**Important AIDS-Defining Illnesses in the UK.**
**Patient Management.**

15. Stephan C., Wolf T., Goetsch U., et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV infected individuals from a low prevalence tuberculosis country. AIDS 2008: 2471–9.
16. National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians, 2006.
17. Pozniak A.L., Miller R.F., Lipman M.C.I., et al. BHIVA treatment guidelines for TB/HIV infection 2005. http://www.bhiva.org/documents/Guidelines/TB/TB_HIV_FINAL2005.pdf (Accessed 2nd July 2010).
18. Hirschtick R., Glassroth J., Jordan M.C., et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. N Engl J Med 1995; 333:845–51.
19. Kohli R., Lo Y., Homel P., et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemio¬logic research (HER) study. Clin Infect Dis 2006; 43:90–8.
20. Rimland D., Navin T.R., Lennox J.L., et al. Prospective study of etiologic agents in community aquired pneumonia in patients with HIV infection. AIDS 2002; 16: 85–95.
21. Centre for Disease Control and Prevention Public Health Image Library. Image 1217. Http://phil.cdc.gov/phil/details.asp. (Accessed 2nd July 2010).
22. Tirelli U., Franceschi S., Carbone A. Malignant tumours in patients with HIV infection. BMJ 1994; 308:1148–53.
23. Powles T., Matthews G., Bower M. AIDS related systemic non- Hodgkin's Lymphoma. Sex Transm Infect 2000; 76: 335–41.
24. Centre for Disease Control and Prevention Public Health Image Library. Image 6436. Http://phil.cdc.gov/phil/details.asp. (Accessed 2nd July 2010).
25. Centre for Disease Control and Prevention Public Health Image Library. Image 6058. Http://phil.cdc.gov/phil/details.asp. (Accessed 2nd July 2010).
26. Palella FJ Jr., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853–60.
27. Juhi T., BibhaBati M., Aradhana B., et al. Cryptococcal meningitis in a Tertiary Hospital. J Med Mycol 2009; 50: 95–9.
28. Adapted from British HIV association. UK National guidelines for HIV testing 2008. http://www.bhiva.org/documents/Guidelines/TB/TB_HIV_FINAL2005.pdf (Accessed 2nd July 2010). P7-8.

## Authors

**Emma Clarke, MBChB, BMedSc**
Foundation Year Two Doctor
GU Medicine department
University Hospital Birmingham
Email: eclarke4@nhs.net

## Corresponding author

**Kaveh Manavi MD, FRCP**
Consultant in GU/HIV medicine
GU Medicine Department
University Hospital Birmingham

**Emma Clarke, MBChB, BMedSc**
Foundation Year Two Doctor
GU Medicine department
University Hospital Birmingham

# INFECTIVE ENDOCARDITIS: HOW IMMUNOLOGY TESTS MAY HELP OR MISLEAD

John Maher

**Infective Endocarditis: How Immunology Tests May Help or Mislead Good Clinical Care.**


## Abstract

Immunopathology plays an important role in infective endocarditis. In this context, two cases are presented here. In both patients, several abnormal immunological test results were obtained. Some findings were typical, whereas others were unanticipated and potentially misleading. Failure to interpret such findings correctly could lead to selection of inappropriate and potentially highly dangerous treatment. Pitfalls associated with immunological testing in this model of chronic infection are discussed. The need for clinicopathological liaison in the interpretation of diagnostic results is emphasized.


## Case Studies

### Case 1

A 53-year-old man was admitted with a history of weight loss, poor appetite, progressive breathlessness on exertion, malaise, intermittent nosebleeds, nasal stuffiness and palpitations. His medical history was significant for metal valve replacement for mitral valve prolapse 5 years earlier. Medications given were warfarin and flecanide. On examination, temperature was 37.5°C. No stigmata of endocarditis were apparent. Prosthetic heart sounds were normal. However, a purpuric rash was observed on both legs. Dipstick urinalysis revealed protein + and blood ++.

Electrocardiography showed sinus tachycardia and 1st-degree heart block. Chest X-ray, liver function, renal function and arterial blood gases were normal. Erythrocyte sedimentation rate was 48 mm/hour, and C-reactive protein elevated at 92 mg/dL. Haemoglobin was 9.1 g/dL, white cell count 3.9 × 109 cells/L and platelet count 165 × 109/L.

Immunological testing revealed the presence of rheumatoid factor (110 IU/mL; range <20 IU/mL). mildly reduced complement C3 (0.57 g/L; range 0.65–1.65 g/L) and gross reduction of C4 (0.03 g/L; range 0.16–0.6 g/L). Hypergammaglobulinaemia was indicated by IgG of 26 g/L, IgA 2.84 g/L and IgM 4.95 g/L. Serum electrophoresis demonstrated two low-level paraprotein bands (gGκ and gGκ). Anti-neutrophil cytoplasmic antibody (ANCA) was positive with a typical cytoplasmic (C)-ANCA fluorescence pattern. Reactivity of the C-ANCA with Proteinase 3 (PR3) was confirmed by ELISA (22 arbitrary units (AU)/mL; cut-off 5 AU/mL). This positive finding was confirmed in three separate tests and prompted consideration of a diagnosis of Wegener's granulomatosis.

On the following day, toxic granulation was noted on a blood film, and blood cultures yielded growth of anaerobic peptostreptococci. Treatment with vancomycin, gentamicin and metronidazole was immediately initiated. Transoesophageal echocardiography showed extensive vegetations around the mitral valve with trivial mitral regurgitation and no abscess. Thus the final diagnosis was infective endocarditis involving a prosthetic mitral valve.

### Case 2

A 49-year old man was admitted with a 9 day history of progressively increasing right upper quadrant pain radiating to the right side of the chest and in association with nausea, vomiting, diarrhoea and anorexia. His medical history was significant for intravenous heroin abuse and chronic hepatitis B and C virus infection. A previous history of multiple pulmonary emboli was noted 9 years earlier. At presentation to hospital, an acute abdomen was suspected clinically. The patient was empirically commenced on cefuroxime and metronidazole and underwent exploratory laporatomy, which revealed no abnormality. Thereafter, he became oliguric, and despite intravenous fluids and renal dose dopexamine, the patient progressed to anuria and required haemodialysis.

Post-operative chest X-ray revealed new onset of consolidation in left lower zone with a suspicion of cavitation. Staphylococcus aureus was isolated from sputum and flucloxacillin added. Urgent transthoracic echocardiogram did not show any cardiac vegetations.

# INFECTIVE ENDOCARDITIS: HOW IMMUNOLOGY TESTS MAY HELP OR MISLEAD

John Maher




**Infective Endocarditis: How Immunology Tests May Help or Mislead Good Clinical Care.**

Immunology investigations revealed mild hypergammaglobulinaemia (IgG 18.0 g/L, IgA 6.18 g/L, IgM 0.72 g/L) without paraprotein. Autoantibody screen demonstrated an anti-smooth muscle antibody at a titre of 1/160. Strikingly, complement C3 was undetectable, while C4 was mildly reduced at 0.12 g/L. Rheumatoid factor, cryoglobulins and ANCA were all absent.

To investigate the absence of detectable C3, laboratory staff undertook a C3 nephritic factor test, which proved positive. Features of partial lipodystrophy were sought and noted to be absent. Shortly thereafter, transoesophageal echocardiography showed multiple prolapsing vegetations around the tricuspid valve. A renal biopsy was performed and revealed features consistent with mesangiocapillary glomerulonephritis with crescentic change. Deposition of complement C3 was observed in the mesangium and capillary walls. The final diagnosis was infective endocarditis (presumed staphylococcal, although this organism was never isolated in blood cultures), associated with septic pulmonary emboli and crescentic mesangiocapillary glomerulonephritis. Fig. 1 shows that as CRP fell on antibiotic therapy, levels of C3 rose to within normal limits. Although re-testing for C3 nephritic factor was not performed, these findings clearly link the absence of C3 to sepsis.




**Fig. 1. Serial measurement of C-reactive protein, complement C3 and complement C4 in Case 2. The lower limit of the normal range is indicated by a horizontal line in each plot.**

## Discussion

It is widely appreciated that interpretation of immunology tests can present many pitfalls in diagnosis1. A good example of this occurs in the setting of chronic infection, where immunopathology contributes to the disease process and can influence several diagnostic tests. Here, two cases of infective endocarditis are presented in which immunology testing yielded several abnormal findings. Some of these are typical of infective endocarditis, including polyclonal hypergammaglobulinaemia, presence of rheumatoid factor and hypocomplementaemia. Importantly however, some of these test results had the potential to lead towards incorrect diagnosis.

In case 1, the potentially misleading immunological finding was the detection of a C-ANCA with reactivity against PR3. To test for ANCA, most immunology laboratories employ a two-stage process. Sera are initially screened by immunofluorescence microscopy—a procedure that yields three types of positive staining patterns. C-ANCA are indicated by coarse fluorescent granules throughout the cytoplasm, with centrally accentuated staining intensity between the nuclear lobes. By contrast, P-ANCA are characterized by fluorescence in a perinuclear distribution. Fluorescence patterns that do not fit these two categories are conveniently labelled as “atypical” or “flat” ANCA, and generally have uncertain clinical significance.

Although widely used in diagnostic immunology, immunofluorescence microscopy is a subjective test and thus observers may disagree on patterns seen. Consequently, sera which yield any positive fluorescence in the initial ANCA screen are cascaded for ELISA testing to determine which antigen is recognized. The two clinically important ANCA targets are proteinase-3 (PR3) and myeloperoxidase (MPO). In general, anti-PR3 positivity associates with a C-ANCA pattern and, most typically with Wegener’s granulomatosis. Reactivity with MPO typically exhibits a P-ANCA pattern and may be found in microscopic polyarteritis, crescentic glomerulonephritis and some cases of Wegener’s granulomatosis. ANCA may also be found in patients with cancer, inflammatory bowel disease, secondary to drug treatment and in association with several chronic infections. However, these “false positive” ANCA are generally of the “atypical” variety and do not react with either PR3 or MPO. Nonetheless, exceptions do occur.

# INFECTIVE ENDOCARDITIS: HOW IMMUNOLOGY TESTS MAY HELP OR MISLEAD

John Maher

Distinguishing between infective endocarditis and ANCA-associated vasculitis (AAV) can be very challenging. Many clinical features overlap, owing to the presence of an acute phase response (with elevated CRP and ESR) and small vessel vasculitis (e.g., glomerulonephritis, skin rash) in both conditions. To compound this further, case 1 illustrates that even PR3-reactive C-ANCA may occur as a false-positive finding in infective endocarditis.

A number of reports describe patients with infective endocarditis who presented with features mimicking AAV and in whom PR3-reactive C-ANCA was found2–9. This may cause diagnostic confusion, especially in patients with culture-negative endocarditis or in whom tissue biopsies yield features that could be consistent with a necrotizing vasculitis (e.g., crescentic glomerulonephritis). In some cases, this finding has resulted in incorrect diagnosis and instigation of immunosuppressive therapy3,6,9.

Complement activation is also a well-recognized immunopathological feature of chronic infections such as infective endocarditis. Immune complexes (between antibody and bacterial antigen) can activate the classical pathway, indicated by reduced C4 (+/- C3) levels. This profile is consistent with the findings observed in case 1. In many cases of endocarditis, the alternate complement pathway may also be directly activated by bacterial products. Typically, this leads to a different complement profile in which C3 is reduced, whereas C4 levels remain normal10. This profile is consistent with the pattern observed in case 2.

Case 2 was unusual in that a complete absence of C3 was found. Although inherited C3 deficiency occurs rarely, this possibility is excluded by the return of C3 levels to normal as sepsis was treated (Fig. 1). To investigate further, the laboratory tested for and demonstrated the presence of C3 nephritic factor activity in this patient. The C3 nephritic factor is typically an autoantibody that causes uncontrolled C3 consumption, often in conjunction with mesangiocapillary nephritis (also present in this case) and partial lipodystrophy11. Transient presence of C3 nephritic factor has also been reported in post-streptococcal glomerulonephritis, another clinical situation in which profound C3 reduction is a diagnostic clue12. The association of C3 nephritic factor with infective endocarditis has been described once before, in which it was ascribed to a bacterial product13.

These two cases illustrate how a chronic infection can be subtle, difficult to diagnose and lead to several abnormal and sometimes spurious results in immunological testing.



As a foundation doctor, it is not essential to appreciate all of the subtleties of how immunology tests can prove deceptive. Rather, it is important to view with a critical eye the meaning of test results as they inform the diagnostic process. Few tests in immunology are absolutely diagnostic in their own right. Careful clinicopathological correlation is critical to maximise the yield of diagnostic testing.

## Learning Points

**1. The presence of ANCA does not definitively indicate the presence of a necrotizing vasculitis.**

**2. Do not rely on a transthoracic echocardiogram to exclude endocarditis.**

**3. Abnormal complement proteins C3 and C4 make ANCA related disease unlikely as these are pauci-immune diseases little or no immune complex deposition. Pronounced hypergammaglobulinaemia is likewise is not often seen in ANCA-associated vasculitis.**

# INFECTIVE ENDOCARDITIS: HOW IMMUNOLOGY TESTS MAY HELP OR MISLEAD

John Maher



**Infective Endocarditis: How Immunology Tests May Help or Mislead Good Clinical Care.**

## References


1. Lock R.J., Virgo P.F., Unsworth D.J. Pitfalls in the performance and interpretation of clinical immunology tests. J Clin Pathol 2008; 61:1236–42.
2. Choi H.K., Lamprecht P., Niles J.L., et al. Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. Arthritis Rheum 2000; 43:226–31.
3. Tiliakos A.M., Tiliakos N.A. Dual ANCA positivity in subacute bacterial endocarditis. J Clin Rheumatol 2008; 14:38–40.
4. Sugiyama H., Sahara M., Imai Y., et al. Infective endocarditis by Bartonella quintana masquerading as antineutrophil cytoplasmic antibody-associated small vessel vasculitis. Cardiology 2009; 114:208–11.
5. Bonaci-Nikolic B., Andrejevic S., Pavlovic M., et al. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge. Clin Rheumatol 2010 (in press).
6. Kishimoto N., Mori Y., Yamahara H., et al. Cytoplasmic antineutrophil cytoplasmic antibody positive pauci-immune glomerulonephritis associated with infectious endocarditis. Clin Nephrol 2006; 66:447–54.
7. Chirinos J.A., Corrales-Medina V.F., Garcia S., et al. Endocarditis associated with antineutrophil cytoplasmic antibodies: a case report and review of the literature. Clin Rheumatol 2007; 26:590–5.
8. Bauer A., Jabs W.J., Süfke S., et al. Vasculitic purpura with antineutrophil cytoplasmic antibody-positive acute renal failure in a patient with Streptococcus bovis case and Neisseria subflava bacteremia and subacute endocarditis. Clin Nephrol 2004; 62:144–8.
9. Turner J.W., Pien B.C., Ardoin S.A., et al. A man with chest pain and glomerulonephritis. Lancet 2005; 365:2062.
10. O'Connor D.T., Weisman M.H., Fierer J. Activation of the alternate complement pathway in Staph. aureus infective endocarditis and its relationship to thrombocytopenia, coagulation abnormalities, and acute glomerulonephritis. Clin Exp Immunol 1978; 34:179–87.
11. Walport M.J. Complement. First of two parts. N Engl J Med 2001; 344:1058–66.
12. Frémeaux-Bacchi V., Weiss L., Demouchy C., et al. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity. Nephrol Dial Transplant 1994; 9:1747–50.
13. Craddock C.F., Richards N.P., Powell R.J., et al. Novel C3 nephritic factor activity in the glomerulonephritis of staphylococcal endocarditis. Q J Med 1987; 65:895–8.


## Best of five multiple-choice questions

**1. In Infective endocarditis.**

a. The presence of rheumatoid factor is a minor Duke's criterion.
b. Immune complexes result in complement consumption via the classical pathway.
c. The presence of cryoglobulins is a recognized feature.
d. Paraproteins indicate the presence of a co-existing lymphoproliferative disorder.
e. Marked C3 reduction (with normal C4) is a recognized feature of infective endocarditis.

**2. In evaluating ANCA test results provided by your immunology laboratory:**

a. Samples are screened for ANCA by immunofluorescence microscopy followed (if positive) by ELISA to test potential reactivity with PR3 and MPO.
b. ANCA is a well-recognized accompaniment of chronic infective states.
c. ANCA that are reactive with PR3 or MPO are consistent with a diagnosis of necrotizing vasculitis.
d. In infective endocarditis, the presence of ANCA indicates vasculitis.
e. The clinical significance of ANCA with an atypical or flat fluorescence pattern is unclear.

## Solutions

**Question 1**

**1a. True**

Rheumatoid factors are antibodies that react with the Fc portion of IgG. About 75% of patients with rheumatoid arthritis will have a rheumatoid factor and this tends to correlate with more aggressive disease and worsened prognosis. However, the test is not sufficiently specific or sensitive to be used to diagnose rheumatoid arthritis. Rheumatoid factors are often also found in chronic infections, including infective endocarditis or hepatitis C infection. Presence of rheumatoid factor remains a minor Dukes criterion for diagnosis of infective endocarditis. Other conditions in which rheumatoid factor is commonly found include Sjogren's syndrome and tuberculosis.

# INFECTIVE ENDOCARDITIS: HOW IMMUNOLOGY TESTS MAY HELP OR MISLEAD

John Maher

**1b. True**

Infective endocarditis is considered a prototypic immune complex disorder, reflecting the formation of antibody-antigen complexes in the circulation and in tissues. Immune complex mediated pathology may account for some of the classical features of the disease, including Osler's nodes, Janeway lesions, Roth spots, splinter haemorrhages and glomerulonephritis.

**c. True**

Cryoglobulins are antibodies that precipitate in the cold. Because of this, it is important that diagnostic blood samples are kept at 37°C until they reach the laboratory, otherwise the cryoglobulin may precipitate before the sample arrives in the lab, yielding a false-negative result. Actually getting blood samples to the lab at 37°C can be challenging. In some cases, lab staff will take the blood in order to ensure this. In other cases, labs keep a supply of sand that is maintained in a 37°C incubator and into which the blood sample can be immediately transferred to keep it warm during rapid transit. In the lab, the serum is rapidly separated and then placed at 4°C in order to promote precipitation of the cryoglobulin. Three types of cryoglobulin have been described: (i) monoclonal (e.g., a paraprotein); (ii) mixed (where a monoclonal protein has rheumatoid factor activity and thus forms a complex with polyclonal IgG); (iii) mixed (where a polyclonal antibody population has rheumatoid factor activity and forms a complex with polyclonal IgG).

**d. False**

One or more low-level paraproteins are not uncommon as a component of the immune response in chronic infection. They probably represent antibodies that are produced at such a level that they can be detected on an electrophoretic strip against the background of polyclonal hypergammaglobulinaemia.

**e. True**

Infective endocarditis is well recognized as a cause of grossly reduced C3 levels. This may also be seen in post-streptococcal glomerulonephritis. Reduced C3 without reduction in C4 excludes immune complex mediated complement consumption as a full explanation for this finding. In the alternate complement pathway, C3 is activated by "protected" surfaces, which include bacterial products.

**Question 2**

**a. True**

An international consensus statement has been produced that makes recommendations for testing and reporting of ANCA. Samples are screened initially by immunofluorescence microscopy and, if any positive fluorescent signal is seen, they are cascaded for ELISA testing.

**b. True**

ANCA are commonly found in several types of chronic infection, including hepatitis C virus infection, cystic fibrosis, endocarditis and mycobacterial infections.

**c. True**

ANCA that are reactive with PR3 or MPO are consistent with a diagnosis of necrotizing vasculitis. These are the two clinically significant targets of ANCA. The presence of such antibodies provides support for a diagnosis of a necrotizing vasculitis but, as illustrated here, false positives may occur. Antibodies that react with PR3 tend to be more strongly associated with Wegener's granulomatosis rather than other forms of necrotizing vasculitis, but one cannot be dogmatic about this in an individual patient. The diagnosis of a necrotizing vasculitis (e.g., Wegener's granulomatosis, microscopic polyarteritis) usually requires a biopsy of an involved organ.

**d. False**

ANCA occur frequently as false positives and do not by themselves indicate the presence of a vasculitic condition. Nonetheless, the detection of ANCA that are reactive with MPO or PR3 are consistent with a vasculitic process.

**e. True**

These are atypical ANCA and may occur in many non-vasculitic conditions. Occasionally however, they are found in patients with a necrotizing vasculitis. Consequently, atypical ANCA are considered to have uncertain clinical significance.

## Author

**John Maher MRCPI MRCP MSc PhD FRCPath**
Senior Lecturer in Immunology
Research Oncology
Hon Consultant
Allergy & Clinical Immunology

Department of Immunology, Barnet and Chase Farm NHS Trust, Barnet, Hertfordshire, EN5 3DJ, UK

Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Bessemer Wing, Denmark Hill, London SE5 9RS, UK

Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital, St. Thomas Street, London SE1 9RT, UK

## Correspondence

**Dr John Maher**
E-mail: john.maher@kcl.ac.uk



# CROSSWORD ON IMMUNOLOGY AND DISEASE

**A great time to test your knowledge.**
**Test Yourself.**

## Across Questions

1. From trees and grasses they make some sneeze (6,9)

8. Chew it in the department for STI (1,1,1)

9. Applause for an old name for gonorrhoea (4)

10. Hospital department for allergic rhinitis (1,1,1)

11. Polio, pertussis and rabies vaccines are killed with this type of energy (4)

12. Lymphoid tissues where B cells differentiate (8,7)

13. Prefix meaning stranger, used for a transplant from another species (4)

14. A substance or event which contributes to malignant transformation (10)

17. Hidden by witches, sometimes in faeces (6)

18. First stages of sleep (1,1,1,1)

19. Suffering from rabies (5)

21. Your own abbreviation for short-sightedness (2)

22. These cells contract to expel secretions from exocrine glands (13)

24. Organs and diffuse patches which produce B and T cells (8,7)

## Down Questions

1. CD44 is a _____ _____ marker (12, 4)

2. A medicine taken by licking, a confection (8)

3. Gram negative bacterium from the lower gut (11)

4. A malignant neoplasm of blood vessel endothelial cells (12)

5. A white cell responsible for specific immunity (10)

6. Extensor hallucis longus (1,1,1)

7. Lymphocytes that slow down or stop the immune response, now called regulatory (10,1,5)

9. T lymphocytes which destroy infected cells (9,5)

15. Watery discharge from membranes, especially eyes or nose (5)

16.Nucleotide-binding oligomerization domain (1,1,1)

19.Coeliacs are intolerant of this cereal (3)

20. Lack of visual perception (5)

21. Dermatitis actually caused by its caterpillars (4)

23. Nosocomial infection (1,1,1)

# CROSSWORD ON IMMUNOLOGY AND DISEASE




Crossword on Immunology and Disease by Michael Brookman.
Test Yourself.

# CROSSWORD ON IMMUNOLOGY AND DISEASE

**A great time to test your knowledge.**
**Test Yourself.**

## Across Answers

1. Pollen allergens
8. GUM
9. Clap
10. ENT
11. Heat
12. Germinal centres
13. Xeno
14. Carcinogen
17. Occult
18. NREM
19. Rabid
21. My
22. Myoepithelial
24. Lymphoid tissue

## Down Answers

1. Proteoglycan cell
2. Lincture
3. Escherichia
4. Angiosarcoma
5. Lymphocyte
6. EHL
7. Suppressor T cells
9. Cytotoxic cells
15. Rheum
16. NOD
19. Rye
20. Blind
21. Moth
23. HAI

# ISOLATED PROTEINURIA - HOW TO SCREEN, HOW TO MEASURE, HOW TO INTERPRET

Dr Muhammad Azhar Khan MBBS MRCP, Dr Jamie Barfield MBChB, Dr Michael Schulz MD FRCP

**Isolated Proteinuria - how to screen, how to measure, how to interpret.**
**Patient Management.**


## Abstract

Proteinuria is an important indicator of underlying kidney disease and its presence and quantity is an independent risk factor for both progression of CKD and cardiovascular disease. Routine urinalysis for screening purposes is recommended for high risk patients particularly those with diabetes or hypertension. Furthermore changes in proteinuria have been suggested as a surrogate outcome for kidney disease progression. This article will review the evaluation of a patient with isolated proteinuria and the way of screening and measuring for proteinuria will be explained here.


## Case History

A 54 year old man was referred by his general practitioner to the nephrology clinic. He was a school teacher who did not smoke or drink and lived with his wife. He took regular amlodipine 5mg for hypertension which was diagnosed six years ago. He went for a routine visit and a blood pressure check where it was noted that his albumin:creatinine ratio (ACR) was significantly raised. Subsequently he was referred to a speciality clinic.

His only physical complaint was swelling of his ankles for the preceding few months. He denied any urinary symptoms and there was little to suggest any systemic disease. A chest x-ray showed normal size heart without any evidence of heart failure, his renal ultrasound was normal as well as his immunology and renal function tests. His blood pressure in the clinic was 150/90 and there was evidence of mild bilateral pedal oedema.

Quantification and monitoring of proteinuria was done by using total protein:creatinine ratio (PCR) and a 24 hour urinary protein excretion as part of evaluation of isolated proteinuria. He was monitored closely for a period of few weeks before the decision of commencing any treatment was made. In a view of normal renal function, absence of haematuria and stable mild proteinuria, renal biopsy was not offered.

He was treated with an angiotensin converting enzyme (ACE) inhibitor which resulted in improvement in protein excretion and blood pressure control (target < 130/80).

## Background

Isolated proteinuria is defined as Proteinuria without haematuria and without renal impairment. Proteinuria is grouped into three basic classes: tubular, overflow and glomerular.

Isolated proteinuria is usually discovered incidentally in asymptomatic patients when a urine dipstick is performed. This benign presentation is different from that of patients with more prominent renal disease who have one or more of the following: heavy proteinuria (>3 g/day), progressive kidney disease, oedema, and/or an active urine sediment containing red cells.

Tubular Proteinuria occurs in tubulointerstitial disease, when low molecular weight proteins such as ß2-microglobulin, immunoglobulin light chains, retinol-binding protein, and amino acids are filtered but not completely reabsorbed. Tubular proteinuria is often not diagnosed clinically since the dipstick for protein does not detect proteins other than albumin and the quantity excreted is normally relatively small. A classical example is the so called Bence Jones proteinuria where there is increased but mild excretion of immunoglobulin light chains in the urine (in contrast to the marked increase of excretion of monoclonal light chains in overflow proteinuria).

Overflow proteinuria occurs when there is an excessive production of a particular (small) protein, leading to an increase glomerular filtration in quantities that exceed a threshold of re-absorption capacity and result in an "overflow" into the urine. In most instances the protein is immunoglobulin light chains in multiple myeloma however lysozyme (in acute myelomonocytic leukaemia), myoglobin (in rhabdomyolysis), or haemoglobin (in intravascular haemolysis) are also seen. Because the level of protein filtered is in excess of the reabsorptive capacity of the tubule it can cause acute kidney injury.

In glomerular proteinuria there is increased filtration of macromolecules across the glomerular membrane. Predominantly the proteinuria is composed of albumin and this is seen classically in diabetic nephropathy but also other glomerular diseases.

# ISOLATED PROTEINURIA - HOW TO SCREEN, HOW TO MEASURE, HOW TO INTERPRET

Dr Muhammad Azhar Khan MBBS MRCP, Dr Jamie Barfield MBChB, Dr Michael Schulz MD FRCP

A healthy adult will excrete less than 150mg/day of protein. Many biological factors affect proteinuria such as heavy physical activity, fever, urinary tract infections (UTI), upright position (orthostatic proteinuria), and heart failure as well as kidney disease.

When approaching a case of proteinuria a detailed history, physical examination, and urinalysis is crucial. Transient proteinuria should be excluded by simply repeating the urinary investigation. A morning sample is best as the urine is most concentrated and thus the concentration of protein will be highest and more likely to be detected. If clinically suspected rule out orthostatic proteinuria by taking split urine sample tests - one during the day and the other during the night.

Persistent proteinuria is almost always due to kidney disease or a systemic disorder and warrants a thorough evaluation even when accompanied by normal urine sediment. The evaluation should include measurement of serum creatinine and an ultrasound examination to rule out structural causes.

| | Urine Albumin | Urine total protein | Clinical meaning/ cause |
|---|---|---|---|
| **Microalbuminuria** | 20-200mg/g creatinine (men)<br>30-300mg/g creatinine (Women) | 150-300 mg/day | Associated with increase risk of progressing kidney disease and future cardiovascular events in general population |
| Assume diabetic nephropathy in long-term diabetic patient if: | **ACR > 2.5mg/mmol men**<br>**ACR > 3.5 mg/mmol women** | | |
| **Macroalbuminuria** | | | |
| significant Proteinuria in patient without diabetes if: | **ACR is ≥30 mg/mmol** (approximately equivalent to **PCR ≥50 mg/mmol**) | (approximately equivalent to urinary protein excretion ≥0.5 g/24 h) | |
| **Glomerular proteinuria** | | 1-20 g/day | protein passed through glomerular capillary blood into the urine |
| **Tubular proteinuria** | | <2g/day | Tubular defect prevents reabsorption of low molecular weight proteins |
| **Overflow proteinuria** | | Up to 20g/day | Overproduction of small proteins lead to increase glomerular filtration and leakage in the urine |
| **Nephrotic range proteinuria** | | >3.5grams/day | Nephrotic syndrome = nephrotic range proteinuria + hypoalbuminaemia + oedema |

**Table 1: Types Of Proteinuria**

## Screening

Routine screening for proteinuria is not undertaken as it is widely thought to not be cost effective. However, early detection seems to identify patients with higher cardiovascular risk and enables better management of chronic kidney disease and therefore screening is applied to high risk groups.

The National Institute for Health and Clinical Excellence (NICE) has recommended (3) that testing for proteinuria should be offered to people if they have any of the following risk factors: an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73 m2, diabetes, hypertension or elements of cardiovascular disease including ischaemic heart disease, chronic heart failure, peripheral vascular disease and cerebral vascular disease. Moreover patients with structural renal tract disease, multiple renal calculi or prostatic hypertrophy and with multisystem diseases with potential kidney involvement such as systemic lupus erythematosus should also be offered testing for proteinuria.

## Monitoring of Proteinuria

Quantification of proteinuria is vital in the assessment of chronic kidney disease and there are several qualitative and quantitative tests available for its measurement.

At the point of care the standard urine dipstick detects the presence of urinary albumin via a colorimetric reaction with the dipstick-impregnated reagent. It is important to note that most dipsticks are insensitive to the presence of non-albumin proteins and thus a positive dipstick usually reflects glomerular proteinuria. Proteinuria on the urine dipstick is graded from 1+ to 4+, which reflects progressive increases in the urine albumin concentration as demonstrated in table 2.

| Result | Protein (Albumin) g/L |
|---|---|
| Negative | 0 |
| Trace | ~0,15-0,3 |
| + | ~0,3-1,0 |
| ++ | ~1,0-3,0 |
| +++ | ~3,0-10,0 |
| ++++ | ~> 10,0 |

**Table 2 - Sensitivity of standard urine dipstick to urinary albumin (rouge guide)**

# ISOLATED PROTEINURIA - HOW TO SCREEN, HOW TO MEASURE, HOW TO INTERPRET

Dr Muhammad Azhar Khan MBBS MRCP, Dr Jamie Barfield MBChB, Dr Michael Schulz MD FRCP

**Isolated Proteinuria - how to screen, how to measure, how to interpret.**
**Patient Management.**

Although qualitative dipstick testing is rapid and easy to perform, the false-positive and false-negative rates limit the utility. The reagent strips are subject to false positives because of patient dehydration, exercise, infection, and extremely alkaline urine. False negative results occur as a result of excessive hydration and urine proteins other than albumin and the color changes in the best case can only be a semi-quantitative estimate. In the management of Diabetes Mellitus it is very important to screen for the development of diabetic Nephropathy, but the amount of Albumin leaked with the urine can be very small in the early stages (Microalbuminuria) thus a standard dipstick might miss the early manifestation of diabetic Nephropathy.

Therefore The National Institute for Health and Clinical Excellence (NICE) has recommended that to detect (Micro)albuminuria the urinary albumin:creatinine ratio (ACR) should be used in preference to other tests of proteinuria unless reagent strips are used to identify proteinuria which are capable of specifically measuring albumin at low concentrations. Standardizing the albumin measurement to the quantity of creatinine in the urine helps to avoid errors introduced by diluted or concentrated urine samples.

Patients with persistent proteinuria should undergo a quantitative measurement of protein excretion. The 24 hour urine measurement is still considered by some to be the "gold standard" for the quantitative determination of the degree of proteinuria. However the variation in results from 24 hour urine samples can be high due to over- and under-collection, suggested for example by volumes < 500ml/day or creatinine excretion rates below or above the laboratory reference range.

An alternative to 24-hour urine measurement is the estimation of the Protein:creatinine ratio (PCR), which correlates with daily protein excretion. Reporting the total 24-hour urine protein standardised to the 24-hour urine creatinine (gProtein/gCreatinine) will help to adjust for variations in the duration of collection. PCR is a simple single-voided test and is more reliable and practical than timed urine collections , .

NICE suggests to detect and identify proteinuria, use urine ACR in preference, as it has greater sensitivity than PCR for low levels of proteinuria. For quantification and monitoring of significant proteinuria, PCR should be used.



## Discussion

Our patient was referred to the nephrology clinic because of the presence of significant proteinuria which was persistent with normal serum creatinine and an ACR of more than 30mg/mmol. Urinalysis did not show any active sediments and he was screened for proteinuria because of his past medical history of hypertension as per NICE guidelines. He was evaluated by through and detailed history, physical examination and investigations. There was no evidence to suggest systemic disease and renal ultrasound was normal .We used both PCR and 24 hour protein excretion to quantify and monitor the proteinuria. Since his proteinuria was mild and stable without any rise in serum creatinine, kidney biopsy was not considered.

NICE has recommended that non-diabetic patients who have hypertension and Chronic kideney disease (CKD) and an ACR ≥30 mg/mmol (approximately equivalent to PCR ≥ 50 mg/mmol, or urinary protein excretion ≥ 0.5 g/24 h) should receive treatment with an ACE inhibitor or angiotensin receptor blocker 3. The aim is to prevent or ameliorate progression of chronic kidney disease. Our patient received treatment with an ACE inhibitor which resulted in decreased proteinuria and improved blood pressure control.

## Test Yourself

**Q1. When looking for proteinuria you should...**

a) Screen all patients under your care
b) Screen patients with cardiovascular disease or diabetes
c) Rely on urine dipstick to guide treatment goals
d) Use PCR in patients who have diabetes
e) Ask your patient to fast prior to the urine dipstick test

**Q2. When treating proteinuria...**

a) Perform a renal biopsy before starting any medications
b) Aim for a blood pressure of 150/80 mm Hg
c) ACE inhibitors should be used if there is a high normal serum potassium detected
d) ACE inhibitors should be used if there is hypertension, CKD and an ACR > 30mg/mmol
e) A decreased proteinuria does not impact on the progression of chronic kidney disease

# ISOLATED PROTEINURIA - HOW TO SCREEN, HOW TO MEASURE, HOW TO INTERPRET

Dr Muhammad Azhar Khan MBBS MRCP, Dr Jamie Barfield MBChB, Dr Michael Schulz MD FRCP

## Answers

**Answer b)**

It is not cost effective to screen all patients and so only those at high risk should be screened. This includes patients with diabetes, hypertension and cardiovascular disease. The urine dipstick test is only semi-quantitative and will report a false positive if patients are dehydrated and should not be used for guiding treatment goals. In patients with diabetes and proteinuria you should calculate eGFR and ACR to monitor the degree of proteinuria and kidney disease.

**Answer d)**

Renal biopsies are invasive procedures with substantial risks that should be weighed against the benefit of obtaining a diagnosis. In cases of isolated, mild proteinuria there is mostly no clinical indication for biopsy. Target blood pressures are 140/90 and 130/80 if there is diabetes present. ACE inhibitors are recommended for the treatment of proteinuria if there is hypertension, CKD and the ACR is > 30mg/mmol. Reducing the level of proteinuria can help to slow the progression of chronic kidney disease.

## References

1. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35: S97–S105

2. Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G: Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int Suppl 1997; 63: S54–S57

3. National Institute for Health and Clinical Excellence. Chronic Kidney Disease. September 2008 Available from **http://www.nice.org.uk/nicemedia/pdf/CG073QuickRefGuide.pdf**

4. Mir S, Kütükçüler N, Cura A. Use of single voided urine samples to estimate quantitative proteinuria in children.Turk J Pediatr.1992;34(4):219-24

5 .Schwab SJ, Christensen RL, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med. 1987;147(5):943-4



**Isolated Proteinuria - how to screen, how to measure, how to interpret.**
**Patient Management.**

# PLASMAPHERESIS PRN: PRINCIPLES, REVIEW, NUTS & BOLTS

Rammohan S Bhat, Michael Schulz

**Plasmapheresis PRN:**
**Principles, Review, Nuts & Bolts**
**Good Clinical Care.**




## Introduction

Plasmapheresis is an extracorporeal blood purification procedure, resulting in large molecular substances being removed from the plasma. It is used to treat patients with immunological, neurological, hematological, renal and metabolic disorders. This article is a concise and comprehensive review of the subject targeted at doctors in training who might be dealing with patients requiring plasmapheresis. The 'Principles' and 'Nuts and Bolts' sections are particularly intended for easy understanding and to provide practical tips to the junior doctors on the floor.

## Principles

Plasmapheresis (from the Greek plasma, something molded, and apheresis, taking away) is the removal (via filtration or centrifugation), treatment, and return of (components of) blood plasma from blood circulation. It is thus an extracorporeal therapy. Synonym = Therapeutic Plasma Exchange (TPE).

TPE has a role in the treatment of various neurological, haematological and immune mediated diseases.

TPE is aimed at removal of large molecular weight substances present in plasma which are deemed pathologic in the disease process (e.g., autoantibodies, immune complexes, myeloma light chains, cryoglobulins, cholesterol-containing lipoproteins).

There are two ways of providing plasmapheresis—centrifugal plasmapheresis and membrane plasmapheresis, both of them have equal efficacy.

Removed plasma is replaced with substitution fluid, most commonly albumin solution and less commonly saline or fresh frozen plasma (FFP).

Most common complications include hypotension, citrate-induced hypocalcemia, coagulation abnormalities and infection.

## Review

### Introduction

Plasmapheresis is used to describe removal of plasma from normal donors for use in transfusions or for preparation of components. Therapeutic plasmapheresis refers to use of the procedure as a treatment modality. Some authors prefer to use the term 'Therapeutic Plasma Exchange' (TPE), on the logical grounds that plasma is removed via filtration and exchanged for a substitute fluid 3.

There are two different methods of performing unselective TPE—centrifugal and membrane, both of which are equally effective 3. Centrifugal TPE (Fig. 2) is the most common technique used in North-America, whilst Membrane TPE is more commonly used and gaining more popularity in Europe. Centrifugal TPE is performed with centrifugation devices used in blood banking procedures. These devices offer the advantage of allowing selective cell removal (cytapheresis). Membrane TPE is done using highly permeable filter with standard haemodialysis equipment.

Few specialist centres offer selective plasma separation methods with complex, highly specialist apparatus. These machines process the filtered plasma further in a secondary circle (adsorption, precipitation or simply second filtration "cascade filtration") in order to remove the target protein selectively to allow for the reinfusion of autologous plasma. This reduces the risk of side effects of the procedure in particular avoiding coagulation abnormalities. These selective plasma separation methods along with the selective removal of cellular components of the blood—referred to as 'Cytapheresis'—are out of scope of this review.

Unselective TPE with standard haemodialysis equipment is widely available and allows for example the sufficient removal of pathogenic autoantibodies. This reduces further damage and may permit reversal of the pathologic process in certain diseases. It is important to note that the rapid removal of disease-causing autoantibodies from the circulation in some diseases can be life saving (e.g., Goodpasture syndrome), but TPE has an adjunctive role and is in most cases not a standalone therapy. For example the production of new autoantibodies must be stopped, this requires concomitant immunosuppressive treatment.

# PLASMAPHERESIS PRN: PRINCIPLES, REVIEW, NUTS & BOLTS

Rammohan S Bhat, Michael Schulz

## Plasmapheresis PRN: Principles, Review, Nuts & Bolts Good Clinical Care.

For TPE to be a rational therapeutic choice, the substance targeted for removal should satisfy at least one of the followings[1]:

(a) Sufficiently large (molecular weight > 15,000 Da), such that it cannot be easily removed by less expensive purification techniques like haemofiltration and high-flux haemodialysis.

(b) Sufficiently long half-life, so that extracorporeal removal is much more rapid than endogenous clearance pathways.

(c) Substance acutely toxic or pathologic and resistant to conventional therapy, so that rapid elimination from extra cellular compartment is indicated.

## Indications

Applications of TPE can be broadly subdivided into two general categories: (1) acute (self-limited) diseases where TPE is used to acutely lower the circulating pathogenic substance and (2) chronic diseases where there is ongoing production of pathogenic autoantibodies. The use of TPE in chronic diseases has been more controversial than in acute self-limited diseases due to the phenomenon of rebound antibody production and because it does not address underlying pathology. A special situation is the treatment of thrombotic thrombocytopenic purpura (TTP) with TPE. Here it seems that the provision of a missing factor (e.g., ADAMTS13) with the allogeneic plasma infusion may be effective treatment and TPE "only" allows for the re-infusion of large volumes without the risk of intravascular volume overload. Another exception is the hyperviscosity syndrome where in the case of myeloma TPE may be used to decrease blood viscosity.

American society for apheresis (ASFA) has found that more than half of all TPE procedures were performed for neurologic conditions such as Gullian-Barre syndrome, Myasthenia Gravis, etc2. Haematologic conditions formed the next common indication followed by systemic immunologic disorders like Goodpasture's disease and ANCA related vasculitis. ASFA has divided conditions treated with TPE into four categories based upon support for clinical efficacy found in the literature (Table 1).

| Category I (Standard and Acceptable Therapy) | Category II (Generally Accepted in a Supportive Role) | Category III (Not Clearly Indicated) | Category IV (Demonstrated to Have a Lack of Efficacy) |
|---|---|---|---|
| Acute and chronic inflammatory demyelinating polyradiculoneuropathy | Cold agglutinin disease | Aplastic anaemia with pure RBC | AIDS |
| Demyelinating polyneuropathy with IgG and IgA | ABO- mismatched transplant (recipient) | Systemic Lupus Erythematosis | Amyotrophic lateral sclerosis |
| Anti-GBM disease (Goodpasture's disease) | Coagulation factor inhibitors | Raynaud's phenomenon | Chronic ITP |
| Gullian-Barre syndrome | Lambert- Eaton Myasthenia syndrome | Relapsing or progressive multiple sclerosis | Lupus nephritis |
| Phytanic acid storage disease | Acute CNS inflammatory demyelinating disease | Thyroid storm | Psoriasis |
| Familial Hypercholesterolemia (selective adsorption) | Cryoglobulinemia with or without polyneuropathy | Autoimmune haemolytic anaemia | Renal transplant rejection |
| Thrombotic thrombocytopenic purpura | Rapidly progressive glomerulonephritis | Haemolytic Uremic Syndrome | Rheumatoid arthritis |
| Myasthenia gravis | Myeloma paraproteins or hyperviscosity syndrome | Renal transplant Sensitisation | Schizophrenia |
| Post-Transfusion Purpura | Acute Kidney Injury due to Myeloma Proteins | Recurrent Focal Glomerulosclerosis | Systemic Amyloidosis |
| | Familial hypercholesterolemia | Heart transplant rejection | |
| | Sydenham's chorea | Acute hepatic failure | |
| | Paediatric autoimmune neuropsychiatric disorders | Drug overdose or poisoning | |
| | Polyneuropathy with IgM (with or without Waldenstrom's) | Vasculitis | |
| | | Haemolytic disease of the newborn | |
| | | Inclusion body myositis | |
| | | Paraneoplastic neurologic syndromes | |

**Table 1. Indications for Plasmapheresis Taken from Prescription and Technique of Therapeutic Plasmapheresis.**

Adapted from Smith, JW et al. Therapeutic apheresis: A summary of current indication, categories endorsed by the AABB and the American Society for Apheresis. Transfusion 2003; 43:820 **(http://www.uptodate.com/online/content/plasmapheresis).**

# PLASMAPHERESIS PRN: PRINCIPLES, REVIEW, NUTS & BOLTS

Rammohan S Bhat, Michael Schulz

## Prescription and Technique

In general, large molecular weight compounds equilibrate slowly between vascular space and interstitium. Thus calculations of the rate of removal by TPE can be simplified to first-order kinetics. A single plasma volume of exchange will lower plasma macromolecular levels by 60%. General practice is to perform 1–1.5 plasma volume exchanges per session which can take up to 1.5–3 hours in time.

## Formula Used to Estimate Plasma Volume in an Adult[4]

**Estimated plasma volume (Litres) = 0.07 * Weight* (1 – haematocrit)**

Successful execution of TPE requires reliable venous access, which most commonly is dual lumen central venous catheter. The procedure can also be performed via two large bore peripheral venous access. The optimal blood flow for TPE is 100–150 ml/min, and the consecutive filtrate- and substitution-fluid flow is approximately 30% of the blood flow.

Iso-oncotic Albumin is the most common replacement fluid and is used with or without normal saline. FFP is used in certain circumstances like when treating Thrombotic thgrombocytopenic purpura, or when clotting abnormalities are noted after repeated plasma exchanges with albumin. Albumin has the advantage of lack of viral transmission and carries minimal risk of anaphylactoid reactions. It however carries a slight increased risk of depletion coagulopathy and net loss of immunoglobulins.

The ASFA general recommendation for conditions requiring plasmapheresis is that one exchange be performed every second or third day for a total of 3 to 5 procedures1. Certain conditions however necessitate more aggressive treatment until clinical improvement occurs.




**Image 1: Typical set up of TPE**

## Complications

Despite the impressive results which have been achieved with plasmapheresis in recent years, this form of therapy can involve significant side effects. Adverse reactions are substantially more common with FFP than with albumin replacement The reported case fatality rate for TPE is 3–5 per 10,000 (0.03 to 0.05%)[5]. Some of the commonly encountered complications are briefly explained below.

Complications related to vascular access are the usual problems of indwelling vascular catheter and should be rare in specialist centres. It mainly involves catheter related infections with a small contribution from complications during central line placement (arterial puncture, pneumothorax, haemothorax and cardiac arrhythmia)

## Complications due to Type of Replacement Fluid

1. Complications related to use of Albumin as replacement fluid—These include coagulation abnormalities, depletion of immunoglobulins with repeated frequent exchanges, and risk of flushing and hypotension in patients also receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB). After a single plasma volume exchange, prothrombin time increases by 30%, and partial thromboplastin time doubles. This usually normalises in 4 hours, unless the patient has had frequent exchanges. Substituting 1 or more litres of FFP as replacement fluid prophylactically, or in those with active bleeding should be considered[1].

2. Complications related to use of FFP - Citrate is used as the anticoagulant in FFP which can lead to symptomatic hypocalcemia by binding to free calcium. Symptoms could include perioral and distal extremity paraesthesia to life-threatening cardiac dysrhythmia. Close monitoring of calcium (ionized) level is critical and pre-emptive (intravenous) calcium supplementation should be considered. Citrate can also cause metabolic alkalosis which can exacerbate hypocalcemic complications. FFP is also associated with anaphylactic reactions which are mostly mild and include fever, rigors, wheeze and hypotension. Cardioplulmonary collapse is rare. Pretreatment with intravenous steroid and anti-histamine can reduce the risk and severity of these reactions. Viral transmission of hepatitis B, C and HIV is a potential risk but decreasing with stringent measures[1].

3. Complications related to procedure itself—Hypotension, increased propensity for infection, dilution hypokalemia and drug removal during the procedure are some. Hypotension could be due to intravascular volume reduction, vasovagal reaction or anaphylactic reaction. It is treated by lowering patient's head, stopping the procedure temporarily, increasing the fluid return rate, or infusing additional replacement fluid. Increased propensity for infection is a theoretical risk, however in reality infection rates are similar to those receiving immunosuppression without plasma exchange[1].

# PLASMAPHERESIS PRN: PRINCIPLES, REVIEW, NUTS & BOLTS

Rammohan S Bhat, Michael Schulz

**Plasmapheresis PRN:
Principles, Review, Nuts & Bolts
Good Clinical Care.**



## Nuts and Bolts

Plasmapheresis is an expensive, labour-intensive modality of treatment which when utilized in the appropriate circumstances is a very effective primary or adjunctive treatment.

Patients receiving plasmapheresis need close regular senior (registrar and consultant) review to decide on frequency and prescription of TPE.

As a junior doctor you may be expected to coordinate the treatment process by arranging the appropriate replacement fluid, monitoring clotting and calcium profile, and liaising with the staff providing TPE.

Keep in mind the potential complications of TPE, when reviewing patients daily—Vascular access problems (infection, malfunction, etc.); clotting abnormalities; hypocalcemia and metabolic alkalosis when FFP is used regularly, and hypocomplementimia and low immunoglobulins when albumin is used as replacement fluid. Patients are more prone for infection, which should be identified as early as possible and treated aggressively.

Baseline IgG level should be checked in all patients and monitored subsequently if patient is undergoing aggressive TPE (consequetive daily exchanges or two to three plasma volumes per exchange). If IgG levels fall significantly and is associated with ongoing or new infection, consider immunoglobulin infusion.

Beware of the potential complications during the procedure, as detailed before, and treat appropriately. Stop ARB or ACE inhibitor at least 24 hours prior to starting TPE, otherwise patients are at a small risk of developing various symptoms (flushing, hypotension, abdominal cramping) which are thought to be due to increased kinin generation. This occurs when albumin is used as the replacement fluid.

Levels of drugs which have significant protein binding is reduced during the procedure and hence best administered after TPE.

Discuss with senior colleagues to identify clinical and lab parameters of response, which varies based on the disease process treated, and monitor patient accordingly.

## References

1. Prescription and technique of therapeutic plasmapheresis. **http://www.uptodate.com/online/content/plasmapheresis**

2. Leitman S.F. American Association of Blood Banks/ American Society for Apheresis Survey. Unpublished data. 1992.

3. Rolf Bambauer, Reinhard Latza, M. Rigdon Lentz (eds.). Therapeutic Plasma Exchange and Selective Plasma Separation Methods, 3rd edn. Lengerich: Pabst Sceince Publishers 2009.

4. Kaplan A.A. A simple and accurate method for prescribing plasma exchange. ASAIO Trans 1990; 36: M597.

5. Mokrzycki M.H., Kaplan A.A. Therapeutic plasma exchange: Complications and management. Am J Kidney Dis 1994; 23:817.

## Authors

**Rammohan S Bhat MD MRCP**
Specialist Registrar Nephrology

**Michael Schulz MD FRCP**
Consultant Nephrologist
Royal Liverpool and Broadgreen University Hospital
Liverpool, United Kingdom

# RENAL ANAEMIA - DIAGNOSIS AND THERAPY

H.Wodeyar, J.Barfield, M.Schulz

## Renal Anaemia - Diagnosis and Therapy. Patient Management.


## Abstract

Erythropoietin deficiency is the major cause of anaemia in chronic kidney disease (CKD), but it is import to rule out other causes of anaemia first before diagnosing renal anaemia.

Recombinant human erythropoietin (EPO) has been used for more than two decades in the treatment of renal anaemia, but as much it is accepted that it improves the physical and mental health of patients with renal anaemia the long-term benefits with regards to cardiovascular morbidity and mortality remain less clear. Consequently the target haemoglobin still remains a controversial topic. Tailoring anaemia management to each patient remains a challenge to the attending physician.


## Case Study

A 75-year old lady with CKD stage 4 (eGFR-24) secondary to diabetes was referred to the renal clinic for further management of her anaemia. She had a 25-year history of type 2 diabetes for which she started insulin 7 years ago. Additionally she was hypertensive which had been treated for the last 10 years.

She did not have any symptoms other than tiredness. On clinical examination she was euvolaemic with blood pressure on 160/80, and systemic examination was normal. Her blood results are summarized in Table 1.

| Test | Value | Normal Range |
|---|---|---|
| Hb | 9.5 g/dL | 11.8–14.8 |
| Haematocrit | 30.6% | 36.0–44.0 |
| Mean cell volume | 87.5 fl | 80.0–100.0 |
| Platelets | 332 x 109/L | 150–400 |
| WBC | 9.2 x 109/L | 3.5–11.0 |
| Creatinine | 207 µmol/L | 50–130 |
| eGFR | 24 ml/min/1.73m2 | >60 |
| Iron | 13.7 µmol/L | 13.0–32.0 |
| Transferrin | 2.50 g/L | 2.20–4.00 |
| Ferritin | 140 µg/L | 13–150 |
| Serum B12 | 782 ng/L | 191–663 |
| Serum folate | 10.4 µg/L | 4.6–18.7 |

**Table 1. Blood Results of Patient with CKD Stage 4**

Urine dipstick showed protein ++, and ECG was suggestive of left ventricular hypertrophy (LVH). An ultrasound scan of the kidneys showed no hydronephrosis and her immunology screen and myeloma screen was negative.

Her initial treatment goal was to aim for a blood pressure of 125/75, thereby reducing the proteinuria, and aiming for good glycaemic control. A normocytic anaemia with a haemoglobin of 9.5 with symptoms of tiredness but without any history suggesting blood loss or malignancy suggested a need to initiate erythropoietin therapy.

## Background

Relative erythropoietin deficiency is common among patients with anaemia and CKD, but measuring erythropoietin levels is not very helpful and instead other possible causes of renal anaemia should be ruled out before establishing the diagnosis of renal anaemia. Therefore a clinical and laboratory evaluation should always precede initiation of EPO therapy.

The likelihood of renal anaemia in patients with CKD increases as the renal function progressively declines. NHANES III data suggest a prevalence of anaemia of 1%, 9% and 33% in CKD patients with an eGFR of 60, 30 and 15 ml/min, respectively . Interestingly patients with diabetic nephropathy (as assumed for our patient) develop anaemia of CKD much earlier when the renal function is less reduced compared with non diabetics.

The current version of the Renal Association guidelines for “Anaemia in CKD” state that CKD should be considered as a possible cause of anaemia when the glomerular filtration rate (GFR) is <60 ml/min/1.73 m2. It is more likely to be the cause if the GFR is < 30 ml/min/1.73 m2 (<45 in diabetics) and no other cause, e.g., blood loss, folic acid or vitamin B12 deficiency, is identified. The guidelines advise on the laboratory investigations outlined in Table 2.

# RENAL ANAEMIA - DIAGNOSIS AND THERAPY

H.Wodeyar, J.Barfield, M.Schulz

| Investigation | Comments |
|---|---|
| Full blood count | ? microscopic anaemia |
| Absolute reticulocyte count | To assess bone marrow responsiveness |
| Serum ferritin | To assess iron stores |
| Serum transferrin saturation or reticulocyte Hb content | To assess adequacy of iron for erythropoiesis. |
| Percentage of hypochromic red blood cells | (To assess adequacy of iron for erythropoiesis) |
| Serum B12 and red cell folate concentrations | ? deficiency |
| Hb electrophoresis and bone marrow examination (if indicated) | ? underlying haematology condition |
| Plasma/serum C-reactive protein | to assess inflammation |
| Plasma/serum levels of haptoglobin, lactate dehydrogenase, bilirubin, Coombs' test | Tests for haemolysis (if indicated) |
| Plasma/serum and/or urine protein electrophoresis | To rule out myeloma |
| Plasma/serum and/or urine protein electrophoresis | |

**Table 2 - Laboratory investigations recommended for the investigation of anaemia in CKD.**

It is very important to investigate further causes of anaemia other than renal anaemia especially when the severity of the anaemia is disproportionate to the deficit in renal function (possibly with the exception of patients with diabetic nephropathy), if there is evidence of iron deficiency or evidence of haemolysis, or if the coincident finding of leucopaenia or thrombocytopenia suggest a bone marrow disorder.

The isolation of the EPO gene and its subsequent synthesis in the late 1980s has revolutionized the management of renal anaemia . Prior to the introduction of EPO therapy, renal patients suffered serious chronic anaemia with all its associated symptoms such as shortness of breath and extreme tiredness and this obviously had a significant impact on their quality of life. Renal patients, particularly dialysis patients, were in need of frequent transfusions which are costly and carry significant risk.

NICE guidelines recommend that management of anaemia should be considered in people with anaemia of CKD when their Hb is less than or equal to 11 g/dL . Treatment with EPO should be offered to people with anaemia of CKD who are likely to benefit in terms of quality of life and physical function. People receiving EPO maintenance therapy should be given iron supplements to keep their iron storage replete and maintain either a transferrin saturation level above 20% or (serum ferritin levels between 200 and 500 g/L, and either transferrin saturation level above 20% percentage hypochromic red cells less than 6% (unless ferritin is greater than 800 g/L) .

## Discussion

As our patient was symptomatic with tiredness due to her renal anaemia, we decided to start her on EPO treatment. In addition she was considered to have significant cardiovascular risk with her medical history and the ECG suggestive of LVH. There is some evidence suggesting anaemia to be a important determinant in development of LVH in renal failure and LVH in turn is a independent risk factor for cardiovascular morbidity and mortality in patients with end-stage renal disease.

When giving EPO the benefits of a near normal Hb do help to improve quality of life but there appear to be potential risks to the patient with poorer blood pressure control, increased risk of vascular events and even increased mortality. CREATE and CHOIR were two large studies that failed to show a benefit for higher haemoglobin outcome and early correction of anaemia to normal Hb in CKD patients. In fact there are some indications that higher outcome target Hb has detrimental effect on cardiovascular morbidity and mortality.

The current NICE guidelines were put forward before the results of the TREAT study, which for the first time compared treating patients with renal anaemia with EPO or not to treat them (placebo study arm). The results suggest that use of EPO in diabetic CKD patients with moderate anaemia did not reduce the risk of either a cardiovascular event or progression to end-stage renal disease nor death.

Moreover the study suggests an association of increased risk of stroke with EPO treatment. In addition, we might need to be vigilant and concerned if we treat (pre)dialysis CKD patients with a history of malignancy as there might be potential detrimental effect of EPO treatment. Currently, there seem to be a need of more clinical trials in order to assess the effects of EPO on tumours and their treatment.

Therefore, risk of prescribing EPO in some patient populations might outweigh the potential benefits. In our patient, we decided to aim for a lower than normal Hb and only treat her with EPO as long as she remained symptomatic from her anaemia.

# RENAL ANAEMIA - DIAGNOSIS AND THERAPY

H.Wodeyar, J.Barfield, M.Schulz



**Renal Anaemia - Diagnosis and Therapy.**
**Patient Management.**

## Test Yourself Questions

**1. Treatment with erythropoietin**

a) increases life expectancy

b) can improve quality of life

c) should be commenced on every patient with anaemia

d) is especially useful when there is a proven malignancy

e) should aim for a very high haemoglobin

**2. When investigating anaemia in patients with CKD**

a) there is no need to look for bleeding as the anaemia is always secondary to renal disease

b) there is little correlation between the diabetes and anaemia

c) the ferritin and transferrin saturation levels are important to know

d) ensure you check erythropoietin levels to assess intrinsic function

e) all patients should have a bone marrow biopsy

## Test Yourself Answers

**Answer b)**
Treatment with EPO does not increase life expectancy and might in fact increase mortality, especially if the haemoglobin is maintained at a very high level. However, good symptomatic relief is observed when the haemoglobin is moderately increased from the baseline. Not every patient should be commenced on EPO unless other causes of anaemia have been ruled out in the presence of CKD and benefit risk ratio for EPO should be considered carefully in patients with known or suspected malignancy.

**Answer c)**
Whenever investigating anaemia in any patient you should rule out potentially serious and life threatening causes first although renal anaemia is present in 33% of patients with an eGFR of 15 though this figure rises if there is concurrent diabetes. There is little value of testing erythropoietin levels in renal patients and bone marrow biopsies are only indicated if a haematological dyscrasia is suspected. It is essential to know the ferritin and transferrin saturation levels to assess the iron storage or the need of iron supplementation prior to commencing EPO therapy and to rule out iron loss as cause for the anaemia.

123Library

www.123Library.org


# Sharing **more** knowledge



Contact us on
0207 253 4363
or email
sales@123library.org
for a
FREE TRIAL

## What is 123Library?

123Library is a fast growing and innovative eBook and **digital content provider for libraries** in the field of healthcare.

## What are the benefits for your library?

1. FULL FLEXIBILITY ✔
2. KNOWLEDGE ✔
3. CUSTOMER CARE ✔
4. NO HASSLES ✔
5. FULL SECURITY ✔
6. GET FEEDBACK ✔
7. SUPPORT ✔
8. EASE OF USE ✔
9. SAVING MONEY ✔

Benefit today, visit **www.123Library.org**

# ONLINE COURSES.
## YOUR REVISION'S LIFELINE.

**123DOC.COM** has developed a database of thousands of exam questions to **HELP YOU PASS YOUR EXAMS!**

- **UNLIMITED TIMED MOCK EXAMS WITH RATING**
- **100+ NEW PAST EXAM THEME QUESTIONS**
- **STUDY BY TOPIC OR BY DIFFICULTY LEVEL**
- **OPTION TO POST COMMENTS ABOUT A QUESTION TO OUR ONLINE FORUM**
- **THOUSANDS OF EXAM QUESTIONS**

**123DOC.COM** databases of exam questions include:

- ✓ **UKCAT**
- ✓ **GPST / GPVTS**
- ✓ **MRCP Part 1**
- ✓ **MRCP Part 2**
- ✓ **MRC Psych**
- ✓ **MRCS Part A1 and A2**
- ✓ **MRCPCH Part 1**
- ✓ **MRCPCH Part 2**
- ✓ **FRCA Primary**
- ✓ **Primary FRCR**
- ✓ **PLAB Part 1**
- ✓ **Medical Student**
- ✓ **MRCOG**




123Doc.com
ONLINE COURSES




# GET PUBLISHED!

**Get Your Article Published**
in The Foundation Years Journal

123 Doc EDUCATION

## Article guideline:

- Articles written by an FY doctor should be co-signed by a consultant or an SpR
- Each article should relate to a specific medical speciality
- Articles should comply with Authors' Guidelines

## In particular:

- Discuss a clinical case
- Include 5 multiple-choice questions with teaching notes at the end for testing purposes
- Be concise and discuss one of the key topics highlighted by the MMC Curriculum


**For more information and authors guidelines,**
**write to agnesg@123doc.com**

# ORDER FORM

## HOW TO ORDER (PLEASE WRITE IN BLOCK CAPITALS)

Call us on: **+44 (0) 207 253 4363**
Scan and email the form to: **subscriptions@123doc.com**
Through our website at: **www.123doc.com**
Post this form to: **123Doc, 72 Harley Street, London, W1G 7HG**

| CUSTOMER (PLEASE TICK ✓ APPROPRIATE BOX) | TYPE OF SUBSCRIPTION | PRICE |
|---|---|---|
| ❑ INDIVIDUAL CUSTOMER | ONLINE COPY | £59 |
| ❑ INDIVIDUAL CUSTOMER | PRINT + ONLINE COPY | £159 |
| ❑ INSTITUTION | ONLINE COPY | £299 |
| ❑ INSTITUTION | PRINTED COPY ONLY | £399 |
| ❑ INSTITUTION | PRINT + ONLINE COPY | £499 |

## YOUR DETAILS (PLEASE TICK ✓ APPROPRIATE BOX)

| | | | | |
|---|---|---|---|---|
| ❑ DR | ❑ MR | ❑ MRS | ❑ MS | ORGANISATION |
| FIRST NAME | | | | EMAIL |
| SURNAME | | | | TELEPHONE |
| JOB TITLE | | | | MOBILE |
| DEPARTMENT | | | | FAX |

## PAYMENT BY CHEQUE (PLEASE MAKE CHEQUES PAYABLE TO 123DOC MEDICAL EDUCATION)

A CHEQUE FOR £ _ _ _ . _ _ IS ENCLOSED

## PAYMENT BY INVOICE (PLEASE SEND INVOICE TO)

PURCHASE ORDER NUMBER (IF AVAILABLE)

NAME

ORGANISATION

ADDRESS

POST CODE

## PAYMENT BY CREDIT CARD (PLEASE DEBIT MY VISA/MASTERCARD/SWITCH)

CARDHOLDER'S NAME

CARD NUMBER _ _ _ _ | _ _ _ _ | _ _ _ _ | _ _ _ _

VALID FROM _ _ | _ _ | EXPIRY DATE _ _ | _ _

SECURITY CODE _ _ _ | ISSUE NUMBER _

SIGNATURE

CARD BILLING ADDRESS (IF DIFFERENT)

POST CODE

123Doc EDUCATION

**SUBSCRIBE TO AN ONLINE E-COURSE, VISIT WWW.123DOC.COM**
**FOR MORE INFO CALL 0207 253 4363 OR EMAIL INFO@123DOC.COM**

Volume 5, Issue 2: **Nephrology Immunology**

## How We Can Help You Succeed?

To find out how 123Doc can help you dramatically increase your medical knowledge, register your interest on our website.

**123Doc Education**
72 Harley Street
London
W1G 7HG

Tel: +44 (0) 207 253 4363
Web: www.123doc.com
Email: info@123doc.com

## ISSN

**1753-6995**

## 2011 Past Issues

**Volume 5, Issue 1:** Vascular Diseases

## 2010 Past Issues

**Volume 4, Issue 10:** Dermatology & Paediatrics
**Volume 4, Issue 9:** Diabetes & Endocrine
**Volume 4, Issue 8:** General Practice
**Volume 4, Issue 7:** ENT
**Volume 4, Issue 6:** Ophthalmology
**Volume 4, Issue 5:** Acute Medicine
**Volume 4, Issue 4:** Oncology
**Volume 4, Issue 3:** Neurology
**Volume 4, Issue 2:** Anaesthesia
**Volume 4, Issue 1:** Surgery

## 2009 Past Issues

**Volume 3, Issue 10:** A&E
**Volume 3, Issue 9:** Geriatric-Palliative Care
**Volume 3, Issue 8:** Orthopedics-Rheumatology
**Volume 3, Issue 7:** Psychiatry
**Volume 3, Issue 6:** Respiratory
**Volume 3, Issue 5:** Urology
**Volume 3, Issue 4:** Gastroenterology
**Volume 3, Issue 3:** Gynaecology & Obstetrics
**Volume 3, Issue 2:** General Practice, Cardiology
**Volume 3, Issue 1:** Infectious Disease, Immunology
**Volume 2, Issue 10:** Renal Medicine, Clinical Chemistry

Designed by Tim Lawrenson Creative.
**Please visit www.pure-tlc.com.**